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There is little research investigating factors that facilitate or inhibit timely 
access to palliative care medicines from community pharmacies. Though 
palliative care is recognised within the UK government’s strategy and 
community pharmacists are considered to have a role it is uncertain to what 
extent this aim is incorporated into local practice. 
This thesis uses mixed methods to investigate the time taken to access 
palliative care medication from five community pharmacies in one area of 
England. The effect of prescription errors, stock availability and other factors 
is examined. Furthermore, semi-structured interviews with five community 
pharmacists and eleven other healthcare professionals explore medication 
access and the community pharmacist’s role in palliative care using the 
Framework method. 
Stock availability led to delays with one in five customers going to more than 
one pharmacy to get urgently required palliative care medications. Legal 
prescription errors were more common on computer generated prescriptions 
but did not lead to delays. Three subthemes were identified in accessing 
palliative care medicines: environment and resources; communication and 
collaboration; skills and knowledge. 
 ii 
 
The community pharmacist’s role in palliative care was limited due to 
reluctance from other healthcare professionals to share information, poor 
access to patient records and lack of integration into the primary healthcare 
team. 
This study highlights implications for professionals, commissioners and 
providers to improve services for those trying to access palliative medication. 
Community pharmacies remain a largely untapped resource for supporting 
patients, relatives and carers towards the end of life in both cancer and other 
advanced life-limiting diseases. 
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Chapter 1: Introduction 
1.1 Context of Palliative Care 
Palliative care is a holistic approach to prevent suffering for those with 
serious advanced life-limiting disease addressing physical, psychosocial and 
emotional symptoms for both them and family members. Graham and Clark 
on behalf of The World Health Organisation (WHO) define palliative care as:  
"…an approach that improves the quality of life of patients and their 
families facing the problem associated with life-threatening illness, 
through the prevention and relief of suffering by means of early 
identification and impeccable assessment and treatment of pain and 
other problems, physical, psychosocial and spiritual” Graham and Clark 
(2008)  
Globally 40 million people need palliative care every year, however, only one in 
ten receives it, with only 50% of WHO member state countries having palliative 
care integrated within their healthcare systems in 2015 (WHO 2016). 
Furthermore, only 43% of WHO member state countries have access to oral 
morphine in primary care in more than 50% of pharmacies (WHO 2016). In 
2014, the World Health Organisation passed a resolution to improve access to 
palliative care with an emphasis on primary and community/home-based care 
(WHO 2014). They called on every country to include palliative care as an 
essential component of modern healthcare and address barriers such as lack of 
resources, access to essential medicines and a lack of knowledge by healthcare 
professionals and members of the public on the benefits of palliative care. 
One third of people in need of palliative care have cancer while others have: 
- progressive life-limiting illnesses affecting the lungs, heart, liver, kidney, 
brain or  
- HIV or  
- drug resistant tuberculosis (WHO 2014).  
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As the proportion of older people grows together with increased life expectancy, 
there will be a ‘palliative care explosion.’ The challenge of an increased 
incidence of dementia with one in three elderly dying with dementia, and an 
increased incidence of cancer combined with life-prolonging treatments leading 
to people living longer with symptoms and the effects of cancer treatments, and 
multi-morbidity will lead to a greater demand for palliative care. There will also 
be an increased burden on caregivers requiring support both before and after 
death, and an increased need for institutionalised care (Bhatnagar and Gupta 
2015). 
Research demonstrates that early palliative care increases duration of patient 
survival and improves quality of life (Temel et al. 2010), supporting the need for 
early identification and integration of a palliative approach into the patient’s 
usual primary care team. The Gold Standards Framework (GSF) is a quality 
improvement programme in primary care that incorporates early identification, 
care assessments, planning and coordination of care for those in the last year of 
life (Clifford et al. 2016). Primary care teams that participate in the GSF 
programme have enabled more people to ‘live well and die well’ and halved the 
number of hospital admissions and hospital deaths while increasing the number 
of people dying in their usual place of care (Clifford et al. 2016: 2). 
Palliative care research is not well funded. In the USA, less than 1% of 
government research funding is directed to palliative care (WHO 2014) and in 
the UK, palliative care research is under-represented in the UK Research 
Excellence Framework (REF) (Fordham and Noble 2016). With some countries 
only more recently integrating palliative care into their healthcare system and the 
great gap that exists between current unmet provision and future need, there is 
much to do to investigate new models of care that can support communities, 
caregivers and the growing number of patients in the future. Similarly, research 
in palliative care in the community pharmacy setting is limited, making it difficult 
to gather evidence and translate this into practice in different political and 
economic environments.  
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1.2 Palliative Care in UK 
In England and Wales, there were 525,048 deaths in 2016, with cancer being 
the cause in 28.5% of registered deaths (Office for National Statistics (ONS) 
2017). It is estimated that between 70-80% of deaths are likely to need 
palliative input (Hughes-Hallett et al. 2011) making the current estimate of 
need at about 393,786 patients (using the midpoint of 75%) per year. In 
2011, the Secretary of State for Health in England commissioned an 
independent review to look at the funding of palliative care for adults and 
children in England.  It was estimated within the palliative care funding review 
that 92,000 patients in England had unmet palliative care needs (Hughes-
Hallet et al. 2011). Need for palliative care is expected to increase in line with 
population changes, with one in twelve of the UK population being aged 80 or 
over by mid-2039 (ONS 2016). 
The End of Life Care (EOLC) Strategy for England (Department of Health 
(DH) 2008a) sets out a promise for patients to be cared for in familiar 
surroundings with family and friends present. Similarly, the NHS England 
Five Year Forward View (NHS England 2014) states that end of life care will 
be increasingly provided in community settings. Over two thirds of patients 
across six countries in Europe including England have expressed a 
preference to die in the home environment (Higginson and Sen-Gupta 2000; 
Gomes et al. 2012); so primary care healthcare professionals will 
increasingly see end of life care as part of their day-to-day work. Changes in 
population demographics, advances in healthcare and greater demand for 
palliative care services will place increased pressure on general practitioners 
to support patients and their families near the end of life and through 
bereavement. To achieve this, there is a need to assess new models of care 
in order to increase collaboration in the provision of palliative and end of life 
services in the community, and improve community resilience. 
Guidance published by the National Institute of Health and Care Excellence 
(NICE) has been developed to improve palliative care in adults, including 
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quality standards for the care of the dying (NICE 2017a), quality standards 
for end of life care for adults (NICE 2017b), pathways on opioids for pain 
relief in palliative care (NICE 2016), and guidance on care of the dying (NICE 
2015). NICE quality standards describe high-quality care to improve the 
safety, effectiveness and experience of patients towards the end of life 
including timely access to medicines and consistent care at any time of day 
or night. There is, however, no published data worldwide on the time it takes 
to access palliative care medications in the community setting, or patients’ 
and carers’ experiences in accessing such medicines. For instance, there is 
no information on whether patients and carers receive an incomplete 
dispensing of their medication or are referred to another provider to access 
the medicines they need. This highlights a need for commissioners to include 
community pharmacists in the care pathway, allowing access to information 
about the patient’s medical condition, care plan and preferences to ensure 
high-quality care (NICE 2017b). 
Patients with progressive chronic illnesses may have an uncertain disease 
trajectory (Murray et al. 2005) meaning it may be difficult to predict when they 
will need end of life care medicines for symptom management. The 
unpredictable nature of this demand means that obtaining urgent medicines 
in a timely manner, especially from a community pharmacy, may be 
paramount to prevent a hospital admission. 
1.3 Pharmacists in Palliative Care 
Pharmacists working in palliative care are integral members of the hospice 
and palliative care interdisciplinary team, and make important contributions to 
reduce medication risks and improve clinical outcomes (Walker 2010; Wilson 
et al. 2011a). Their expertise and therapeutic knowledge of medicines 
supports patients who may be at high risk of medication related problems 
due to unlicensed use and complex regimes (Crawford 2008).  
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The specialist role of pharmacists working in palliative care is recognised in 
the US (Hernandez-Torres 2004; McCracken and Dole 2004; Walker 2010; 
Wilson et al. 2011b), UK (Austwick and Brooks 2003), Australia (Swetenham 
et al. 2014; Tait and Swetenham 2014) and some other developed countries 
(Gilbar and Stefaniuk 2002; Pawłowska et al. 2016). In the US, the American 
Society of Heath-System Pharmacists (ASHP) has produced guidelines on 
the diverse roles that pharmacists undertake within palliative and hospice 
care from direct patient care through to transitional care, collaborative 
working, advocacy, research and scholarly activities, optimising patient 
outcomes while maintaining fiscal responsibility (Herndon et al. 2016), and 
Walker et al. (2010b) provides ‘Fifty reasons to love your palliative care 
pharmacist’.  In the UK, the role of the pharmacist in palliative care has been 
recognised within the expert professional curricula (EPP) for advanced and 
specialist pharmacists in palliative care by the Royal Pharmaceutical Society 
(RPS) (RPS Faculty 2013). In Australia, the US and UK, the advanced 
practice role has been piloted with positive outcomes within home based 
palliative care teams (Hill 2007; Scholes 2010; Mellor 2014; Swetenham et 
al. 2014; Tait and Swetenham 2014). Likewise, a palliative care pharmacist 
within an ambulatory role evaluated positively in the US (Atayee et al. 2008) 
and within a hospital outpatient clinic in the UK (Austwick and Brooks 2003). 
Advanced practice roles have supported transitions of care to improve 
access to medicines at the end of life, facilitating a home death for those that 
choose this (Swetenham et al. 2014). Community palliative care pharmacist 
roles exist in the UK (Mellor 2014; Bartlett 2017: pers. comm., 21 September) 
(see Appendix A). However, there is no national funding and such roles are 
not widespread. 
1.4 Community Pharmacy Services in the UK 
Community pharmacists are highly trained healthcare professionals who 
provide direct patient care from a community or retail pharmacy without the 
need for an appointment. Pharmacists are recognised as playing an 
important role in the management of long-term conditions (LTCs), including 
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dementia, Chronic Obstructive Pulmonary Disease (COPD), and heart 
failure, and they are experts in medicines use; so can ensure the best 
outcomes for patients and minimise avoidable harm (RPS England 2016). It 
has been established that 79% of the population visit a pharmacy at least 
once a year, 37% visit a pharmacy at least once a month, and 75% of adults 
visit the same pharmacy all the time (Public Health England (PHE) and Local 
Government Association 2016). Pharmacies are often convenient for those 
that cannot easily access other health services. In England, 89.2% of the 
population live within a 20-minute walk of a community pharmacy, rising to 
99.8% within the most deprived areas (Todd et al. 2014). This increases to 
99% of the population who are able to access a community pharmacy within 
20 minutes by car and 96% by walking or using public transport (Department 
of Health (DH) 2008b). There are over 11,500 community pharmacies in 
England, many of which are open extended hours and are highly accessible 
without the need for an appointment (Loader 2014). The current national 
pharmacy contract for NHS England & Wales was introduced in 2005 (DH 
2005) and for the first time included clinical services alongside the traditional 
dispensing of prescriptions. NHS Pharmaceutical services in England and 
Wales are divided into three categories: essential services, advanced 
services and enhanced services. Pharmacy contractors must deliver all 
essential services before advanced or enhanced services can be provided. 
Advanced services such as Medicines Use Reviews (MURs) are contracted 
nationally while enhanced services including the provision of palliative care or 
specialist medicines and are often commissioned locally based on an 
identified need in a Pharmaceutical Needs Assessment (PNA). Further 
changes to the national pharmacy contract in England, announced in October 
2016; included a Pharmacy Integration Fund to transform community 
pharmacy services in particular urgent and emergency care, as well as 
support community pharmacy workforce development (DH 2016). NHS 
Scotland contracts a range of pharmacy services including Minor Ailments 
Scheme (MAS) and Chronic Medication Service (CMS) for people who 
voluntarily register with their pharmacy as well as enhanced and locally 
negotiated services. Local Scottish NHS Boards commission local services 
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including networks of community pharmacies participating in the provision of 
palliative care. 
Information on local pharmacies, their opening hours, location, address and 
phone number is available on the NHS choices website, which provides a 
directory of NHS services in England as well as information on a range of 
health conditions and care options (UK Government 2017). Pharmacies self-
manage the content and can receive a quality payment for updating criteria 
including the hours of opening and available services (Pharmaceutical 
Services Negotiating Committee (PSNC) 2017) but access to palliative 
medicines is not listed on the NHS choices website. 
1.5 Community Pharmacists and Palliative Care 
Community pharmacists are integral to providing joined up services as 
reflected within the Royal College of General Practitioners (RCGP) and Royal 
Pharmaceutical Society (RPS) joint statement on ‘Breaking down the barriers 
– how community pharmacists and GPs can work together to improve patient 
care’ (RPS and RCGP 2011: 2) that  recommends: 
‘Community Pharmacists working with general practices and specialist 
palliative care teams ensure reliable and prompt medicine supply, and 
supportive advice (especially about analgesia) for patients, lay carers 
and other members of the health care team’. 
There has been little further mention of community pharmacists within 
national strategic documents in England or how the vision laid by the RCGP 
and RPS will be achieved. Only recently has there been some recognition of 
community pharmacists’ potential role within the RPS England Improving 
Care for Long Term Conditions (2016) that suggests  networks of 
pharmacists could be established to provide access to palliative care 
medicines and have specialist expertise. By contrast, there is some evidence 
supporting the community pharmacists’ role in palliative care in the US and 
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Australia (Atayee et al. 2008; Jiwa no date) as well as in the UK (Needham 
2002; Akram et al. 2012; Bennie et al. 2012); however, much of this work has 
not been published within peer-reviewed journals. 
Within England there is no nationally commissioned access to palliative care 
medicines service but local NHS England teams can commission a local 
enhanced service (LES) from community pharmacies under a standard NHS 
contract to provide ‘on demand access to specialist drugs’ as defined within 
The Pharmaceutical Services (Advanced and Enhanced Services) (England) 
Directions (DH 2013). The purpose of such a service is to provide seven-day 
access to urgent palliative care medicines near the end of life from 
commissioned pharmacies; this may include extended hours and on-call out-
of-hours (OOH) cover. Palliative care services can also be commissioned 
from other local commissioners including CCGs, Local Authorities and Local 
Health Boards depending on whether NHS or joint budgets are held; 
however, these are referred to as Locally Commissioned Services (LCS) and 
not enhanced services. A nationally agreed template for ‘on demand 
availability of specialist drugs’ developed by the Pharmaceutical Services 
Negotiating Committee (PSNC), Department of Health and NHS Employers 
(2005) is available for contracting palliative care medicines on the PSNC 
website. Local Pharmaceutical Committee (LPCs), pharmacy contractors and 
commissioners can also develop their own specification according to local 
needs. 
No reliable national data can be sourced on locally commissioned or 
enhanced palliative care services but the community pharmacy contractor 
organisation PSNC, collects some data from LPCs and makes it publicly 
available. The PSNC website includes a spreadsheet listing the geographical 
areas that commission ‘on demand availability of specialist drugs (palliative 
care)’ in England. Similarly, Community Pharmacy Wales and Local Health 
Boards in Scotland provide information on locally commissioned services in 
their respective areas. In England, 54 palliative care access schemes are 
listed on the PSNC website covering 68 geographical areas; some specify 
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cover OOHs when many pharmacies are closed (PSNC 2017b). Not all areas 
are covered and the list of commissioned services is not complete, for 
instance Sheffield provides a LCS but is not listed on the PSNC spreadsheet. 
It is likely the list underestimates the total number of schemes since it relies 
on LPC members to submit these for addition to the website. Some service 
specifications regarded as ‘on demand availability of specialist drugs 
(palliative care)’ on the PSNC spreadsheet include anticoagulation, 
intravenous antibiotics or vitamin K injection in addition to palliative care 
medicines (PSNC 2017b) so may not be specifically ‘palliative’. Another 
source of national information covering ‘on demand availability of specialist 
drugs’ in England is available from NHS Digital, which lists 344 such 
enhanced schemes commissioned from community pharmacies in 2015/16 
(NHS Digital 2016). Even though areas such as London, East and West 
Midlands, Lancashire and Greater Manchester have no ‘on demand 
availability of specialist drugs’ recorded on NHS Digital, such services are 
documented on the PSNC spreadsheet. This could be because NHS Digital 
only collects information on enhanced services commissioned through NHS 
England and not locally commissioned schemes. In a similar manner to the 
PSNC data, NHS Digital may include specialist medicines that are not 
specific to palliative care. Further to this, commissioning bodies may make 
alternate arrangements, for example: through GP OOH providers; hospital 
pharmacy departments; an on-call hospital or on-call community pharmacist 
rota, which are not designated enhanced services making it difficult to obtain 
a full picture of all services and areas covered. 
1.6 Palliative Care in Sheffield 
The study location was chosen for various reasons including: convenient 
location, good access to pharmacy services, higher than England death rate 
in hospital and a history of innovative community pharmacy services in the 
area. 
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 A third of Sheffield households have one person living alone and 29,000 
(12.6% of all households) have one lone elderly person. A fifth of all 
households comprise of people over 65 years. One third of households do 
not have access to a car or van (ONS 2011; Dabinett et al. 2016). In 
Sheffield, 53.8% of deaths occur in hospital compared to the England 
average of 50.7%, while 19.7% of deaths are at home and 19.4% in a care 
home. In Sheffield 50.0% of deaths for those 85 and over occur in hospital; 
higher than the England average of 48.8% (ONS 2014a; ONS 2014b) 
suggesting there is room to improve palliative and end of life care services in 
the city. 
Sheffield has good access to community pharmacies. On average Sheffield 
pharmacies serve a population of 4,547 people; slightly lower than the 
England average of 4,654 per pharmacy, and there is at least one pharmacy 
in each of the 28 electoral wards. In Sheffield, 99.2% of residents live within 
one mile of a pharmacy and no GP practices are more than 0.5 miles from a 
pharmacy (Pharmaceutical Needs Assessment Steering Group 2015). 
Sheffield has a pro-active LPC with a history of innovation in community 
pharmacy services, being one of the first places in the UK to introduce a 
needle-exchange scheme to minimize harm for injecting drug users. The 
Sheffield LPC has worked with local pharmacies and commissioners to 
provide a wide range of public health, minor ailment, and care home services 
(CPS 2017) in addition to the nationally contracted pharmaceutical services. 
Furthermore in 2014, Sheffield community pharmacies were part of a proof of 
concept pilot to access the patient’s summary care record (SCR) (PSNC 
2015) with the decision being made to roll out access to all community 
pharmacies across England in 2015 (NHS Digital 2015). Being a pathfinder 
site for use of and access to patient treatment records has meant earlier 
implementation within the city with pilot pharmacies having had access to 
SCR for more than two years prior to this study taking place. This will allow 
the researcher to establish what impact if any SCR has on accessing 
palliative care medication particularly in the OOH period when it can be more 
difficult to contact the prescriber. 
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More recently, Community Pharmacy Sheffield (CPS) representing 
contractors within the Sheffield Health and Wellbeing Board has established 
a living with and beyond cancer programme in partnership with Macmillan 
Cancer Support. Within this scheme, pharmacists are trained to support 
patients going through or recovering from cancer treatment and its effects. 
Pharmacists can issue general sales list and pharmacy medicines to support 
patients with symptoms such as mucositis, dry eyes or skin thereby negating 
a need to visit the cancer treatment centre for supportive treatments 
(Freedman 2016). Though the scheme is for those living with and beyond 
cancer, many of these patients may have a large symptomatic burden 
resulting in palliative care needs or may be future users of the access to 
palliative care medicines service. 
Sheffield has 19 pharmacies participating in a Locally Commissioned Service 
(LCS) to provide access to palliative medicines; this study providing an 
opportunity to review the LCS and how this was working in practice. 
The researcher’s knowledge of the local healthcare system, having worked in 
primary care, hospital and specialist palliative care in the city, supported 
access to gatekeepers and potential recruitment of participants onto the 
study. Furthermore, the study location was convenient for the researcher to 
access yet was at arm’s length to minimise bias in conducting research in 
local healthcare system as the researcher was not employed or influenced by 
the participants. 
1.7 Community Pharmacies in Sheffield and the Provision of Palliative 
Care 
Sheffield has 128 pharmacy contractors, including three distance selling 
pharmacies, one essential small pharmacy and 19 community pharmacies 
participating in a Locally Commissioned Service (LCS) for access to palliative 
care medicines (Pharmaceutical Needs Assessment Steering Group 2015; 
Community Pharmacy Sheffield (CPS) 2017). They provide services to 
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563,700 people in the city of Sheffield (Dabinett et al. 2016) as well as those 
living across adjacent borders, visiting or working in Sheffield. The palliative 
care LCS includes at least one pharmacy within 17 out of 28 council wards in 
the city (Pharmaceutical Needs Assessment Steering Group 2015). 
Sheffield pharmacies dispensed an average of 7,7921 items per pharmacy 
per month compared to the England average of 6,628 in 2012-13 (NHS 
Digital 2016). Most pharmacies open between 8.30am – 9am Monday to 
Friday and close between 5pm - 6pm, with most also open on Saturdays and 
28 are open on Sundays. There are seventeen 100-hour pharmacies as well 
as three pharmacies commissioned by the CCG providing an extended-hours 
service to cover bank holidays and Sundays (UK Government 2017). 
Patients can obtain prescriptions out-of-hours through the GP Collaborative 
(OOH service), the GP walk-in centre or from four new primary care OOH 
hubs established through the former Prime Minister’s Challenge Fund, now 
called the GP Access Fund (NHS England 2015). Healthcare professionals 
can also access emergency medications including palliative care medications 
through the GP Collaborative, which has access to an on-call hospital 
pharmacist provided by the Sheffield Teaching Hospitals (STH) NHS 
Foundation Trust. In December 2016, shortly after the completion of Phase 1 
data collection, the collaborative implemented direct access to palliative care 
packs for doctors working within the service. 
In 2011, a LCS was piloted in two Sheffield pharmacies to assure availability 
of palliative care medicines during regular service hours and for an extended 
OOHs period. This service evaluated positively and was deemed cost 
effective (Tsoneva 2011) providing access to palliative care medicines seven 
days a week; so was subsequently rolled out to 19 community pharmacies 
across Sheffield by the Primary Care Trust, which was the commissioning 
body prior to more recent NHS changes. Although the service evaluation 
                                                          
1 Figure excludes three distance selling pharmacies so is based on total of 125 pharmacies. 
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provided evidence of the number of times medicines were accessed and the 
activity data in the regular and OOHs periods, there was no information on 
whether medicines were available in a timely manner and there was 
insufficient data to determine whether patients or their carers had to visit 
more than one pharmacy to obtain their prescription. It was noted by 
Tsoneva (2011) that there did not appear to be a significant problem for 
patients accessing palliative care medicines that would require the 
commissioning of additional services. In addition, it appeared that an 
increase in prescriptions for midazolam and levomepromazine at one of the 
pharmacies may have been because patients or their carers had been 
signposted or referred to the ‘palliative care pharmacy’ (Tsoneva 2011). 
Since the service does not operate 24 hours a day, is not advertised in the 
local press, on the NHS choices website or promoted within the local 
palliative care directory, it is unclear whether referrals are being made. 
Currently, there is no mechanism to collect information on prescriptions to 
establish whether the carer had been referred to another pharmacy to get 
urgently needed items or received a part dispensing of their prescription 
items, requiring them to return for the balance. 
Sheffield community pharmacies are establishing close working relationships 
with a linked GP practice through an enhanced integrated primary care 
model established through the second wave of the GP Access Fund (NHS 
England 2015) that received an award in 2016 for GP partnership working 
(CPS 2016). The model involves local community pharmacists working in 
neighbouring GP practices to provide a range of patient-facing and 
administrative services to improve medicines use and increase the number of 
GP appointments available (Kelly 2016). It is likely that increased joint 
working between GPs and community pharmacists will provide scope to 
identify and support patients with more complex needs, which could include 
those receiving palliative care or who are at risk of deteriorating. Joint 
working between community pharmacists and GP practices is likely to 
increase trust between the professional groups and may provide a route for 
pharmacy teams into local commissioning and collaborative working. 
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Electronic Prescribing Analysis and CosT (ePACT) data from the NHS 
prescription services information database for the Sheffield Clinical 
Commissioning Group suggests there is room for improvement in the 
prescribing of drugs at the end of life. For example, midazolam, which is used 
for agitation and restlessness in the terminal phase, should be prescribed as 
10mg/2ml to allow higher doses to be administered within palliative care. Yet 
electronic prescribing (ePACT) data shows that 24.77% of midazolam 
prescriptions for the 12 months to August 2015 (NHSBSA 2015) were for 
strengths not recommended in palliative care and not on the Sheffield 
community pharmacy palliative care stock list. During the evaluation of the 
pilot palliative scheme, LCS demand for several items not on the palliative list 
was as high as for items that were on the list. For example, there were 598 
requests for diamorphine 5mg and 622 requests for diamorphine 10mg 
ampoules but only the 10mg strength was on the Sheffield community 
pharmacy palliative stock list at the time (Tsoneva 2011). This may have 
been due to national stock shortages affecting some strengths of 
diamorphine where supplies have been difficult to access in the past (Hall 
2006). Following the service evaluation, it was deemed necessary to add the 
lower strength of diamorphine to the palliative care medications stock list as 
well as the higher strength. When medications are requested that are not on 
the recommended stock list this can lead to delays where the commissioned 
pharmacies do not hold the medications in stock. This can subsequently lead 
to poor access for the patient and a poor experience for the family carer who 
may have to leave the patient to run around and fetch drugs. It could also 
manifest in pain and other unrelieved symptoms where the patient is unable 
to take or access other medication. 
1.8 Community Pharmacist Involvement – Facilitators and Barriers 
Community pharmacists are not considered part of the primary care 
interdisciplinary team by GPs and other healthcare professionals (Ise et al. 
2010; O'Connor et al. 2011b), despite being easily accessible (Loader 2014) 
and having a primary relationship with patients, families and carers 
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(O'Connor et al. 2011a). As mentioned previously, Sheffield pharmacies are 
participating in the GP Access Fund increasing the number of pharmacists 
who work within local GP practices (ibid). This is likely to improve 
relationships and integration of pharmacists within the primary healthcare 
team. 
Greater involvement by community pharmacists could support the increasing 
number of patients with palliative care needs; a vision supported by 
O'Connor et al. (2011b) and Savage et al. (2012) who envisage pharmacists 
working collaboratively with GPs and nurses embedded in the palliative care 
team. Much of this is already happening in Scotland where networks of 
community pharmacies are supported by Macmillan Pharmacist Facilitators 
to provide enhanced access to palliative care medications (Bennie et al. 
2012). Likewise, it is a vision for the RPS in Improving care for people with 
Long Term Conditions (RPS England 2016) to see networks of pharmacies 
having expertise in this area of practice. 
An advantage of pharmacies is that pharmacy-support staff often reflect the 
neighbourhood where they are based, which could mean staff speak more 
than one language helping them to communicate and build relationships with 
customers. Pharmacists are considered trusted healthcare professionals in 
the local community, and provide ease of access to healthcare information 
and medicines without the need for an appointment to see a doctor (Thornley 
et al. 2017). The pharmacist’s on-going relationship with their regular patients 
allows them to engage and support patients in a range of healthcare services 
other than just supplying medicines. Pharmacies are also businesses and 
may see the economic benefits of engaging with palliative care patients to 
provide daily aids to living. Primary care commissioners have been 
challenged to find new models to help support healthcare (Loader 2014), 
which provides the impetus for upskilling alternative providers such as 
pharmacy teams in the face of the current workforce crisis within GP practice. 
Providing support for the increasing number of patients with palliative care 
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needs could allow a home death for those that desire this, having economic 
benefits due to a reduced number of hospital admissions. 
Research suggests that incorrectly written or illegible prescriptions impinge 
on the pharmacists’ delivery of palliative care services (Lucey et al. 2008), 
and prescriptions that do not meet the legal requirements cause ethical 
dilemmas (Akram et al. 2012), particularly OOHs. There is no routinely 
collected data or published studies on incorrect or illegible prescriptions 
available and there are no published studies. Lucey and colleagues (2008) in 
Ireland found that 31.5% of responses in a survey of 168 GPs and 
pharmacists in North Dublin experienced delays due to incorrectly written 
palliative care prescriptions, and 17% reported delays with illegible 
prescriptions; however, no specific prescription data was audited and the 
response rate was low. In an unpublished study of 850 CD prescriptions by 
Stuart (2013), prescribing errors were detected in one out of every eight 
controlled drug prescriptions with half of the errors in prescriptions requesting 
injectable palliative care medications. There is an increasing move to issue 
computerised prescriptions, including within OOH providers; however, the 
impact of this change on CD prescribing is unknown. 
Lack of access to patient clinical records has been identified as a barrier to 
community pharmacists’ input in palliative care (Ise et al. 2010; Akram et al. 
2012; Savage et al. 2012); however, as Sheffield community pharmacies 
have access to the patient’s SCR where consent is provided, this could help 
resolve prescription queries supporting timely access to medicines especially 
in the OOH period. 
Community pharmacists are not currently included within GP practice 
multidisciplinary palliative care case review meetings (O'Connor et al. 2011b; 
Akram et al. 2012; Savage et al. 2012). Their physical and professional 
isolation can make it difficult to attend such meetings and collaborate with 
other primary healthcare professionals (Bradley et al. 2008; Akram et al. 
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2012). Since a number of Sheffield community pharmacists provide an in-
reach service to GP practices, this may help to break down professional 
barriers, support collaboration, and enhance the community pharmacists’ 
clinical role in patient care. Whether this might have any effect on palliative 
care provision is uncertain. 
1.9 Rationale for this study 
There is a lack of research and understanding of how community 
pharmacists contribute to and collaborate in the care of palliative care 
patients in the primary healthcare team. This study plans to explore the 
community pharmacist’s role in providing timely access to palliative care 
medicines, and investigate the pharmacists’ and other healthcare 
professional’s experiences and perspectives to make recommendations for 
future service provision and development. 
Creswell (2007) and Silverman (2010) suggest having a statement of 
purpose to clarify the intent of the study.  The statement of purpose for this 
study is as follows: 
The purpose of this two-phase, sequential mixed methods study will 
be to collect quantitative data on palliative care prescriptions 
presented to a purposive sample of community pharmacies in 
Sheffield. In the study, pharmacy logs will be used to identify factors 
associated with a delay in supplying palliative care medicines. In the 
second phase of the study, qualitative interviews with a sample of 
community pharmacists and healthcare professionals providing 
palliative care services will further explore the experiences of team 
members to understand those factors that facilitate or limit the 
community pharmacists’ contribution to palliative care. 
It was hoped to specifically include clinical services such as Medicines Use 
Reviews (MURs) to determine barriers to use, and whether patients or carers 
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found them helpful in the palliative care situation; however, as none of the 
clinical services in the current national community pharmacy contract include 
palliative medications or analgesics within the target groups, it would not be 
possible to undertake such a study without additional resources. It was felt 
that through in-depth interviewing of the pharmacists in the study, it would be 
possible to investigate any emergent themes related to the provision or lack 
of provision of nationally contracted clinical services in order to establish if 
there may be an effect on patients and their carers. 
1.10 Aims and Objectives 
This study seeks to answer the question ‘What is the community 
pharmacist’s role in the delivery of palliative care services’. 
Research aim 
The aim of this research is to investigate the delivery of palliative care 
services by community pharmacists in Sheffield to make 
recommendations to commissioners to improve local services. 
Research objectives 
The study will be conducted in two phases; Phase 1 will collect quantitative 
data from purposively chosen community pharmacies and Phase 2 will 
involve qualitative interviews with community pharmacists and other 
healthcare professionals. Specific objectives within each phase of the study 
are set out below. 
Phase 1 objectives: 
• Investigate the prevalence of prescribing errors on palliative care 
prescriptions presented to a sample of community pharmacies. 
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• Explore whether the prescription error rate varies according to the 
practice, prescriber status, or the nature of the prescription. 
• Establish whether errors on palliative care prescriptions are 
associated with time delays in obtaining urgent palliative care 
medicines. 
• Establish the maximum waiting time for palliative care medications 
from the community pharmacy setting. 
• Establish what processes exist for patient referral when palliative care 
medicines are not available. 
 
Phase 2 objectives: 
• Identify factors from Phase 1 of the study causing delays in obtaining 
palliative medicines. 
• Clarify factors from Phase 1 of the study that facilitate or limit the 
community pharmacists’ involvement in providing palliative care 
services. 
• Determine whether community pharmacies within an enhanced 
palliative care service fulfil more than a supply function. 
• Explore the pharmacists’ perceptions and experiences in the delivery 
of palliative care services. 
• Explore whether the delivery of palliative care services within 
pharmacies has any effect on community pharmacy staff. 
• Explore the community pharmacists’ current and future role in 
palliative care according to the views of pharmacists and other 
healthcare professionals. 
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• Make recommendations to improve the pharmaceutical care of 
palliative care patients and processes for obtaining urgent palliative 
care medication.   
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Chapter 2: Literature Review 
2.1 Overview 
This chapter presents the findings following a search of published and 
unpublished literature in answer to the research question what is known 
about the community pharmacist’s role in the delivery of palliative care? The 
literature review includes studies that directly relate to the research question 
as well as other literature with themes related to the question. 
The search strategy is described following which there is a narrative review 
of the published studies in terms of the methods and quality and how that 
relates to the proposed study. The purpose of the chapter is to determine 
what is currently known on the subject and to identify and highlight any gaps 
in the published literature. 
2.2 Introduction to Literature Review Methods 
There are many ways of conducting a literature review each of which has an 
associated method and reporting style. The choice of the method will depend 
on the associated time and resources available. Fourteen types of literature 
review have been described by Grant and Booth (2009) according to an 
analytical framework on the search, appraisal, synthesis and analysis 
methods used. Where studies are quantitative a meta-analysis can be 
performed to combine results and assess the quality of the trials. Where 
limited time is available a rapid or scoping review can be performed. A 
systematic review seeks to answer the question using a systematic search 
and appraisal method based on criteria such as the CONsolidated Standards 
Of Reporting Trials (CONSORT) statement (Schulz et al. 2010) and is 
considered the most reliable method of reviewing the evidence to reduce bias 
(Higgins and Green 2011). The method for conducting a systematic review is 
published in the Cochrane Handbook for Systematic Reviews of Interventions 
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(2011) and systematic reviews are published in the Cochrane Database of 
Systematic Reviews library. 
Very few published studies are available looking at community pharmacists’ 
involvement in palliative care. Many of the reports found are observational 
studies, not developed as clinical trials with quality assessment criteria or 
specific outcome data, and use a range of methods therefore prohibiting the 
comparison of findings. The paucity and heterogeneity of published studies 
together with inconsistent methods means there would be insufficient power 
to reach a conclusion within a more formal systematic review. Therefore, a 
systematic approach to the literature search has been undertaken to inform a 
narrative literature review of the evidence. 
2.3 Methods 
A comprehensive literature search was undertaken to ascertain what is 
known about the community pharmacists’ role in the delivery of palliative 
care. Databases were accessed from the NHS NICE (National Institute for 
Health and Care Excellence) evidence gateway (www.evidence.nhs.uk) 
using the Health Databases Advanced Search (HDAS). This allowed the 
researcher to access three nursing and management databases not available 
through the University of Bradford. The researcher also searched two 
electronic databases accessed via a personal login at the RPS 
(www.rpharms.com) as it was thought these may include articles specifically 
related to pharmacy services. Subject search terms (see table 2.1) were 
identified for a range of synonyms and keywords using the Participants, 
Interventions, Comparisons, Outcomes (PICO) criteria as recommended by 
Cochrane Collaboration (Higgins & Green, 2011). To increase the sensitivity 
of the results search terms were kept broad with population and intervention 
terms giving higher numbers of results. Limiters were applied according to 
the inclusion criteria to improve specificity. Specific search terms used for 
three medical and nursing health databases can be found in Appendix B.  
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Search terms were modified for other databases as per the thesaurus in each 
database.  
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Table 2.1 – Final Search Terms identified using PICO criteria (Cochrane 
Collaboration Handbook (Higgins and Green 2011) 
PICO category Keywords and search terms 
Population Palliative care; terminal care; bereavement; 
terminally ill; terminal illness; dying; death; palliat*; 
terminal care; terminal stage; end-of-life; cancer 
palliative therapy; dying; palliat* stage; advanced 
cancer patient; life-limiting; progressive disease; 
carer medicine* support, bereavement support, 
infusion subcutaneous; infusion therapy; 
subcutaneous injection; infusion pump; syringe 
driver; syringe pump; just in case; anticipatory 
medic*; anticipatory prescribing; pre-emptive. 
Intervention 1 Prescription*; prescription drug*; drug therapy; 
opioid* analgesic; drugs; narcotic; morphine; 
diamorphine; fentanyl; alfentanil; oxycodone; 
hydromorphone; haloperidol; hyoscine; 
glycopyrrolate; midazolam; levomepromazine; 
cyclizine; metoclopramide.  
Intervention 2 (major 
heading) 
Community pharmac*; pharmacist*; community 
pharmacist; pharmacies; pharmacy; chemist; 
retail pharmacy, community pharmacy service*; 
pharmaceutical service* professional role; 
medicine* review, Medicines use review or MUR, 
New Medicines Service or NMS, pharmacy 
technician; pharmacist attitude*; pharmacy ethics. 
Comparison Any 
Outcomes of Interest Any 
Footnote: *truncation symbol used in HDAS to retrieve results with a common 
root phrase.  
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The search was carried out by the researcher who has received training on 
literature searching through EBSCOhost, University of Bradford and RPS 
libraries as well as through her role as a clinical pharmacist. The University of 
Bradford subject librarian provided support in assessing the completeness 
and quality of the search strategy. The search was originally conducted in 
March 2017 across eleven electronic databases from date of inception to 
current date. An alert was set up to pick up any additional material published 
after the search was conducted. The search strategy was saved and rerun in 
September 2017 within CINAHL, MEDLINE® and EMBASE® to provide an 
update prior to thesis submission. 
The eleven electronic databases included below were chosen because they 
collate peer-reviewed journals within the fora of palliative and pharmacy 
research including subject titles and publication titles of relevant palliative 
care and/or pharmacy journals. 
AMED (The Allied and Complementary Medicine Database):1995 to 2017 
BNI (British Nursing Index): 1992 to 2017 
CINAHL (Cumulative Index to Nursing and Allied Health Literature) with full 
text: 1981 to 2017 
Cochrane Database of Systematic Reviews: 2005 to 2017 
EMBASE (Excerpta Medica Database): 1974 to 2017 
HBE (Health Business Elite): 1922 to 2017 
HMIC (Health Management Information Consortium): 1979 to 2017 
MEDLINE Complete: 1857 to 2017 
PsychINFO: 1806 to 2017 
Biomedical Reference Collection Corporate edition: from inception to 2017 
 26 
 
International Pharmaceutical Abstracts: from inception to 2017 
The search was limited to research papers published in English in human 
adults and includes articles in peer-reviewed journals as well as conference 
abstracts and dissertations (“grey literature”). This was to ensure the review 
picked up potential unpublished material including conference posters and 
studies in progress where it was thought much relevant material may be 
found. Opinion pieces, editorials, newspaper articles and books were 
excluded from the search as they would not provide data on primary studies. 
Due to the large number of initial results only studies published since 2005 
were examined, which is when the new community pharmacy contract was 
implemented in England, as it was thought studies prior to this may be less 
relevant. Results in Medline were limited within major headings of 
intervention 2 (pharmacists, prescriptions etc.) as set out in Appendix B to 
exclude hospital treatments and chronic diseases. 
Database searches resulted in a total of 710 results (see figure 2.1), which 
were extracted to EndNote x8.0.1® bibliographic database where they were 
managed and 26 duplicates were removed leaving 684 articles. Titles and 
abstracts were screened against the study objectives to check for relevancy 
to the study. Articles were excluded if they were opinion pieces, editorials, 
and obituaries or learning articles, were related to drug misuse services, non-
palliative conditions or were based in a specialist, hospice or hospital setting. 
The flow chart of study selection indicating reasons for study exclusion are 
provided in figure 2.1. 
Due to the small number of relevant studies the researcher conducted a 
manual search of references and citations linked to these papers and hand-
searched other published material by the lead author as well as UK 
Universities and national charities involved in pharmacy and/or palliative care 
research. Further to this a search of UK, US, and Australian journals where 
palliative care pharmacy practice research conference abstracts are printed 
was undertaken as these were most likely to provide information on studies 
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in progress. This included the International Journal of Pharmacy Practice (Int. 
J. Pharm. Pract.), American Journal of Health-System Pharmacy (Am. J. 
Health. Syst. Pharm.), Australian Palliative Care Conference website, 
Pharmaceutical Journal (Pharm. J.) and British Medical Journal on 
Supportive and Palliative and Care (BMJ Support. Palliat. Care). 
The researcher also contacted national pharmacy organisations and 
monitoring schemes including Pharmaceutical Services Negotiating 
Committee (PSNC), PharmOutcomes, National Pharmaceutical Association 
(NPA), RPS and members of the Association of Supportive and Palliative 
Care Pharmacy (ASPCP) to find relevant grey literature and service 
evaluations. Personal communications relating to data obtained are available 
in Appendix A where consent has been given. 
Further to this a general search on palliative care or end of life policy 
statements from national UK organisations was undertaken in addition to  
research on prescribing errors in primary care and general reading on 
research inquiry and qualitative research. 
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Figure 2.1: Flow chart of study selection (from PRISMA Group; (Moher et 
al. 2009)) 
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2.4 Search Results 
The electronic search produced 710 results of which 26 were duplicates and 
648 were not relevant to the research based on their title, for instance 
Buntzel et al. (2011) looked at use of complementary medicines in terminally 
ill patients, Austwick and Brooks (2003) looked at the pharmacist’s input into 
a palliative care clinic in a hospital setting and Wright et al. (2016) discuss 
the introduction of a patient’s own drugs scheme in a specialist palliative care 
inpatient unit. The remaining abstracts were reviewed with a further 27 being 
rejected. This included O'Connor et al. (2011b) which was an editorial piece, 
Tait and Swetenham (2014) which looks at the introduction of a pharmacist in 
an advanced practice role specialising in palliative care. The resulting nine 
studies were accessed and read in full. 
Due to the lack of published research a further extensive review was 
conducted identifying non-published reports, as well as the views and 
experiences of patients and carers and other healthcare professionals on the 
community pharmacist’s role within palliative care. Papers from a non-UK 
setting, strategic government and professional organisational papers on 
palliative and End of Life Care (EOLC) were also reviewed. This resulted in 
an additional seven studies that met the inclusion criteria including four 
reports evaluating the community pharmacists’ role in palliative care 
commissioned by collaborating organisations with a University research 
team. 
All studies were qualitative in nature or based on audit, service evaluation or 
survey methods. There were no interventional or controlled studies. A 
summary of the studies including the aims and objectives, study method, 
population, key findings and comments can be found in table 2.2. These 
have been divided into studies that discuss access to medicines and those 
on the community pharmacist’s role.
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Table 2.2:  A review of studies from the literature search 
 
Studies Focusing on Access to Medicines 
 
Author, 
Year & 
Location 
Aims/Objectives Method Population/ 
Sample 
Key Findings Comments 
Akram et 
al. 2012; 
UK 
Investigate 
current provision 
of palliative care 
services in NHS 
Greater Glasgow 
& Clyde (GGC) 
pharmacies and 
develop an action 
plan to improve 
services 
Qualitative - 
Focus group 
interviews 
35 
pharmacists 
from 
Community 
Pharmacy 
Palliative 
Care (CPPC) 
Network in 
GGC 
Medicines not on the 
palliative care list not 
routinely stocked in 
pharmacies. Difficulties 
with illegal prescriptions 
OOHs causing delay in 
supply. Lack of 
information causing 
difficulty in making 
supplies. Training of 
counter-staff to recognise 
palliative prescriptions to 
avoid unnecessary 
delays. Locum staff and 
some health 
professionals do not know 
how to access Network 
pharmacies. 
Funding provided by 
national charity to appoint 
facilitators and improve 
pharmacy services may 
pose limitations on 
reproducibility and 
generalisability to other 
areas. Based on model 
pharmaceutical schemes in 
Scotland. NHS Scotland 
funds free access to 
national palliative care 
formulary. 
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Author, 
Year & 
Location 
Aims/Objectives Method Population/ 
Sample 
Key Findings Comments 
Bennett et 
al. 2008; 
UK 
To identify 
differences in 
cancer pain 
management 
between younger 
& older adults in 
the community. 
Descriptive 
observational 
study 
58 adults ≥ 75 
years and 32 
adults ≤ 60 
years referred 
to specialist 
palliative care 
Experience and 
management of pain no 
different between younger 
and older cancer patients. 
10% had difficulty 
obtaining prescriptions for 
analgesia, 7% ran out of 
analgesia, 75% of 
participants had contact 
with pharmacist in the 
previous 2 weeks while 
only 17% had seen a GP. 
Patients at home drew on 
support from community 
nurses (district and 
palliative), pharmacists and 
family members in 
preference to GPs. 
Bennie et 
al. 2013; 
UK 
Palliative care 
patients and their 
carers 
knowledge of 
community 
pharmacy 
services and 
access to 
information on 
medicines  
Qualitative 
focus group 
interviews 
14 patients 
and 13 carers 
within 
Glasgow 
Health Board 
Knowledge and 
awareness of community 
pharmacy services poor 
occurring through 
friends/family or in a 
crisis. Some participants 
had no regular contact 
with their pharmacist. 
Study showed preference 
to receive information 
face to face. 
Limitations due to sample 
size and gender imbalance 
leading to under reporting 
in male participants. 
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Author, 
Year & 
Location 
Aims/Objectives Method Population/ 
Sample 
Key Findings Comments 
Faull et al. 
2013; 
UK 
Explore issues 
related to 
prescribing, 
dispensing and 
administering 
anticipatory 
medication for 
patients who 
want to die at 
home. 
Qualitative -
focus groups 
& interviews. 
Focus groups 
(54) individual 
interviews (9) 
of purposively 
selected 
HCPs 
 
Challenges included 
resourcing concerns, 
professional expertise/ 
experience, and 
relationships with patients 
and inter-professional 
working/ relationships. 
Communication, expertise 
and confidence seen as 
key factors in prescribing 
medicines at EOL. 
Included 3 pharmacists – 1 
in focus group and 2 in 
interviews.  
Ise et al. 
2010; 
Japan 
Evaluate 
availability of 
narcotics in 
Japanese 
pharmacies, 
pharmacist 
difficulties and 
Anonymous 
postal survey 
Response 
from 
1036/3000 
Community 
Pharmacies 
(34.5% 
response 
rate) 
50% of pharmacies 
dispensed narcotic 
prescriptions however 
70% had fewer than 3 
narcotic prescriptions per 
month.  
 
Regulation of narcotics in 
Japan requires specific 
license which does not 
reflect UK regulations. 
Home care less widely 
accepted in Japan. 
  
 33 
 
Author, 
Year & 
Location 
Aims/Objectives Method Population/ 
Sample 
Key Findings Comments 
Ise et al. 
2010 
(cont.) 
strategies to 
make narcotics 
available 
  Pharmacists’ lack of 
communication skills and 
inability to access patient 
information hinder 
provision of palliative care 
in the home environment 
 
Lucey et 
al. 2008; 
Ireland 
Systems analysis 
of patients under 
SPC highlighting 
factors that delay 
access to 
medication. 
Mixed 
methods – 
postal 
questionnaires 
and 
observational 
methods 
268 GPs 
(47% 
response),  
171 CPs 
(33% 
response),  
57 patients 
(38.5% 
response) 
Pharmacists and 
homecare nurses 
reported not stocking 
medications most likely 
factor to cause delay. 
GPs reported the need to 
clarify advice from 
homecare team as most 
likely to cause delay. 
Some medicines not 
funded under the Irish 
healthcare scheme and so 
are not kept in pharmacy 
stock. 
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Author, 
Year & 
Location 
Aims/Objectives Method Population/ 
Sample 
Key Findings Comments 
MacRobbie 
et al. 
2015; 
UK  
CD audit to 
identify 
prevalence and 
nature of 
prescribing 
errors. Part of a 
service delivery 
and improvement 
programme 
Audit form to 
collect data 
from 
pharmacy/GP 
dispensary 
3 pharmacies and 
4 GP dispensing 
practices in NHS 
Highland total of 
352 prescriptions. 
Legal errors were 3.9% and 
clinical errors 2.3% of all 
CD prescriptions. Legal 
errors related to dose not 
specified, total quantity not 
in words and figures and 
formulation. Error resolution 
was 15mins or less in over 
60% of prescriptions and 
30% were resolved in one 
hour. One prescription took 
over 24 hrs to resolve but 
was not urgent. 
Used data collection 
form from Stuart 
(2013). 
Included all CDs 
except substance 
misuse and 
stimulants. 
Small number of sites 
in remote location 
including dispensing 
practices which could 
skew and potentially 
bias results 
Tait et al. 
2013; 
Australia 
Baseline survey 
to quantify 
access to 13 
palliative care 
medicines in 
South Australian 
community 
pharmacies 
Observational 
study – postal 
survey 
455 pharmacies - 
23.7% response 
rate 
Each pharmacy stocked an 
average of 3 of the 13 
medicines (range 0-12). 
Thirteen (12.3%) of 
pharmacies had none of 
the medicines. 
Low response rate. 
List of medicines from 
inpatient setting not 
reflective of essential 
medicines in 
community setting. 
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Author, 
Year & 
Location 
Aims/Objectives Method Population/ 
Sample 
Key Findings Comments 
Bennie et 
al. 2010; 
UK 
Macmillan 
pharmacist 
facilitator project 
to assess gaps in 
service provision 
to inform a 
quality 
improvement 
programme. 
Mixed 
methods – 
exploratory 
data analysis 
Qualitative – focus 
and individual 
interviews of CPs, 
GPs, DNs, 
purposive sample 
of 5 paid and 16 
family carers 
Difficult for CP to identify 
palliative prescriptions, 
minimal or no clinical 
information transfer OOHs, 
difficulties prescribing & 
accessing unlicensed 
drugs, pharmacists lack of 
knowledge/confidence, lack 
of CD storage space, lack 
of continuity of care, 
medicines not on the 
palliative list/ or wrong 
strength. Changes in 
pharmacy staff on 
weekend, problems 
contacting GP to 
clarify/change prescription. 
Training and use of taxis to 
transfer medicines. 
Problems for carers with 
part supplies, anxiety 
leaving patient on own. 
Pharmacies, approachable 
and accessible. 
Specific funding 
through Scottish 
pharmaceutical model 
scheme and 
Macmillan to support 
pharmacist facilitators 
to work with CPs. May 
not be reproducible 
without funding. Some 
carers had issues due 
to lack of transport 
others experienced 
excellent service as 
pharmacy delivered 
items. Pharmacies 
unable to share 
medicines due to 
changes in Medicines 
Healthcare Regulatory 
Authority (MHRA) 
wholesale licensing 
arrangements. 
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Studies on the theme of the community pharmacist’s role 
 
 
Author, 
Year & 
Location 
Aims/Objectives Method Population/ 
Sample 
Key Findings Comments 
Borgsteede 
et al. 2011;  
Netherlands 
Knowledge of 
pharmacists on 
pain management 
and opioids, co-
operation with 
physicians and 
barriers they 
experience to 
providing good 
EOLC. 
Written 
questionnaire  
Random 
sample of 412  
Lack of knowledge may 
hamper pharmacists’ 
contribution to improving 
palliative care. 
Response rate 45%. 
Non-validated 
questionnaire with 
limited themes. 
Inclusion of 
physician assisted 
euthanasia which is 
not provided in UK. 
Potentially biased 
sample with full time 
pharmacists less 
likely to respond. 
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Author, 
Year & 
Location 
Aims/Objectives Method Population/ 
Sample 
Key Findings Comments 
Jiwa et al. 
no date; 
Australia 
Exploring the role 
of the pharmacist 
in palliative care in 
order to implement 
palliative care 
medicines 
management 
reviews 
Mixed 
methods – 
feasibility trial 
13 pharmacists 
completed 
study on 40 
patients. 
Focus groups 
and individual 
interviews with 
54 pharmacists 
44 nurses and 
10 GPs across 
4 Australian 
states. 
Pharmacists made 145 
recommendations of which 
93% rated positive, 5% 
neutral and 3% negative by 
expert panel. Interviews 
showed lack of 
understanding and 
knowledge could lead to 
pharmacists feeling out of 
depth. GPs see 
pharmacists as limited to 
dispensing medicines and 
obtaining stocks. 
Pharmacists see role in 
medicines supply and 
supporting patients/carers. 
Nurses and pharmacists 
both positive that extending 
the role would be beneficial 
to patients. 
Interrater variability 
of expert panel 
showed 
inconsistency. 
Unclear whether 
carers had separate 
interviews to other 
health care staff. 
Report not peer 
reviewed or 
published in journal. 
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Author, 
Year & 
Location 
Aims/Objectives Method Population/ 
Sample 
Key Findings Comments 
Needham et 
al. 2002; 
UK 
Assess CP 
interventions in 
supporting 
palliative care 
patients 
Non-
randomised 
cohort study 
using panel 
assessment to 
review 
interventions  
25 patients 
over 10 
months. 130 
interventions 
made by 15 
pharmacists. 
81% of interventions were 
judged by the panel as 
likely to be beneficial. 3% 
likely to be detrimental to 
patients’ wellbeing, 6% 
deemed inappropriate, 8% 
could not be categorised by 
the expert panel and 2% of 
cases there was insufficient 
information available for 
categorisation. 
30 (23%) of 
interventions 
excluded from the 
study due to lack of 
information. Unlikely 
to be reproducible 
study due to 
subjective nature of 
panel assessment. 
No evaluation of user 
perspective. Part-
industry funded. 
Ethical approval not 
mentioned. 
O’Connor et 
al. 2011a; 
Australia 
Understand CPs 
understanding of 
effective 
communication for 
palliative care 
patients and 
carers and explore 
what  
Multiple 
qualitative 
case study – 
16 focus 
groups and 19 
interviews 
122 
participants  
identified by 
purposive 
maximum 
variation 
sampling 
including 
CPs identified the need for 
effective communication 
but saw difficult balance in 
responding to emotional 
needs and focusing on 
medication/busy pharmacy 
environment. 
Focus on education 
of CPs. Saturation of 
themes and rigour of 
analysis measured. 
Variety of Healthcare  
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Author, 
Year & 
Location 
Aims/Objectives Method Population/ 
Sample 
Key Findings Comments 
O’Connor et 
al. 2011a; 
(cont.) 
CPs need to 
facilitate effective 
communication 
 54 CPs from 
regional and 
metropolitan 
areas in 
Australia 
CPs may lack strategies to 
deal with emotional distress 
and bereavement support 
Professionals 
(HCPs) and carers 
included. 
O’Connor et 
al. 2013; 
Australia 
CPs attitudes 
towards palliative 
care in particular 
attitudes towards 
providing services 
and support for 
palliative care 
patients and 
predictors of 
attitudes to 
providing services 
and support. 
Cross-
sectional 
descriptive 
survey 
250 CPs 
across 
Australia 
completed the 
survey 
Pharmacists’ knowledge 
and beliefs were predictors 
of positive attitudes to 
providing services and 
supports for palliative care 
patients. 
Building CPs knowledge 
and understanding of 
palliative care underpins a 
positive attitude and the 
provision of services and 
support to palliative care 
patients. 
Response rate low 
26%; may have 
resulted in a biased 
sample. 
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Author, 
Year & 
Location 
Aims/Objectives Method Population/ 
Sample 
Key Findings Comments 
Savage et 
al. 2012; 
UK 
To describe 
pharmacists’ place 
in cancer pain 
pathway; identify 
where 
pharmacists could 
support cancer 
patients medicines 
management and 
opportunities to 
improve 
communication 
with patients and 
healthcare 
professionals 
Semi-
structured 
interviews 
analysed 
using 
Framework 
method. 
25 CPs in 3 
areas of 
England 
Access to palliative care 
medicines problematic, 
MURs rarely done. Limited 
patient or other healthcare 
professional contact 
regarding patient care. 
Pharmacists feel isolated 
from care team but aspired 
to do more. Variable 
knowledge on opioids. 
Pharmacists potentially 
inhibited by fear of 
discussing wider emotional 
and social aspects. Wide 
range of concerns raised by 
family members indicating 
unmet needs. 
CPs from range of 
areas/types of 
pharmacies. 
 41 
 
2.5 Findings from the Literature 
The literature search revealed very little published research into community 
pharmacists’ delivery of palliative care services with most studies being 
exploratory or qualitative in nature. Most of the studies were from the UK and 
Australia with only a minority of studies coming from Europe and Japan. No 
systematic reviews were found. Three unpublished studies were 
commissioned through Universities and one unpublished study was 
completed as part of an MSc qualification. 
Three studies (Akram et al. 2012; Bennie et al. 2010; Bennie et al. 2012) 
evaluated the community pharmacists’ experience of delivering palliative care 
and improving access within a community pharmacy palliative network 
developed under a Scottish model scheme for pharmaceutical care. This 
model was supported through external funding by a national UK charity and 
represents a difference in the UK devolved governments arrangements for 
funding of healthcare services and so is not reflective of the current NHS 
funding for pharmacy services in England. Nevertheless the research offers 
insight into barriers the pharmacists had to overcome to improve access to 
palliative care medicines and may be a positive model that could be adapted 
for implementation in other areas. 
2.5.1 Responsiveness in provision of end of life drugs 
The unpredictable nature of palliative care medication and the requirement to 
provide prompt supplies, particularly OOHs can cause frustration if 
pharmacists do not have adequate supplies available (Akram et al. 2012; 
Savage et al. 2012) This can be a problem with unlicensed medicines or if 
the prescription contains medicines not included on an approved stock list 
(Akram et al. 2012; Bennie et al. 2010; Tait et al. 2013). Bennie et al. (2010) 
and Savage et al. (2012) both found that doctors were not always aware of 
what was on the stock list and sometimes prescribed strengths not available 
in the pharmacies. This finding is replicated in prescribing data from Sheffield 
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CCG, which showed that for the twelve months to August 2015, 24.77% of 
midazolam prescriptions were for strengths not recommended in palliative 
care and not on the stock list (ePACT:NHSBSA 2014). Pharmacies may also 
be unaware of the existence of a specified list (Faull et al. 2013). Further 
delays may be triggered by the legality of prescriptions necessitating the 
pharmacist to make professional and ethical judgements in the pursuit of 
supporting patient care (Akram et al. 2012; Lucey et al. 2008; Savage et al. 
2012). A survey of 168 pharmacists and GPs in primary care by Lucey et al. 
(2008) reported that 31.5% of respondents thought that palliative care 
prescriptions were written incorrectly. An MSc project by Stuart (2013) found 
that one in eight controlled drug prescriptions contained errors, 86% of which 
were legal errors particularly occurring during the OOH period. A further audit 
reported in MacRobbie et al. (2015) found 4% of controlled drug (CD) 
prescriptions contained illegal errors. This raises ethical dilemmas particularly 
when the prescriber cannot be contacted out-of-hours, causing delays in 
obtaining urgent palliative care medications. Further to this it is unclear 
whether criminalisation of dispensing errors, where pharmacists can be 
prosecuted for a dispensing error, and increased CD regulations after the 
Shipman murders (DH 2006) have affected the community pharmacists’ 
involvement in palliative care. 
2.5.2 Community pharmacist involvement in palliative care 
2.5.2.1 Facilitators 
Community pharmacists are said to be accessible with 99% of the population 
including those in the most deprived areas of England able to access a 
pharmacy within 20 minutes by car and 84% of all adults – 78% for health-
related reasons - visiting a pharmacy each year (DH, 2008). In a study by 
Bennett et al. (2009) 75% of older palliative cancer patients reported they 
had contact with their pharmacist in the two weeks prior to their interview but 
only 17% had seen their GP.  
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2.5.2.2 Barriers 
The research identified the following themes as barriers to the community 
pharmacists’ involvement in palliative care;  
• access to patient records and clinical information (Akram et al. 2012; 
Ise et al. 2010; Savage et al. 2012) 
• reimbursement programmes (Walker 2010)  
• education, knowledge and communication skills (Hussainy et al. 2006; 
Hussainy et al. 2010; Ise et al. 2010; Borgsteede et al. 2011; 
O'Connor et al. 2011a; Savage et al. 2012; O'Connor et al. 2013).  
• Regulations surrounding the distribution and control of opioids also 
had a negative effect on access and stockholding in community 
pharmacies in Japan (Ise et al. 2010) 
 
2.5.2.3 Communication 
Despite it being identified that pharmacists can and should have greater 
involvement in palliative care and the need for better communication between 
GPs and community pharmacists, there seems to be a lack of international 
research regarding collaborating within this arena with pharmacists feeling 
isolated from the primary care team (Savage et al. 2012). GPs reported that 
the pharmacists’ role was in medication dispensing and supply (Jiwa no date) 
and they seemed to have a lack of insight into the pharmacists’ role of 
supporting patients and their carers. In contrast GPs in the US acknowledge 
the role of community pharmacists providing pain management and 
symptomatic advice as well as psychological support for palliative care 
patients in the home environment (Atayee et al. 2008). A subgroup of 
pharmacies in an Australian study were statistically more likely to hold stock 
of palliative care medications where they received information on the 
palliative status of a patient and greater communication from healthcare 
practitioners (Tait et al. 2013), a point that the authors regarded required 
further investigation.  
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2.5.2.4 Education and knowledge  
Authors tend to agree that pharmacists’ experiences in palliative care may be 
limited due to time pressures and a fear of getting involved in emotional 
issues for example when bereaved relatives visit the pharmacy (O’Connor et 
al. 2011a; Savage et al. 2012). Furthermore, a lack of information about the 
patient and their diagnosis can inhibit the pharmacists’ interventions and 
clinical input in palliative care (Needham et al. 2002; Savage et al. 2012). 
Pharmacists are physically and professionally isolated from the 
multidisciplinary team within the GP practice; authors suggest that closer 
proximity and increased collaboration would enhance their involvement 
(Needham et al. 2002; Savage et al. 2012). 
Researchers highlight the need for additional communication skills and 
training for community pharmacists to fulfil their role in palliative care 
(Needham et al. 2002; O’Connor et al. 2011a) as well as for pharmacy 
support staff (Akram et al. 2012; Bennie et al. 2013; Bennie et al. 2015). 
Sheffield pharmacy contractors participating in the service specification for 
palliative care medications must identify a responsible pharmacist to 
complete an e-learning pack provided by the Centre for Pharmacy 
Postgraduate Education (CPPE), though this would not necessarily cover all 
pharmacists or staff working in the pharmacy. It is not known whether this 
training or lack of training limits staff contribution without the necessary 
advanced communication skills. Studies of other healthcare professionals 
detail the need for specific educational programmes including communication 
skills training to enable them to undertake their role in palliative care 
(Gardiner et al. 2012a). This corresponds with other research where 
community pharmacists have requested the need for both palliative care and 
communication skills training as well as support in dealing with emotional 
issues (Akram et al. 2012; O’Connor et al. 2011b; Savage et al. 2012). 
Misconceptions on the use of opioids in non-cancerous conditions may limit 
the pharmacists’ contribution to palliative care. A study by Gardiner et al. 
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(2012b) showed that healthcare professionals did not administer opioids to 
COPD patients with dyspnoea as they misconceived that they could hasten 
death. Further concerns on the underuse of opioids in primary care were 
reported following the Harold Shipman murders (Gott et al. 2010). O’Connor 
et al. (2013) highlighted gaps in the community pharmacist’s knowledge in 
palliative care including a misconception that oral morphine should not be 
used by people in respiratory distress and recommended specific education 
and continuing professional development in palliative care targeted towards 
community pharmacists. 
Research has focused on evaluating community pharmacist interventions in 
palliative care (Needham 2002) or qualitatively looking at specific aspects of 
the pharmacists’ role e.g. cancer pain (Savage et al. 2012), or 
communication issues (O’Connor et al. 2011a). There is no research 
focusing specifically on pharmacists providing an enhanced palliative care 
service who also have access to patient care records as in Sheffield, which 
was a pilot site for community pharmacy access to SCR. 
2.5.2.5 GP and other healthcare professionals attitudes to the 
pharmacist’s involvement in palliative care 
GPs are seen to be the main authority on palliative care and prescribing 
(Bennie et al. 2013); however, nurses have an increasing role (Wilson et al. 
2014; Payne et al. 2015). The importance of personal trusting relationships 
on which to facilitate palliative care and anticipatory prescribing 
communication within the primary care team has been previously stated 
(Faull et al. 2013; Wilson and Seymour 2017) however GPs tend to have a 
traditional view of the pharmacist’s involvement in dispensing and supply of 
medication (Jiwa no date) and pharmacists rarely had contact with members 
of the primary care team (Savage et al. 2012). In the study by Jiwa (no date) 
GPs considered community pharmacists would not be able to understand the 
patient or carer’s needs without experience in palliative care but the GPs also 
conceived that it was the pharmacists’ role to focus on medications - though 
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this was not specifically related to palliative care. Where interprofessional 
collaboration occurs between GPs and community pharmacists this improves 
care (Gallagher and Gallagher 2012); however, this may rely on adequate 
remuneration, interprofessional education and previous experience of 
working collaboratively (Gallagher and Gallagher 2012; Van et al. 2012; Jov 
et al. 2014). 
In conclusion, community pharmacists are envisaged to be an important part 
of the national strategy to provide medicines and advice for palliative care 
patients in the community (NICE 2004; Department of Health (DH) 2008a; 
RPS and RCGP 2011; RPS England 2016); however, little is known about 
their role in the primary care team. There is currently no published research 
addressing the delivery of palliative care pharmacy services within the 
context of the English pharmacy contract. Further research with community 
pharmacists will help to understand their experiences and concerns and the 
impact this has on timely access to palliative care medications for patients 
and their carers. The lack of published literature in this area makes a clear 
case for taking forward research into the community pharmacist’s role in 
palliative care, in particular their role in providing timely access to palliative 
care medicines.  
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Chapter 3: Methodology and Methods 
3.1 Introduction 
The following chapter is divided into two parts: methodology and methods. 
The methodology section outlines the underlying theoretical perspective and 
the rationale for using a mixed methods approach. Following this different 
data collection methods are discussed including a critical account to justify 
the methods chosen within this study. After this, the concepts of validity and 
reliability in quantitative and qualitative research are described with further 
information on the research strategy chosen including sampling, access and 
recruitment, and analytical techniques to ensure rigour in the study approach. 
The ethical issues relevant to this study are then considered prior to the 
second section where the specific methods utilised in this study are 
described in more detail. 
3.2 Part One: Methodology 
3.2.1 Theoretical perspective 
Understanding the underlying theoretical and philosophical perspective of the 
research approach is necessary since phenomena can be studied from 
different stances with the researcher not being wholly neutral in the process. 
Research inquiry is based on ‘a range of views about what exists (ontology) 
and how we may know about it (epistemology)’ (Knight 2002: 23). Different 
viewpoints are historically associated with different methods of inquiry. 
Positivism believes in a single reality and is associated with quantitative 
methods while constructivism believes in multiple realities and uses 
qualitative methods (Lincoln and Guba 1985). In reality, investigators take a 
continuum of viewpoints rather than a dichotomous perspective (Teddlie and 
Tashakkori 2009) with the middle ground between the two labelled as 
pragmatism. Pragmatists use the full range of qualitative and quantitative 
methods choosing the most appropriate method for the research question 
depending on whether an inductive or deductive approach is required. The 
 48 
 
choice of methods should be conventional for the epistemological and 
ontological viewpoint or must be fully justified as being appropriate to answer 
the research question. This research study follows a pragmatist approach.  
Certain theoretical frameworks are associated with qualitative enquiry for 
instance: phenomenology, ethnography, and grounded theory (Bryman 2012; 
Charmaz 2006) and these frameworks hold or support the theory generated 
within the study. Theoretical frameworks may also be linked to an 
intervention or be latent arising from the literature review but must be a good 
fit for the research problem. It is suggested by Evans et al. (2011) that a 
theoretical framework aids navigation and organisation of research in what 
Schon (1983) calls the “low, swampy ground” of mixed methods research 
though Evans et al. (2011) go on to report there is no widely accepted 
framework to guide inquiry and few mixed methods studies describe the use 
of a framework. The theoretical framework supports decisions in the study 
design including sampling and recruitment, data collection, analysis and 
interpretation (Evans et al. 2011). Whichever theoretical perspective is taken 
different methods of data collection are used as appropriate for the research 
aims and objectives. To support qualitative data analysis and interpretation 
an analytical framework is used to facilitate coding, management and 
organisation of the data so as to reduce and summarise the data to support 
answering the research questions (Gale et al 2013). Further information on 
data analysis is provided in 3.2.8 and the use of other theoretical frameworks 
within 5.5. 
3.2.2 Quantitative versus qualitative research 
Historically, quantitative research is viewed as deductive with the purpose of 
confirming or testing theory while qualitative research is inductive and 
generates theory. Each method of inquiry is fundamentally different in its 
viewpoint. Critics of quantitative research describe the reliance on tools and 
instruments to accurately measure variables as artificial, failing to take 
account of social constructs and everyday life (Blumer 1956; Schutz 1972; 
Cicourel 1982). On the other hand, Bryman (2012) argues that qualitative 
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research is subjective, is not representative, lacks transparency, may cause 
problems with generalisation, and is difficult to replicate. Hardy and Bryman 
(2004) point out that qualitative and quantitative research are similar in many 
ways. For instance, both are used to answer research questions, reduce 
large amounts of data, seek out variation and frequency, and relate findings 
to the literature. Furthermore, Hardy and Bryman (2004) argue that both 
strategies are concerned with ensuring clarity on procedures for 
transparency, validity, and reducing error. 
Besides the similarities, quantitative and qualitative research may cause 
problems when used together as expressed by Huberman and Miles ‘In the 
disorderly world of empirical research, independent measures never 
converge fully’ (Miles and Huberman 1994: 438). It is necessary to clarify 
how different research methods are combined, the weighting and timing of 
each as part of the mixed methods research design to inform the theoretical 
framework.  
3.2.3 General introduction to mixed methods research 
Combining qualitative and quantitative research within mixed methods 
research is recognised as both feasible and desirable even though they have 
separate and distinctive epistemological and ontological assumptions 
(Bryman 2012). Mixing research methods allows the researcher to use 
different methods to answer the research questions to provide a 
comprehensive account of the phenomenon, which can enhance strengths 
from either method on its own. Additionally, it supports triangulation of data 
increasing the validity and supporting explanation of findings generated by 
the other method, as well as providing a diversity of views and greater 
credibility from either method alone (Bryman 2012). Mixing methods is 
particularly suited to social research where little is known about the 
phenomena and there is a need for greater understanding about a subject 
(Ritchie et al. 2014). 
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In the case of the community pharmacist’s involvement in palliative care, 
there are complexities due to communication factors, attitudes, behaviours, 
motivation and relationships that cannot be measured or described through 
quantitative methods alone. Due to the complexity and multiplicity of factors 
involved in community pharmacists’ provision of palliative care, (Creswell 
2007: 40) suggests the use of qualitative methods to obtain ‘a complex 
detailed understanding of the issue’. In addition, the use of quantitative 
methods allows measurement of the issues, which lends more weight to the 
evaluation. Combining methods provides a number of ontological 
perspectives, answering different questions posed within the research. 
Quantitative methods on their own would not take account of the behaviours 
and complexities involved and would only give a ‘static’ picture of the 
pharmacists’ involvement in palliative care (Bryman 2012). Utilising a 
combination of data collection methods can provide richness and detail 
allowing explanation of delays in obtaining medicines as well as the 
community pharmacists’ experiences in delivering palliative care services. 
A benefit of mixed methods is how the combined approaches ‘triangulate’ 
each other, adding to the phenomena to validate the theory (Ritchie et al. 
2014). Gilbert (2008: 128) states that mixing data from qualitative and 
quantitative methods reveals ‘different dimensions of a phenomenon’ helping 
to provide a fuller picture of the issue. 
Previous international research has not focused on community pharmacists’ 
actual experiences in palliative care; so little is known about their views, 
perceptions and experiences in delivering palliative care services. Utilising a 
qualitative approach captures those experiences and the context to 
understand the pharmacists’ involvement and processes leading to delays in 
obtaining palliative medicines. Combining qualitative and quantitative 
methods answers the research problem, the aims and objectives as well as 
provides greater insight into the experience and perspectives involved.  
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3.2.3.1 Types of mixed methods studies 
Around forty types of mixed methods strategies have been reported within 
the wider literature (Tashakkori and Teddlie 2003), many of which are 
individualised for a specific study. Creswell and Plano Clark (2011) identify 
six major design strategies for combining mixed methods research namely: 
triangulation, embedded, explanatory, exploratory, transformative and 
multiphase designs. It is beyond the scope of the thesis to describe these 
strategies except to say the strategy chosen must help answer the research 
problem, the aims and objectives of the research, and will depend on the 
researcher’s expertise, the available resources, and the audience 
expectation. In this study, a sequential explanatory mixed methods approach 
was chosen with a quantitative phase followed by a qualitative phase. The 
reasons for this choice will be outlined further below. 
3.2.3.2 Factors to consider in the choice of mixed methods 
research strategy 
There are three decisions to make in the choice of a mixed methods research 
strategy namely: the timing of the use of data whether sequential or 
concurrent, whether the qualitative or quantitative methods are given equal or 
unequal weighting, and how the datasets are integrated, e.g. merged, 
embedded or connected (Creswell and Plano Clark 2011). 
Sequential research methods have the advantage that they can be done by a 
single researcher without a research team, which is helpful when there are 
limited resources. In addition, they are straightforward to implement and 
report on. Sequencing a qualitative phase after a quantitative phase supports 
the researcher to explain findings generated from the quantitative data as 
well as giving more detail on the phenomenon (Bryman 2012; Ritchie et al. 
2014). This is particularly helpful where group sizes are small, where a group 
may have perspectives that cannot be fully explored in the quantitative study, 
or where detailed statistical analysis cannot be performed (Ritchie et al. 
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2014). By sequencing the quantitative phase before the qualitative phase, the 
researcher was able to identify participants for purposeful sampling to 
support explanation of significant and outlier results. Though a sequential 
mixed methods approach has the advantages outlined above there is also 
the disadvantage that the research process can be prolonged due to the 
extensive time required for data collection and analysis for each component. 
Furthermore, having the necessary skills and training to undertake both 
components can be problematic. This was mitigated to some extent as the 
researcher completed specific training in qualitative interviewing and data 
analysis, having already completed quantitative and qualitative methods 
within the DPharm programme. Support from research supervisors 
experienced in qualitative methods also supported the qualitative data 
analysis. 
3.2.3.3 Weighting of quantitative and qualitative elements 
Whether qualitative or quantitative methods are given equal or unequal 
weighting depends on the research question, the researcher’s experience 
and the resources available. A pragmatic approach would support an equal 
approach; however, an unequal approach is also acceptable depending on 
the research question (Creswell and Plano Clark 2011). For example, a 
qualitative approach could be given higher priority within a study to determine 
the relevance of findings within the context of a specific culture or setting. 
More resources are required where each is given equal weighting. Previously 
the Sheffield CCG evaluation of the pharmacy LCS was quantitative in 
nature. Likewise guidance from the Medical Research Council (MRC) on 
research methods for developing and evaluating complex interventions 
focuses on measurable outcomes using experimental methods (Craig et al. 
2008). It is therefore expected that the CCG, who commission the pharmacy 
LCS and are the expected audience for this study, would likely be interested 
in facts and quantifiable data, which would support an unequal weighting 
towards a quantitative design.  
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3.2.3.4 Choice of strategy chosen for this study 
Explanatory design is a two-phased mixed method design in which 
quantitative data are collected in Phase 1 and qualitative data in Phase 2 
with the purpose of helping to explain the quantitative results, or guide 
purposive sampling of participants in Phase 2 (Creswell and Plano Clark 
2011). It can be particularly useful in explaining significant, outlier or 
surprising results (Morse 1991). 
The advantages and challenges of an explanatory design as suggested by 
Creswell and Plano Clark (2011) are as follows: 
Advantages - 
• it is straightforward to implement 
• there is a clear delineation between phases, which makes it simple for 
the reader to grasp 
• it can help purposive sampling and therefore a smaller sample size 
for the second phase may be used 
• it can appeal to those who want a quantitative orientation 
Challenges - 
• it can take time to implement two separate phases 
• the qualitative phase may have a small number of participants but can 
take longer than the quantitative phase 
• decisions must be made on the recruitment of individuals to the 
second phase and how these are specified in advance of the findings 
being available. 
An explanatory design was chosen to support answering the objectives within 
each phase of the study. In Phase 1, the pharmacy data collection was 
designed to investigate prescription errors and other variables that may 
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impact on the time to access palliative medicines on prescription within the 
participating pharmacies and in Phase 2, purposively sampled pharmacists 
and healthcare professionals involved in the delivery of palliative care were 
interviewed to ascertain their views on those factors facilitating or limiting the 
community pharmacist’s role in palliative care. 
3.2.3.5  Visual model of strategy 
Creswell (2003) suggests the use of a visual model in mixed methods 
research to show the implementation, priority, integration, and theoretical 
perspective of the study. In this study, the quantitative data was collected 
prior to the qualitative data with the quantitative data originally having priority 
in explaining the research. A visual model depicts this sequential explanatory 
design in figure 3.1 using notation by Morse (1991) as follows: 
Figure 3.1: Visual model of explanatory sequential research design 
(modified from Creswell, 2003) 
 
3.2.3.6  Critical justification of methodology 
Mixed methods research provides a strategy allowing the researcher to 
understand the phenomenon being studied from different perspectives 
allowing explanation and interpretation of the results. Quantitative studies 
measure variables requiring the researcher to have insight into the important 
variables contributing in a given situation but since previous research has not 
accounted for all such variables or their impact on accessing palliative 
medication it would not be possible to undertake a larger quantitative study 
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without examining the feasibility of testing such variables first.  Investigating 
prescription delays and relating this to variables such as prescription errors 
and medicines not stocked on the pharmacy LCS stock list, as supported 
through literature findings, helped the researcher identify such variables as 
well as investigate processes and systems that could be improved to obtain 
timely access to palliative care medicines, which was explored further within 
Phase 2 of the study. The qualitative element provides further investigation 
into those factors that support or hinder the pharmacist’s role in providing 
timely access to palliative care medication as well as explore their wider role 
in supporting palliative patients in physical, psychological and other aspects 
of symptom management. This enabled the researcher to explore the 
pharmacist’s involvement in palliative care beyond a supply function as set 
out in the research objectives and provides new insights not predicated 
beforehand.  
The emphasis within the research was to find factors that support or hinder 
the community pharmacist’s delivery of palliative care services and to 
measure timeliness in accessing medicines. Local commissioners of 
community pharmacy services would be most interested in figures and 
numeric data, and the researcher’s background in audit and service 
evaluation make it easier to emphasise the quantitative component of the 
research. As a single researcher, it would be difficult to collect quantitative 
and qualitative data concurrently; therefore, a sequential phased model was 
chosen. 
A sequential mixed methods research design was chosen to provide a 
flexible approach in answering the research objectives; collection of specific 
quantitative data measured delays in dispensing processes and those 
variables having the most impact on timely access, while qualitative data 
provided an in-depth comprehensive explanation of the delays and other 
contextual information from the perspective of healthcare professionals. The 
quantitative element was explored and analysed first according to the 
research objectives to subsequently inform the sample chosen for the second 
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qualitative phase and inform questions within the semi-structured interview 
guide. This allowed the researcher to focus on those elements that were 
determined to be important factors in supporting access to palliative 
medicines within community pharmacies within the limited timeframe of the 
interviews. Further details on the sampling methodology are provided in 
section 3.2.6. The sampling strategy chosen allowed a deeper look into 
significant results without requiring a large number of participants. This 
reduced the timeframe for this phase as well as reducing the amount of 
resources required. Data from each phase was connected; the analysis of 
one data set leading to the subsequent need for the other data. This 
connection guided the selection of participants for Phase 2 and ensured 
specific research questions were asked in the qualitative phase to provide an 
explanation of significant (and non-significant) results. 
3.2.4 Data collection methods 
3.2.4.1  Introduction to data collection methods 
As explained earlier different data collection methods are associated with the 
various theoretical perspectives. Johnson and Turner (2003) describe six 
data collection techniques associated with mixed methods research 
including: observation, unobtrusive measures, focus groups, interviews, 
questionnaires, and tests.  
Questionnaires and tests can provide measurable data but they usually 
require a large sample size, and the closed questions and fixed responses 
are unlikely to capture the nuances of complex experiences as detailed in the 
research objectives. Nevertheless questionnaires are easy and cheap to 
administer and allow respondents to remain anonymous. A questionnaire 
was chosen for the customer survey within this study for the reason of 
remaining anonymous; more details of which can be found in section 3.2.3. 
Observation is often associated with ethnography where researchers are 
immersed in a culture or field of naturalistic inquiry. This method would 
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require extensive time in the field observing community pharmacists in their 
day to day work but may not be specific to palliative care where this is 
observed at a low frequency in the community pharmacy environment.  
Unobtrusive measures include documentary analysis, diaries and other 
reports. At present no such documentary data is collected either locally or 
nationally making unobtrusive methods or analysis impractical.  
Another option would have been to use focus groups; however, due the small 
number of sites, with pharmacists working across various locations, this 
would be impractical to arrange. In a study by Faull et al. (2013) looking at 
the challenges community health professionals encountered in anticipatory 
prescribing, community pharmacists tended to choose individual interviews 
over focus groups due to such practical reasons. Focus groups could have 
also been chosen for the healthcare professional interviews but would have 
been difficult to arrange considering the small number of consenting 
candidates; most of whom worked across separate locations. Arranging a 
suitable location and work time to conduct the interview would have been 
problematic and could have led to delays in the research process. If a 
suitable time cannot be arranged for a focus group, this could lead to 
problems with recruitment, for instance, where participants have caring 
responsibilities. Furthermore, focus groups could cause difficulties for the 
researcher in recording, transcribing and running the focus group single-
handedly. Seymour and Clark (1998) suggest the use of focus groups and 
documentary analysis in palliative care research though neither of these 
methods would provide the in-depth data given by interviews. 
Interview methods allow exploration of ‘people’s individual and collective 
understandings, reasoning processes, social norms, and so on’ (Mason 
2002: 56) providing an ‘insider’s view’ on the phenomenon. Interviews are 
often employed in qualitative research when an in-depth understanding is 
sought providing an interpretive approach combined with other methods. In 
the next section, I will discuss different interviews and the strategy chosen 
within this study in more depth. 
 58 
 
3.2.4.2 Interviews 
Bryman (2012) summarises twelve major types of interview; ten of which 
relate to qualitative research including semi-structured interview, 
unstructured interview, intensive interview, qualitative interview, in-depth 
interview, focused interview, focus group, group interview, oral history, and 
life history. The other two, structured and standardised interviews, are used 
in quantitative and survey research, and deliver identical questions often with 
fixed answers similar to questionnaires and survey instruments. The 
disadvantages of these approaches have been discussed in section 3.2.4.1. 
In this study, the researcher determined that individual interviews rather than 
group or focus groups would be necessary due to the practical reasons 
detailed in section 3.2.4.1. Individual interviews are necessary to capture the 
detail, description and rich data of the pharmacists’ experiences to answer 
the research questions and objectives. Individual interviews would be 
essential because each pharmacist’s circumstances and perspectives may 
differ. The healthcare professionals had different roles such as GP, nurse, or 
palliative care specialist; so individual interviews allow the researcher to tailor 
the questions to the participant thereby maximising data collection within the 
available time allowed for the interview. Originally the study was designed so 
that interviews were approximately 45 minutes long to generate rich data as 
less than 30 minutes is unlikely to be productive (Robson 2002). Interviews 
with other healthcare professionals were designed to be between 20-30 
minutes long to minimise the time taken away from other patient-facing 
clinical duties whilst maximising time on the relevant research questions.  
Individual interviews were also chosen to minimise resource time for each 
healthcare professional and allow the interviews to fit between surgeries or 
patient visits.  
Rice and Ezzy (1999) state the use of a semi-structured interview guide 
reduces the risk of bias affecting the interviewee’s response. Semi-structured 
interviews were chosen for this study since they provide a flexible delivery 
allowing the researcher to listen and probe further to elicit meaning during the 
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interview as well as modify questions as the research progresses. The use of 
a topic guide ensured that the interview focused on the research questions. 
3.2.5 Ensuring rigour 
3.2.5.1 Introduction to the concept of rigour 
In quantitative research rigour is attained through applying specific tools and 
instruments so that variables are controlled. Validity is assured through using 
a representative sample of the population, randomisation, exclusion or 
inclusion of specific variables, and specific statistical analytical methods. By 
contrast, qualitative research variables may be unexpected and instruments 
may be designed in response to the social setting. According to Holliday 
(2016), researchers need to explain and justify their choice of social setting, 
research activities, themes and focuses, how data is captured and recorded 
as well as being reflexive on opportunities and assumptions in the research 
process to ensure rigour. 
3.2.5.2 Honesty, reliability and validity 
Mason (2002: 39) defines reliability as the ‘accuracy of your research 
methods and techniques’; likewise, validity is ‘measuring what you say you 
are.’ Ballinger (2004) explains that reliability is being able to reproduce the 
same results for a predetermined set of parameters and validity refers to how 
well the results represent the truth. 
The terms have been considered for each of the data collection methods 
used within the study and are presented with corresponding issues in table 
3.1.
 60 
 
Table 3.1: Honesty, reliability and validity in the study 
Tool used Honesty Reliability Validity 
Pharmacy data collection Provides observational field 
data. 
Prolonged data collection 
period. 
Relies on others to complete 
the data form leaving room 
for bias. 
 
Relies on identifying all 
relevant data. 
Relies on pharmacy site to 
complete form. 
Sample bias.  
Use of mixed methods. 
Requires adequate sample 
size. 
Complex paper form which 
could mean data is missed. 
Not a validated form. 
Customer survey Provides customers views. 
Potential sample bias as 
pharmacy team distributes 
survey. 
Way survey is delivered by 
pharmacy team and 
surrounding conditions could 
influence completion. 
Simple form easy to 
complete. 
Relies on customer to read 
and interpret questions. 
Difficulty if customer is 
distressed or in a rush 
leading to unreliable 
answers. 
Not a validated instrument. 
Questions may not be 
answered or form not 
completed resulting in 
missing data. 
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Tool used Honesty Reliability Validity 
Interviews Member checking of 
transcripts. 
Inclusion of broad range of 
healthcare professionals. 
 
Full transcript of recorded 
interview. 
Use of mixed methods. 
 
Researcher bias in 
interpretation. 
Reflexivity of researcher to 
improve validity to minimise 
pre-conceptions and bias. 
Supervisory team involved in 
deduction of themes. 
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Minimising bias is important within research to ensure objectively and 
trustworthiness of results. To minimise bias in the pharmacy data collection, 
a standardised data collection form was developed and piloted with a 
pharmacy, and modified to ensure simplicity and efficiency in the data 
collection process. The pharmacist was briefed on the data collection 
process and a template for introducing the customer survey was developed 
for pharmacy counter-staff as it was understood that sensitivity in introducing 
the survey was needed at what could be a distressing time for patient’s 
relatives. 
To minimise bias in the qualitative study, participants were diverse in that 
there was no exclusion based on age, disability, gender, sexual orientation, 
race, culture, or religion. Wherever possible, participants in the qualitative 
interviews were selected from different areas of the city to exclude local 
differences in services based on social class or exclusion from certain 
services, e.g. hospice or specialist palliative care services. All professional 
groups that are involved in medications for palliative patients were invited to 
participant and no-one was excluded in taking part. District and community 
nursing teams were from two separate locations in the city. 
Minimising bias is also essential when conducting the interviews, which can 
be achieved through training in interviewing techniques to minimise the risk 
of asking leading questions, the use of a semi-structured research guide, and 
being reflexive in approach. To increase honesty of results, member 
checking of interview transcripts can be undertaken. 
Another way of reducing bias is to use different methods for collecting data 
and then triangulate the results. In this study, the pharmacy data collection 
form could be triangulated against the customer survey to check on the 
validity of the information. Interviews of healthcare professionals were used 
to triangulate data from the quantitative phase helping to further verify and 
strengthen the findings. 
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The validity of the qualitative study could have been improved through 
independently co-rating emergent themes for inclusion in the framework. In 
larger studies, more than one researcher may be involved in data analysis 
due to the scale of the data and to improve the validity of findings. Since this 
study was completed as part of the researcher’s DPharm, it was necessary to 
ensure the results are attributable to her efforts, which may have been more 
difficult to ascertain if more than one person completed the analysis. 
Strategies to reduce bias and strengthen the validity of the results were 
utilised through supervisors and discussion of emergent themes within a 
University research group.  In addition, the researcher kept a diary and used 
a reflexive approach. In presenting the results, the researcher has supported 
the discussion with vignettes from transcripts to verify the emergent themes. 
3.2.6 Sampling 
Teddlie and Yu (2007) present the whole taxonomy of sampling techniques in 
the social sciences including probability sampling, purposive sampling, 
convenience sampling and mixed methods sampling. Within mixed methods 
sampling they further describe five techniques including: basic mixed 
methods sampling, sequential mixed method sampling, concurrent mixed 
method sampling, multilevel mixed method sampling, and a combination of 
mixed methods sampling strategies. Mixed methods sampling is considered 
part of a continuum of sampling with probability sampling (often associated 
with quantitative research) at one end and purposive sampling (often 
associated with qualitative research) at the other (Teddlie 2005). 
Probability sampling such as randomisation, used within traditional 
experimental research to minimise bias and improve reliability of results, 
however, posed a problem in this study due to the low volume of palliative 
care prescriptions within primary care. Quantitative studies require the 
researcher to have insight into the important variables contributing in each 
situation but such variables were difficult to predict due to the lack of previous 
research in this field. It would not be possible to obtain a large sample size 
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and the underlying assumptions of normal distribution in the population may 
not hold. In addition, the presence of confounding variables across different 
pharmacies for example the number of support staff would make it difficult to 
analyse data to reach significant conclusions.  
In the quantitative phase, the researcher was interested in whether 
prescription errors caused a delay in obtaining palliative care medicines; so a 
sample size would be calculated based on the observed frequency of errors 
in the population. The researcher had been unable to find any published data 
or studies showing the prescription error rate for palliative care prescriptions. 
Therefore, the sample size was based on the observed frequency of opioid 
and midazolam prescriptions using data from NHS Digital. Due to the low 
frequency of observations in the population, it was necessary to recruit more 
pharmacies to attain an adequate sample size. 
Purposive sampling involves selection of cases ‘based on a specific purpose 
rather than randomly’ (Tashakkori and Teddlie 2003: 713) and can include 
sampling for representativeness or comparability as well as sampling unique 
or a specific group of cases that are the focus of a study (Teddlie and Yu 
2007). In this study, a purposive sampling strategy was utilised in the 
qualitative phase since the study is looking for diversity of opinion and views 
within various participants.  Other sampling methods such as snowballing, 
theoretical sampling and stratified sampling could have been utilised; 
however, they may not have ensured a wide diversity of views within a small 
number of interviews.  
Due to the low volume of palliative care prescriptions in the community, it 
was felt important to purposively identify those pharmacies that had greater 
volumes of palliative care prescriptions for both phases of the study. It would 
be expected that those with greater input into palliative care prescriptions 
would have perceptions and experiences which would be relevant to the 
research problem. Purposive sampling of pharmacies also ensures a wider 
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range of different sites contribute to the research such as independent and 
multiple pharmacies; those co-located or not located near GP surgeries. 
Unfortunately, a low recruitment of pharmacies into the study meant the 
proposed sample size of fifteen pharmacies in Phase 1 was not met. Not 
meeting the sample size could introduce bias and reduce the reproducibility 
of the results. Furthermore, undertaking the data collection in a single city 
reduces the validity and transferability of results to other areas of England. 
As the research is exploratory, sampling of additional healthcare 
professionals helped strengthen the qualitative phase. Teddlie and Yu (2007) 
discuss the trade-off between representativeness in the quantitative sample 
and saturation in the qualitative sample based on available resources. Such 
theoretical saturation in qualitative research is a concept associated with 
grounded theory where you sample until no new data emerges that changes 
a category or the relationships between categories so that categories are well 
established and validated (Strauss and Corbin 1998). Though theoretical 
saturation was not determined in this study, the sampling frame and size 
supported the concept of ‘data saturation’ within the qualitative interviews 
due to the fairly heterogeneous sample and limited focus of the study. Kaae 
and Traulsen (2015) suggest a sample of 15 to 25 semi-structured interviews 
is necessary to achieve ‘data saturation’ in pharmacy practice research. 
3.2.7 Access and recruitment 
Access to study participants was achieved through organisations or 
individuals acting as ‘gatekeepers’. Gatekeepers such as GP practice 
managers and nursing team leaders provide access to study participants and 
could distribute participant information to enable potential participants to 
contact the researcher. Use of gatekeepers can introduce bias as to who is 
approached; however, as the focus of the research was on community 
pharmacists and not an employer or organisation that the individual worked 
for, this was felt to be immaterial. 
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Access relied on convenience so as to interview a number of nursing staff in 
the same location on the same day. Two nursing base locations were chosen 
to increase sampling diversity. 
Recruitment to the study was achieved through a process of informed 
consent prior to any data collection in both phases of the study. Further 
information on the process of informed consent is discussed in section 3.2.9 
and 3.7.1. 
3.2.8 Data analysis 
Quantitative data collects either numerical data or data that can be 
‘quantified’. This may mean coding the data by transforming it into numbers 
to allow data analysis to take place (Bryman 2012). Data analysis reduces 
the amount of data, tests for relationships and allows presentation of the 
results (Bryman 2012). The use of inferential statistical methods allows the 
data to be described. Further information on the quantitative data analysis is 
provided in section 3.3.5.4. 
There are many traditional approaches to analysing qualitative data that vary 
in their epistemological views as well as the focus and aims of the analysis 
(Ritchie et al. 2014). The main approaches and issues have been described 
by Harper and Thompson (2012) and will not be discussed in this thesis. 
Thematic analysis is a widely used technique that is not grounded to any 
particular epistemological position or theoretical approach (Gale et al. 2013; 
Ritchie et al. 2014). Framework is a strategy that assists in thematic analysis 
and was developed at the National Centre for Social Research (NatCen) in 
the UK and described by Ritchie et al. (2014). Framework is a technique that 
is well described and has been used in studies in community pharmacies 
(Bond et al. 2008; Savage et al. 2012; Evans et al. 2016) as well as in 
palliative care (Andrews and Seymour 2011; Akram et al. 2012; Nash and 
Fitzpatrick 2015; Lim et al. 2017) including studies that are similar to this one 
(Akram et al. 2012; Bennie et al. 2012; Savage et al. 2012). 
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The Framework method was chosen for the analysis since it is a flexible 
technique that can be adapted for different qualitative approaches, providing 
a systematic and visual output to arrange themes. It allows the researcher to 
use deductive or inductive processes to code content (Gale et al. 2013). 
3.2.9 Ethical considerations 
Ethical issues that need to be considered during the research process 
include: 
• Voluntary participation  
• Informed consent 
• Privacy – anonymity, confidentiality 
• Doing no harm  
• Doing good – beneficence 
• Responsible dissemination of your work and findings 
• Scholarship issues – honesty, reliability and validity (University of 
Bradford 2010) 
The methods for ensuring voluntary participation, informed consent and 
privacy are discussed in more detail in the methods section 3.4. Issues of 
honesty, reliability and validity have already been addressed in section 
3.2.5.2 and in the methods for each phase of the study. 
Participation in research besides being voluntary is often without 
compensation (Seale et al. 2004). There is the need to consider what 
resources may make it easier for people to participate including 
reimbursement for costs incurred (Ritchie et al. 2014). Individual pharmacies 
participating in the research were offered a payment of £100 for the data 
collection in Phase 1 and £30 for participating in an interview in Phase 2. 
Funding was provided through a research grant and allowed pharmacies to 
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be reasonably resourced for their time in completing the research activity. 
Payment covered all the following activities: local co-ordination and 
management of the study within the pharmacy, which could include 
notification for indemnity insurance purposes, training of staff, data protection 
registration, development of standard operating procedures and notifications 
to patients that the pharmacy is involved in research, the completion of the 
customer survey, data collection forms and intervention logs as well as 
briefing and consent procedures with the researcher. There was also a need 
to resource ongoing communication with the researcher and patients 
regarding the study. 
What would be considered a reasonable payment may be difficult to 
determine and it may be considered unethical to incentivise research activity. 
To calculate a reasonable payment the researcher detailed the time required 
for the various research activities as per table 3.2. 
Table 3.2: Calculation of research time for involvement in the study 
Research Activity Time 
Briefing of lead pharmacist and consent with researcher 30min 
Identify patients and conduct customer survey for up to 30 
customers 
30min 
Complete 30 data collection forms on 30 prescriptions 60min 
Complete intervention log for 4 weeks of study 30min 
Debrief and collection of data forms between researcher 
and lead pharmacist 
15min 
Co-ordination and management time 30min 
Total Time 3hr 15min 
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The hourly rate for pharmacists provided by the Clinical Research Network 
(primary care) NIHR was £55; so the above activity would be over £178 if 
undertaken by the lead pharmacist. It was expected that in most cases a mix 
of staff, including pharmacy counter-staff and pharmacy technicians, would 
support the lead pharmacist. Since the research was being undertaken 
across all hours the pharmacy was open (sometimes 100 hours or extended 
opening hours in many pharmacies providing palliative services), it was 
expected the payment would support dedicated time to brief all staff in the 
data collection, not just for the hours when the lead pharmacist was 
available. 
The payment of £100 on completion of the data collection was considered 
reasonable in terms of the time and resources required to participate. The 
payment was agreed through independent peer review as part of the grant 
funding and through University of Bradford ethics processes. 
The Research Ready Handbook (RPSGB 2017) states that pharmacies must 
ensure they are resourced adequately for participating in health services and 
clinical trial research. Understanding the time commitment involved ensures 
that pharmacists are respected as equal professionals within the research 
community and will hopefully provide a good experience allowing them to 
participate in other studies in the future. 
The funding body sponsoring the study is Pharmacy Research UK, an 
independent charity that does not receive funding from the pharmaceutical 
industry. Sponsorship of the study does not create any financial or vested 
interest for the researcher. All research processes are independent of the 
funding stream besides peer review of the study. The funder has no direct 
influence over the conduct of the study except for the allocation of funding at 
study initialisation, at 12 months, and at the end of the study period. In some 
cases, funding can cause problems where unreasonable timetables and 
budgets have implications on participation and recruitment (Ritchie et al. 
2014); however, this was irrelevant as PRUK provided a flexible approach 
allowing project variations within the available resources.  
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3.3 Part Two: Methods 
3.3.1 Introduction 
In part two, the ethical and governance approval processes are outlined prior 
to discussion of the methods and processes used within the quantitative and 
qualitative phases of the study. Within the quantitative (Phase 1) study, 
further details are provided on the sampling and recruitment of the 
pharmacies, development of the survey and data collection tools, and the 
data management and analytical processes.  Following this the methods 
employed within the qualitative (Phase 2) study are detailed including 
sampling and recruitment of interviewees,  development of the interview topic 
guide, interview transcription, data management, and framework analysis 
development. 
3.3.2 Ethical and research governance approval 
The Chair of the Biomedical, Natural, Physical and Health Sciences 
Research Ethics Panel granted ethics approval for the study at the University 
of Bradford on 17th December 2015 (Appendix C). An ethics amendment to 
include other healthcare professionals in the qualitative interview phase was 
approved by the Chair on 10th October 2016 (Appendix D). 
According to the Governance Arrangements for Research Ethics Committees 
(UK Health Departments 2011), it was not necessary to obtain full NHS 
Research Ethics Committee (REC) approval for this study, which was 
confirmed by the Sheffield Research Development Unit (SRDU) and local NHS 
Trust Research and Development (R&D) office. Specific decision tools to 
determine whether your study is research and whether Research Ethics 
Committee (REC) approval is required are available from the Health Research 
Authority (HRA) website (HRA no date). The study did not randomise 
participants to different groups, change treatments from accepted standards, 
and the results are not generalisable to a broader range of clinical settings; so 
the study is not considered research according to the HRA criteria. Since 
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further approvals may have been required, the local research office for primary 
care and the local NHS Trust Research and Development (R&D) office were 
contacted for further information and confirmed no further approvals were 
required. 
NHS Sheffield has a shared governance arrangement for approval of 
research in primary care co-ordinated by the SRDU hosted by the Sheffield 
Health & Social Care NHS Foundation Trust. The SRDU confirmed further 
governance approval was not required according to the HRA decision tool 
(HRA no date) on 9th November 2015. Following an ethics amendment to 
include other healthcare professionals, the SRDU confirmed again that no 
further governance approval was required. 
Local approval was not required as the study was considered a service 
evaluation and audit within community pharmacies; however, the study was 
registered within the research department at the Sheffield Teaching Hospitals 
NHS Foundation Trust as study STH19123 due to the financial implications 
of receiving grant funding. 
3.3.3 Study procedure Phase 1 and Phase 2 
The research procedure is summarised in figure 3.2 
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Figure 3.2: Study Procedure 
Phase 1 
 
 
 
Phase 2    
 
  
  
Inclusion criteria met 
Data collection on up to 450 
prescriptions (30 per pharmacy).  
Analyse key data. Select pharmacies for 
Phase 2 of study. 
No, excluded 
from study 
15 pharmacies selected. Dates 
for data collection agreed. 
Data analysis on SPSS®. 
5 pharmacists and 11 healthcare 
professionals consent to interview. 
Date for interview agreed. 
 
Invite sent to 
pharmacies/pharmacists to gain 
site access and consent 
Pharmacists and other healthcare professionals 
identified and invited for interview. 
Audio-taped interview at place of work 
(up to 1 hour) 
Data coded manually and analysed 
using framework method 
 
 
 Quantitative data and qualitative data themes analysed 
across cases. 
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3.3.4 Quantitative Methods (Phase 1) 
3.3.4.1 Population 
The population for the study was chosen from Sheffield community 
pharmacies including those participating in a locally commissioned service 
(LCS) for supplying palliative care medicines. The key criterion was to 
include pharmacies providing the commissioned service and extended hours 
or 100 hours as well as pharmacies not commissioned to provide the service. 
3.3.4.2 Sampling 
3.3.4.2.1 Sampling pharmacies 
The intention of the study was to sample pharmacies to provide diversity of 
service provision and data rather than to reach a statistical sample size. 
Indeed random selection of pharmacy sites was not possible due to the low 
level of palliative care prescriptions in primary care and the need to collect 
substantive data for analysis.  
During the evaluation of the LCS by Tsoneva (2011), postcodes in which 
patients resided were mapped out with most palliative care prescriptions 
coming from thirteen out of seventeen Sheffield district postcodes. Following 
Tsoneva’s evaluation, the CCG rolled out the LCS to nineteen pharmacies 
across 128 pharmacies in Sheffield using a LCS specification (Tsoneva 
2010). Although sampling all LCS pharmacies plus comparators not in the 
LCS would have provided extensive results, the researcher had to make a 
pragmatic decision on the number of pharmacies to include due to limited 
resources for data entry and analysis.  Originally fifteen pharmacies were to 
be sampled to ensure a wide spread across the city, including both 
pharmacies in the LCS and comparators not within the LCS. Involving 
pharmacies near Sheffield boundaries would pick up potential problems 
where items not on the Sheffield LCS list are prescribed by non-Sheffield 
GPs.  
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The fifteen pharmacy sites participating in Phase 1 were originally chosen 
according to the following inclusion and exclusion criteria: 
The inclusion criteria were: 
• Sheffield postcode 
• willingness to participate 
• written informed consent provided 
• either part of the locally commissioned service to assure access to 
palliative care medicines or the equivalent ability to dispense thirty 
palliative care prescriptions in a month. This included three 
pharmacies (20% of sample) not participating in the LCS as 
comparators. 
The exclusion criteria were: 
• pharmacists who had not worked in the UK for at least 12 months to 
ensure those participating were familiar with UK and local community 
pharmacy services 
• company or manager have not given permission for access to the 
pharmacy site or pharmacist 
All pharmacies in the Sheffield area were invited to participate with an 
emphasis on pharmacies within the LCS since they were expected to have a 
greater interest, higher numbers of palliative care prescriptions, and more 
patients or carers accessing these services. 
For comparator pharmacies, it was identified that having a prescription 
turnover of at least 5000 items per month with at least 0.5% palliative care 
medicines, e.g. opioids (not substance misuse), and anticipatory or 
subcutaneously administered medicines should provide an equivalent ability 
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to dispense thirty palliative care prescriptions within the data collection 
period. 
If more pharmacies consented to take part than were necessary, pharmacies 
would be purposively selected to provide diversity in ownership including 
independent and multiple pharmacies, those providing extended opening 
times or OOH services, and those located near GP practices to reflect a 
range of postcode areas. Following pharmacy recruitment problems, 
purposive sampling was not required since only five sites consented to 
participate. 
3.3.4.2.2 Pharmacy recruitment 
Pharmacies were initially invited to express interest in participating through 
an electronic briefing circulated on 8th January 2016 by the Sheffield LPC, 
see Appendix E. A further briefing was circulated on 28th January 2016 
following a slow response. Parallel to this, the LPC Chair briefed LPC 
committee members to increase awareness of the study, continued to 
provide a point of contact to develop interest and rapport for the research, 
and allow access to gatekeepers of individual sites. Following the briefing, six 
pharmacies expressed an interest in participating. Of these, two pharmacies 
did not consent as they had low volumes of palliative care prescriptions. 
Due to the slow recruitment and to more actively recruit pharmacies 
participating in the LCS, the researcher sent a fax invite in April 2016 to all 
LCS providers who had not already expressed an interest in participating. 
The researcher received no expressions of interest following the fax invite. In 
addition, the researcher provided a briefing following a local community 
pharmacy development event to try and recruit further pharmacies which 
resulted in two further pharmacies expressing an interest with one consenting 
to take part. 
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Interested pharmacies could contact the researcher via email/telephone to 
discuss the study. All pharmacies that expressed an interest were provided 
with a leaflet providing information on the study, including anonymity, 
confidentiality, and consent procedures as well as details on the pharmacists’ 
responsibilities and payments (see Appendix F). The researcher contacted 
pharmacies to arrange a suitable time to meet and discuss the study further, 
obtain consent (see Appendix F), and drop off a site-specific research file 
containing pharmacy resources including flow chart and data collection forms 
(see appendices G, H, I, J and K). The site-specific research file ensured all 
study information including completed as well as uncompleted data collection 
forms were kept together preventing data from being mislaid. 
3.3.4.2.3 Sampling prescriptions 
The prescription sample was taken as the first thirty sequential palliative care 
prescriptions submitted to the participating community pharmacies for 
dispensing, or in pharmacies with less than 30 cases all palliative care 
prescriptions, during the data collection period. As community pharmacists 
may not be aware of whether a patient is receiving palliative care, especially 
if they are not under a specialist palliative care team, it was felt necessary to 
have a consistent definition of how to identify a palliative care prescription. 
The following criteria were used to identify palliative care prescriptions 
eligible for inclusion in the study. 
A prescription could be included if it was for an adult aged 18 years or over 
and contained one or more of the following: 
• A long acting strong opioid whether oral or transdermal, co-prescribed 
with a short acting opioid which is not for acute pain, dental treatment 
or substance misuse. This could include prescriptions where patients 
had recently received a short acting opioid which was not on the same 
prescription. 
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• PecFent®, Abstral®, Effentora® or other fast acting fentanyl; 
• Syringe driver or subcutaneous use of an opioid such as alfentanil, 
diamorphine, methadone, morphine, oxycodone, or non-opioids such 
as clonazepam, cyclizine, dexamethasone, furosemide, 
glycopyrronium bromide, granisetron, haloperidol, hyoscine 
hydrobromide, hyoscine butylbromide, levomepromazine 
metoclopramide, midazolam, ondansetron, or ranitidine; 
• A prescription issued by the specialist palliative care team at St Luke’s 
Hospice; 
• An unlicensed medicine used in palliative care – ketamine (oral or 
subcutaneous), lidocaine 0.2% mouthwash, antacid and oxetacaine, 
morphine hydrochloride 10mg/5ml, tranexamic acid liquid 500mg/5ml, 
sublingual use of lorazepam (genus brand), midazolam oromucosal 
10mg/1ml; 
• Methylnaltrexone injection given every other day or less frequently 
It was also necessary to identify urgent palliative care prescriptions within the 
sample. The criteria for identifying urgent palliative care prescriptions utilised 
a combination of pre-defined categories and customer2 input. Urgent 
prescriptions were identified as those where: 
• the customer advised the prescription was urgent; 
• the customer advised that the prescription was for a new medicine 
and therefore was needed urgently for new symptoms and the patient 
did not have a previous supply of the medicine; 
• the customer stated they had run out of their medicine, or expected to 
run out before the medicine was delivered; 
                                                          
2 Anyone presenting a prescription to the pharmacy for dispensing is referred to as a customer 
including patients, carers or their representatives. 
 78 
 
• the prescription was for a syringe driver; 
• the prescription was for anticipatory subcutaneous medicines per the 
community last days of life algorithms (diamorphine, haloperidol or 
levomepromazine, hyoscine and midazolam); 
• the prescription was from an out-of-hours GP; 
• the prescription was from the specialist palliative care team; 
• the patient had previously taken the prescription to another pharmacy 
and been referred on because the medicine was not available. 
Anticipatory medicines are those medicines prescribed in advance of 
symptoms towards the last days of life to cover symptoms of pain, anxiety, 
sickness, secretions, and breathlessness. According to the Sheffield EOLC 
algorithms, this is normally prescribed as diamorphine, haloperidol, hyoscine 
butylbromide, and midazolam; however, there may be exceptions if the 
patient has been discharged from hospital or is under specialist palliative 
care. GPs can be reluctant to prescribe pre-emptively in advance of 
symptoms as identified in a UK study by Faull et al. (2013); so classifying 
these prescriptions as urgent within the study simulates the time taken for 
carers to obtain these medications in a crisis. 
The sample of 30 prescription forms for each pharmacy was calculated using 
NHS Digital prescription data. In 2012-13, the NHS supplied 1,030 million 
prescriptions in primary care; 0.6% of which were prescriptions for opioid 
analgesics for the treatment of pain, or midazolam (BNF sections 4.7.2 and 
15.1.4). In 2012-13, the average monthly prescription items per pharmacy in 
South Yorkshire and Bassetlaw was 7780, equating to an average of 39 
opioid/ midazolam items per pharmacy per month (Prescribing and primary 
care Health and Social Care Infomation Centre (HSCIC) 2014). There may 
be some duplication where both a slow release and immediate release opioid 
is prescribed on the same form so choosing 30 forms per pharmacy would 
ensure that the average sized pharmacy would be able to complete the 
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required data collection within a four-week period allowing a greater number 
to potentially participate and not just those within the LCS. Collating data 
across a number of pharmacies ensures sufficient data is collected to reliably 
analyse factors within the research. 
Collecting data from 30 prescription forms from each of fifteen pharmacies 
meant a total of 450 prescription forms were intended to be sampled. The 
total number of medicines or prescription items was significantly higher since 
often more than one item is prescribed on each form. 
The data collection period covered all opening hours for the participating 
pharmacies, including weekends and bank holidays to ensure prevalence 
data for palliative care prescriptions could be calculated accurately and 
eliminate sample selection bias. This also ensured data was collected during 
the OOHs period when it is expected there may be more issues with 
accessing palliative care medicines or with contacting GPs when there are 
problems with prescriptions. 
It was recognised that various confounding factors could limit the data for 
instance the time of day the prescription was presented the number of staff 
working, whether the pharmacy held the medication in stock. It was intended 
to account for these factors through having a pharmacy specific variable in 
the analysis.  
3.3.4.3 Development of customer survey 
The short customer survey consisted of seven questions taking less than five 
minutes to complete, providing feedback on the customer’s experience of 
accessing and obtaining medicines on one occasion against a palliative care 
prescription. The survey was modified using questions from the PSNC 
national Community Pharmacy Patient Questionnaire (CPPQ) and piloted 
with three customers in one pharmacy before being further refined and 
piloted again with two patients within the Therapies and Rehabilitation Centre 
 80 
 
(TARC) at St Luke’s Hospice (SLH). Feedback was also obtained from the 
Hospice Patient User Co-ordinator, Hospice Risk Manager, and LPC 
Pharmacy Secretary. The modified customer survey is available in Appendix 
H, Form A. 
3.3.4.3.1 Content of customer survey 
The customer survey intended to elicit non-confidential details about the 
circumstances of the prescription collection from the customer’s point of view. 
This included whether the pharmacy was the patient’s usual pharmacy, 
whether any items were urgent, whether they could collect all the items they 
required, and whether they had to visit more than one pharmacy. There was 
also an opportunity to provide free-text comments on their visit and 
experience in accessing the medicines (Appendix H, Form A). Each 
customer survey form was numerically linked to the pharmacy data collection 
form (Appendix I, Form B) providing a cross reference between the 
customer’s experience, product availability, and the time taken for each 
specific pharmacy.  
3.3.4.3.2 Sampling of customer survey 
Pharmacy staff within the participating pharmacies were requested to provide 
customers over the age of 16, presenting with a palliative care prescription 
with a short customer survey (see form A, Appendix H) to complete over the 
counter whilst waiting for the prescription to be dispensed. Customers were 
provided with written information on the study that they could take away 
whether they wanted to take part in the survey or not (see Appendix J). 
Home delivery prescriptions and care home prescriptions where the patient 
or their representative did not physically present in the pharmacy were 
excluded as it was impractical to obtain informed consent for them to take 
part. A total of up to thirty customer surveys could be completed in each 
pharmacy; the total number in each pharmacy depending on whether 
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customers necessarily consent to taking part, which would equate to a total 
of 450 within the study if all customer forms were completed. 
3.3.4.3.3 Distribution and return of customer survey 
The survey was distributed by participating pharmacy staff face to face. 
Pharmacy counter-staff were requested to support the completion of the 
survey for those who could not read or write English or where customers 
asked for assistance. Since the customer survey was optional and only 
provided by pharmacy counter-staff, it was identified that there may be 
gatekeeper issues and difficulties in customers accessing the survey. In 
order to counteract this, counter-staff were provided with a suggested script 
(Appendix L) to capture the data where customers are willing to participate 
but are unable to complete the survey independently. In addition, a briefing 
session was conducted with pharmacy counter-staff prior to the data 
collection to ensure staffs are aware of how to introduce and conduct the 
survey in their pharmacy. 
Completed surveys were either handed back to pharmacy staff immediately 
or could be returned to a customer survey/comments box as per local 
pharmacy procedures. Customers could take the survey out of the pharmacy 
to complete but were advised to return it when collecting their prescription. 
The majority chose to complete this while waiting for their prescription to be 
filled in the pharmacy. Completed surveys were filed in the site-specific 
research file together with the pharmacy data collection form to minimise risk 
of lost data. There were no missing questionnaires within the study; so all 
those not completed either were not suitable or did not consent to take part. 
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3.3.4.4 Method 
Figure 3.3  Method of pharmacy data collection process 
 
Data on thirty sequential palliative care prescriptions was initially to be 
collected from each of the five participating pharmacies over a period of four 
weeks during an eight-week period from 1st May 2016. Data was collected 
utilising a standardised data collection form (see Appendix I, Form B) to 
ensure validity and consistency in data collection across the participating 
sites. 
When a prescription was presented at the pharmacy, counter-staff would 
identify if it was appropriate for inclusion in the study with support from 
dispensary staff that checked whether the prescription met the inclusion 
criteria (see figure 3.1). After completing initial checks and prescription 
charge payment or exemption declaration, the prescription was passed to 
dispensary staff to annotate the ‘time in’ on data form B. Counter staff would 
then have the opportunity to discuss the customer survey using the 
suggested script (Appendix L) whilst dispensary staff process the prescription 
in the usual way. 
Prescription mets 
inclusion criteria
'Time in' 
completed on 
data form B
Customer survey 
form A
Prescription 
dispensed
Prescription 
ready for 
collection
Data form B 
completed
Data form C 
completed if any 
interventions
Survey A and 
form B filed in 
site file
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The pharmacy data collection form was then clipped together with the 
prescription to enable completion of data either during the dispensing 
procedure or at a convenient time afterwards depending on the 
circumstances, e.g. urgency of prescription, patient waiting, and concurrent 
workload. Pharmacies were briefed on the process to ensure the data 
collection did not impact on the time to dispensing. 
Information collected on form B included: the name of the medicines 
supplied, number of errors on palliative care prescription forms, the type and 
nature of any error(s), and whether the medication is available for dispensing. 
Pharmacies timed the process from when a palliative care prescription was 
presented for dispensing to when it was ready for collection in order to 
calculate the waiting time for accessing urgent palliative care medications. 
Pharmacies were asked to identify any delays in the dispensing process. 
When stock was not available and the patient requested to take the 
prescription elsewhere, it was requested that the pharmacy complete the 
information on the form indicating a referral was made. 
All medication on the prescription form was included on the data collection 
form whether there was a problem or not and whether it was specifically for 
palliative care symptom management or not, e.g. antihypertensive and other 
co-prescribed medicines were included. This was important to provide further 
information to the researcher on the number of medicines the patient was 
taking, the timeliness of completing the prescription considering the number 
of items on the prescription form, and any other issues on the prescription 
that may relate to the customer survey; for example, if a part supply of an 
item required the patient or their representative to return to the pharmacy. On 
completion of an urgent prescription, the time the prescription was ready for 
collection/ delivery was noted. Where prescriptions did not meet legal 
requirements, this was recorded with a note of the intervention undertaken on 
form B. Clinical interventions that were not legal errors were filled on form C 
(see Appendix K, Form C) indicating the corresponding form B number to 
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ensure matching of data. Error codes were used from the PRACtICe study 
(Avery et al. 2012) as follows: 
1- unnecessary drug 
2- incorrect drug 
3- duplication 
4- allergy error 
5- contraindication error 
6- interaction error  
7- dose/strength error 
8- formulation error 
9- frequency error 
10- timing error 
11- information incomplete 
12- generic/brand error 
13- omission error relating to failure to prescribe concurrent medication 
Once completed all forms were filed together in the site-specific research file. 
a new form A and new form B were used for each new prescription 
presented. All completed forms were collected by the researcher upon 
completion of the data collection. A further collection of data and site-specific 
files by the researcher occurred at the end of the data collection period. 
3.3.4.5 Quantitative data analysis (Phase 1) 
Data from Phase 1 was coded into SPSS® (V 23.0, IBM) (Statistical Package 
for the Social Sciences) for analysis using appropriate statistical tests to meet 
the study objectives according to the quantitative data analysis plan in 
Appendix M. 
Demographics of the sample and descriptive data of the prescriptions were 
analysed including: method of prescription generation, urgency of supply, 
time of presentation (in or out-of-hours) and the type of drugs requested. The 
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prevalence of prescription errors both legal and clinical errors was calculated 
from the sample and crosstabs used to check for relationships with the 
method of prescription generation. Further analysis of the time to supply 
medication was completed reporting on the mean, median and standard 
deviation as well as the effect of errors on this process using crosstabs. 
Descriptive data from the customer survey was reported including referrals 
where customers had to attend more than one pharmacy to obtain the 
medication on the prescription. Analysis also included use of SCR and 
whether any other interventions were recorded by the pharmacists. 
Following statistical tests of pairwise univariate tests, a regression model of 
significant variables was to be built to test the significance of these factors on 
the output. It was intended to control for any pharmacy specific variables 
such as number of staff that could have affected the analysis. 
The researcher requested audit data from other areas across the UK through 
personal request on a forum within the Association of Supportive and 
Palliative Care Pharmacy (ASPCP). This resulted in personal communication 
with three people (see Appendix A) who gave more information on their local 
schemes, including an audit across Birmingham and raw data on a scheme 
in Northern Ireland. Where possible these personal communications have 
been used in the discussion to allow the researcher to compare and contrast 
the Sheffield scheme to other unpublished data. 
3.3.5  Qualitative Methods (Phase 2) 
3.3.5.1 Sampling 
In the qualitative study (Phase 2) a sample of five pharmacists was selected 
from those participating in Phase 1. Pharmacists were invited to participate in 
Phase 2 according to the results of the data collected in Phase 1 as per the 
sequential mixed methods design. Pharmacies were purposively selected 
with the aim of maximising data diversity and richness, and to help explain 
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unexpected results. Pharmacies were to be purposively selected based on 
higher or lower numbers of errors on prescription forms, higher numbers of 
referrals to other pharmacies, or longer or shorter than average waiting times 
for urgent palliative care medicines. The type of pharmacy and whether it 
was included in the LCS were also considerations to increase case diversity. 
Following analysis of data from Phase 1 in SPSS®, all five pharmacies 
participating in the Phase 1 data collection had data that met these criteria 
and so were invited to participate in Phase 2. All five pharmacists consented 
to take part in the interview. 
A sample of five was chosen to explore the cases in depth using in-depth 
framework analysis to support interpretation of the qualitative themes and 
understand quantitative data arising from Phase 1. 
Other healthcare professionals were purposively sampled to ensure diversity 
of representation from GPs, community and district nurses, and specialist 
palliative care team staff (medical and nursing). The researcher approached 
gatekeepers including practice managers, OOHs provider managers, and 
team leaders to identify staff who may be willing to be involved and to pass 
on the participant information leaflet (see Appendix N). In addition, a briefing 
was sent to all GPs and emailed invitations to nurse managers and team 
leaders.  Although a poster was displayed and information distributed within 
the OOH provider, the researcher received no contact so this group was not 
included in the sample.  
In most cases, healthcare professionals contacted the researcher to take part 
having already received the participant information leaflet. Where a 
convenience sample of district and community nurses was obtained through 
a team leader at a community nurse base, all potential participants were 
given time to read the information leaflet and ask questions before 
consenting to take part in the study. 
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3.3.5.2 Interviews 
3.3.5.2.1 Development of pharmacist semi-structured interview  
The topic guide for the semi-structured interview was adapted from 
Moustakas (1994) and Creswell (2007) with feedback from a Hospice Patient 
User Co-ordinator. This was piloted with a research pharmacist with 
experience in qualitative interview methods. Piloting is essential to check 
interview guide, technique and language of questions, allowing questions to 
be modified to improve the quality of the data (Vivar 2007). 
The guide was further refined following the data analysis from Phase 1 to 
incorporate specific questions relating to the individual pharmacy and any 
unexpected results from the data collection. The pharmacist interview 
covered their experience in palliative care concentrating on the pharmacist’s 
role in palliative care, accessing palliative medicines, collaborative working 
with other healthcare professionals, interactions with palliative care patients 
and their carers, decision making, effect on other staff in the pharmacy, and 
any things they feel could be improved to meet the needs of palliative 
patients. The topic guide can be found within Appendix O.  
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3.3.5.2.2 Development of healthcare professional semi-structured 
interview 
The interview guide developed for the pharmacists was used as a template to 
develop the healthcare professional topic guide. Questions relating 
specifically to pharmacist participation were removed and key themes arising 
from the pharmacist interviews were added. A pilot of the healthcare 
professional topic guide did not take place as the researcher had experience 
from using the guide within the pharmacist interviews. The interview guide 
was further refined during each subsequent healthcare professional interview 
depending on the participant. The topic guide was tailored to the interviewee 
depending on whether they were an independent prescriber. The topic guide 
for healthcare professionals can be found within Appendix P. 
3.3.5.2.3 Recording and transcription 
Interviews were digitally audio-recorded by the researcher ensuring 
anonymity through use of an identifier number on the recording and 
transcribed verbatim either by hospice medical secretarial staff for 
pharmacist interviews or the researcher for healthcare professional 
interviews. Interview transcripts were checked by the researcher against the 
recording to increase accuracy and any personal details or information that 
could identify subjects was removed at the transcription stage and given an 
anonymous code. All transcripts were password protected before being sent 
electronically to participating pharmacists for member checking, which is 
suggested to increase the truth-value of the data (Mays and Pope 2000). No 
amendments were suggested. Other healthcare professionals were asked if 
they would like to be sent a copy of their interview transcript for checking; 
however, this offer was not taken up by any of the interviewees. 
3.3.5.3 Method 
The selected pharmacists were contacted to consent to take part in an in-
depth interview and a suitable time and venue were arranged in which to 
 89 
 
conduct a face to face interview. One pharmacist from each of the five 
selected sites was interviewed for approximately 45 minutes utilising the topic 
guide in Appendix O. Other healthcare professionals were identified through 
team leaders or voluntarily contacted the researcher following an email or 
briefing to all GPs. Healthcare professional interviews were between 14 and 
45 minutes long and were conducted face to face at a suitable venue and 
time utilising the topic guide in Appendix P which was modified to the specific 
staff member. 
At the interview, pharmacists and healthcare professionals were asked to 
consent to audio recording of the interview as per the consent form in 
Appendix N. The signed consent form was kept by the researcher and stored 
securely while the participant kept an unsigned consent form.  
At the end of the interview, participants were debriefed to ensure feelings 
were normalised, which is considered important in palliative care research 
due to the emotive content of the topic (Addington-Hall 2007). Information 
was provided on how to contact the researcher and the supervisory team if 
they had any concerns following the interview. In addition, participating 
pharmacists were given information on contacting Pharmacy Support, a 
charity that supports pharmacists and who had verbally agreed to providing 
this support as part of the interview process. 
3.3.5.4 Qualitative data analysis (Phase 2) 
Originally the study procedure stated that pharmacies with the highest or 
lowest number of errors on forms, highest or lowest number of referrals or 
the longest or shortest waiting times would be selected for Phase 2 
interviews to ensure diverse cases were chosen to further explain the results. 
Initially transcripts from Phase 2 were reviewed by the researcher to become 
familiar with the content and coded manually using annotations of themes in 
the margins and highlighting significant phrases. Codes were manually 
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developed into a framework using broad themes based on the research 
questions. Subthemes that arose from the data that did not align within the 
framework were placed in an ‘other’ code and discussed with a supervisor 
with experience in qualitative methods. Themes were reviewed and agreed 
with supervisors at several face to face and Skype® supervisory meetings. 
The Framework Method involves seven stages: transcription, familiarisation, 
coding, developing an analytical framework, applying the analytical 
framework, charting data into the framework matrix, and interpreting the data 
(Gale et al. 2013). The following process was taken in developing and 
analysing the data according to the method described by Gale et al. (2013). 
1. All interviews were audio recorded and transcribed verbatim and 
checked against the recording by the researcher to ensure accuracy. 
 
2. Original transcripts were read a number of times in order for the 
researcher to become familiar with the content. This allowed the 
researcher to get an overview of the data and make notes on any 
emergent or recurrent themes.  
 
3. Themes arising from the transcripts were coded according to the topic 
and annotations were made on the transcript, and subsequently using 
a word processing programme. 
 
4. A thematic framework was developed with main themes based on the 
research questions and objectives. Codes were charted into the 
themes and grouped into sub-themes. Any codes not fitting into any 
sub-themes or categories were put into an ‘other’ category. Themes 
for developing the framework were induced from the data based on 
topics arising in the interviews. Following discussion and reflection 
with supervisors, several revisions of the thematic framework took 
place to refine this further. All ‘other’ codes were reviewed to apply 
within the framework. 
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5. The framework was applied across the whole dataset with all coding 
labels on the transcripts entered onto the matrix. Separate pages were 
used for each major theme, and sub-themes were in headed columns. 
A separate row was used for each participant in the matrix to allow 
comparison across individuals and professional groups for each of the 
sub-themes. 
 
6. Summaries of data were added to the matrix to capture the 
participant’s views. Cross-referencing of interview transcript line 
numbers ensured an audit trail of evidence. 
 
7. Mapping and interpretation of findings through discussion and 
reflection across individuals and professional groups to understand the 
essence of the phenomena and support explanation of meaning. 
Themes from the qualitative part of the study were analysed separately to 
Phase 1 quantitative data before being synthesised across all parts of the 
project. Themes from the research were then compared with other relevant 
research nationally and internationally. 
3.4 Ethical Considerations 
As discussed in section 3.2.9, it is important to consider all ethical issues in 
designing a study. Voluntary participation, informed consent and ensuring 
privacy were particularly relevant due to the small size of this study and the 
business context within community pharmacies.  
3.4.1 Informed consent 
Voluntary written informed consent was obtained prior to the data collection 
in Phase 1 using the consent form in Appendix F and prior to the interview in 
Phase 2 using the consent form in Appendix N. All participants were advised 
they could withdraw their consent at any time by contacting the researcher, 
which was reinforced at the end of the data collection and interview as well 
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as through the participant information leaflet.  Prior to obtaining consent, 
participants were given the opportunity to read about the study and express 
an interest in participating, giving participants time to fully consider the study 
requirements and their responsibilities. In interviews of district nursing staff 
who were identified through team leaders, they were given time to read 
through the participant information leaflet and ask questions of the 
researcher prior to discussing the consent procedure. Only if consent was 
given were interviews undertaken. Before obtaining written informed consent, 
the researcher confirmed that the participating pharmacist met the inclusion 
criteria for Phase 1. Two copies of the consent form were signed; one was 
kept by the researcher and the other by the participating pharmacist. In 
Phase 2, the participant kept a blank copy of the consent form with the 
signed copy being kept by the researcher. Only after providing written 
consent were participating pharmacies provided with a site-specific research 
file containing all pharmacy resources and data collection forms. The study 
procedure was confirmed and the researcher offered to provide a briefing 
session to pharmacy staff tailored to the pharmacy. This included providing 
an example script for pharmacy counter-staff to engage with customers when 
delivering the customer survey as part of the study. Utilising a personalised 
visit supported building relationships with pharmacy staff participating in the 
project and helped identify any specific issues for data collection at the 
individual pharmacy to ensure data quality and integrity. 
3.4.2 Anonymity and confidentiality 
Due to the small size of the study and the small number of pharmacies and 
healthcare professionals participating in Phase 2, it was particularly important 
that neither pharmacies nor healthcare professionals could be identified in 
any outputs from the study. The researcher ensured strict processes for 
confidentiality and anonymity between healthcare professionals, their 
employers and within the study. Personal details and any information that 
could identify participants were removed at the transcription stage and an 
identification number applied. Any vignettes used in any outputs from the 
 93 
 
study were reported using an identifier number. By ensuring responses were 
anonymised, no individual participant could be identified. 
Anonymised prescription data was collected from sequentially presented 
palliative care prescriptions to each pharmacy. This included the first half of 
the patient’s postcode to determine geographical spread of the prescriptions 
and whether this location was supported by pharmacies participating in the 
locally commissioned service (LCS) for the supply of palliative medicines. 
Pharmacies recorded the patient’s medication record (PMR) code on the 
data collection form to enable the pharmacist to go back and check on any 
details if there were any queries or missing data. The use of the PMR code 
was deemed necessary as all prescription forms are sent to the NHSBSA at 
the end of the month for payment. It would therefore not be possible for the 
pharmacist to go back and check data entry at the end of the data collection 
period without this code. The PMR code is unique to each pharmacy and 
does not allow patient identification outside the pharmacy. 
Patients, their carers and agents were invited to complete a short ‘customer 
survey’ to collect feedback on their experience and outcome in accessing 
palliative care medicines on their visit. Participation in the customer survey 
was voluntary and responses were anonymous with no information collected 
that would identify the respondent. The survey was very short and could be 
completed while waiting for a prescription. When a customer was willing to 
participate in the survey but was unable to complete the form independently, 
pharmacy staff could offer to support them. A briefing session was provided 
for pharmacy staff to support them in this role. The customer survey was 
numerically linked to the data collection form providing a check on the validity 
of the pharmacy data; however, no patient identifiable data was collected. 
All data were anonymised to ensure confidentiality of the participants. Audio-
recordings and hard copies of data were kept secure in a locked filing 
cabinet, which only the researcher had access to at the St Luke’s Hospice, 
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as agreed by STH research governance. All electronic data were stored 
securely on a password-protected computer that only the researcher had 
access to. Audio recordings were stored securely and destroyed on 
completion of the checked transcripts. 
Interview participants were debriefed at the end of the interview to ensure all 
feelings were normalised due to the potential emotive nature of the topic. 
They were provided with information on contacting the researcher, the 
researcher’s supervisor, and the Listening Friends Service at Pharmacist 
Support in case they had any concerns following the interview. None of the 
participant’s contacted the researcher or the researcher’s supervisor 
following the interview. 
To facilitate the community pharmacists’ participation, a financial payment 
was made to cover costs. This consisted of £100 paid to each pharmacy on 
completion of data collection in Phase 1 and £30 for each pharmacist 
consenting to interview in Phase 2. Funding was made available through 
Pharmacy Research UK. Any payment could be considered an inducement 
to take part therefore a strict process of briefing and consent was followed to 
ensure the pharmacists were volunteering without any coercion. The 
researcher did not approach individual pharmacists until they showed an 
interest in being involved in the research. Briefing information (see Appendix 
E) was distributed via the Sheffield LPC to gain interest and recruit potential 
pharmacist participants. This information was also shared with employers 
and other gatekeepers so they were aware of the research and agreed to site 
access. 
3.4.3 Trustworthiness 
As mentioned above, a number of strategies have been used to ensure 
trustworthiness of the data analysis. These methods include: member-
checking of pharmacist transcripts, the most in-depth interviews conducted; 
quotations from the interview data to illustrate points in the analysis; the 
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researcher’s own reflective stance and personal reflections throughout the 
data collection and analysis in a diary; supervisors with experience in 
qualitative methods and analysis providing regular support, and an audit trail 
of themes coded within the transcripts through to the final framework analysis 
in an Excel spreadsheet. 
To increase honesty of results, the pharmacists selected for interview were 
all provided with a copy of their interview transcript for member checking. The 
pharmacists were asked to check they were happy with the contents of their 
interview in case they wanted to withdraw any statements, which, for 
example, may reflect on their employer. Four out of five pharmacists replied 
to say they were happy with the transcript and did not wish to make any 
changes with a further pharmacist not replying. Healthcare professionals 
were verbally asked if they would like to check a copy of their transcript but 
all declined. 
As a registered pharmacist, the researcher has taken the professional 
standards of the General Pharmaceutical Council and their own professional 
ethics into account whilst conducting the research. Reflexivity during 
research means being open to different perspectives and acknowledging the 
researcher’s own bias that could influence the results. Allowing scrutiny of 
codes and themes during the research, utilising outside experts as well as 
keeping comprehensive notes and an audit trail of changes in the developing 
analytical framework helped support reflexivity within the research. 
3.4.4 Stakeholder involvement 
The Sheffield LPC and Sheffield CCG were consulted during the research 
design process with the LPC agreeing to be a conduit with local community 
pharmacies to engage interest and be a point of contact as needed. Both 
continued as stakeholders during the research and continue into the 
dissemination process. 
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Patient involvement can greatly benefit research to ensure it is relevant to 
service users (Savory 2010; INVOLVE 2014). Due to limited life expectancy 
and ethical constraints, it can be difficult to formally engage with patients 
about palliative and end of life care (Gandy and Wilford 2012); so a proxy in 
the form of a Hospice Patient User Co-ordinator was asked to review the 
research design and ask for patient feedback where possible. 
As part of the research, patients, their carers and agents were asked to 
complete a short ‘customer survey’ collecting feedback on their experience 
and outcome in accessing palliative care medicines when visiting the 
pharmacy. Patients were involved in the content of the customer survey as 
well as providing the impetus of the need for the research. 
To strengthen the validity of the results and ensure any potential 
recommendations are of benefit to patients, the researcher proposes to take 
back the results through the Hospice Service User co-ordinator and discuss 
recommendations within a patient focus group. The resulting 
recommendations can then be focused and prioritised according to patient 
need before wider dissemination to commissioners and providers. 
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Chapter 4: Results of Data Collection in Community Pharmacies –      
Phase 1 Study 
4.1 Introduction 
This chapter presents the results of the first part of the study where 
prescription data and customer feedback was collected in participating 
pharmacies. The objectives within this phase were to: 
• Investigate the prevalence of prescribing errors on palliative care 
prescriptions presented to a sample of community pharmacies. 
• Explore whether the prescription error rate varies according to the 
practice, prescriber status, or the nature of the prescription. 
• Establish whether errors on palliative care prescriptions are 
associated with time delays in obtaining medication. 
• Establish the maximum waiting time for palliative care medications 
from the community pharmacy setting. 
• Establish what processes exist for patient referral when palliative care 
medicines are not available. 
The chapter has been structured so as to present demographic information 
on participating pharmacies and patients recruited into in the study before 
summarising the prescription data. Following this is a review of other 
interventions recorded, customer survey information, use of Summary Care 
Records (SCR), use of Electronic Prescription Service (EPS), and use of 
unlicensed medicines within the data collection. Summary statistics are 
presented before the chapter ends with a synopsis of what further information 
is needed to answer the objectives. 
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4.2 Demographics 
Data collection took place in 3.9% (5/128) of community pharmacies in 
Sheffield, 40% (2/5) of the sample provide assured availability to palliative 
care medications as part of the locally commissioned service while 60% (3/5) 
of the sample are not part of the service but are expected to provide 
medicines ‘with reasonable promptness’ as part of the national pharmacy 
contract. The sample included two pharmacies that are classified as 
“independent” having five or fewer branches and three which are “multiples” 
having six or more branches. Two of the pharmacies provide services 
beyond normal opening hours (i.e. after 6pm weekdays) and two pharmacies 
are co-located with GP services. 
A total of 75 data collection forms were completed by the five pharmacies, 
totalling 271 individual prescription items. A breakdown for each participating 
pharmacy is shown in table 4.1, which shows the mean (15), median (14) 
and range (2-33) of prescription items and forms per pharmacy. 
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Table 4.1 Data collection forms and prescription items 
Pharmacy  Number of 
forms 
Number of 
 items 
Average items 
per form 
Pharmacy 1 20 139 6.95 
Pharmacy 2 33 95 2.80 
Pharmacy 3 14 22 1.57 
Pharmacy 4 6 8 1.33 
Pharmacy 5 2 7 3.5 
Total 75 271 3.61 
Mean per 
pharmacy  
15 54.2  
Median per 
pharmacy 
14 22  
 
The data was originally to be collected over a 4-week period in May 2016; 
however, due to slow recruitment of pharmacies and a lower than expected 
prevalence of palliative care prescriptions in participating pharmacies data 
collection continued up until the end of October 2016, meaning the true 
duration was between 3 and 6 months, depending upon the individual 
pharmacy. A pilot study to evaluate the availability of palliative care 
medications from community pharmacies was carried out by the Sheffield 
CCG between 7th February and 31st August 2011 at two community 
pharmacies in Sheffield; this involved 801 patient interactions across a 29- 
week period, which approximates at about 27 patient interactions per week 
so prevalence of palliative care prescriptions in the study was much lower 
than expected from the results of the pilot. 
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The prevalence of palliative care prescriptions in each pharmacy was 
estimated using dispensing figures from pharmdata.co.uk in December 2016 
for each participating pharmacy. Due to monthly dispensing volume 
fluctuations, the average number of prescription items and forms dispensed 
in each pharmacy over a 6-month period was used and divided to obtain an 
average monthly figure. The average number of palliative care prescription 
items and forms per month was calculated using the data submitted by each 
pharmacy divided by the reported data collection period.  An estimated 
prevalence of palliative care prescriptions in each pharmacy was calculated 
using the average number of palliative care prescription items divided by the 
average total dispensing figure per month. This estimated prevalence was 
also calculated for the average number of palliative care prescription forms. 
The estimated prevalence of palliative care prescription items per month 
ranged from 0.02 – 0.4% across the 5 pharmacies while the estimated 
prevalence of palliative care forms ranged from 0.01 - 0.13%. 
269/271 prescriptions came from 16 Sheffield postcodes (0.7% (2/271) 
missing data) covering 20 GP practices, 2 OOH service providers and 1 
specialist provider. The 16 postcodes covered 15/17 active Sheffield city 
postcodes (S1 – S35) and 1 Rotherham postcode (S66) out of 45 active 
Sheffield district postcodes. 
Neighbourhoods showing the first part of the postcode from where 
prescriptions originate is shown in figure 4.1. Contains OpenStreetMap® data 
available under the Open Data Commons Open Database License by the 
OpenStreetMap Foundation. The cartography is licensed under the CC-BY-
SA Creative Commons Attribution-ShareAlike 2.0 license with kind 
permission.  
Figure 4.1: Map of Sheffield postcodes within prescription data 
Map data © OpenStreetMap contributors  
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From the 75 forms presented to the pharmacies in the study, pharmacy staff 
identified 40 as being regular users of the pharmacy while 35 were not 
regular pharmacy users. Table 4.2 compares regular and non-regular users 
according to whether the pharmacy is in the LCS service. 
Table 4.2 Use of pharmacy  
Use of pharmacy Pharmacy 
not in LCS 
(%) 
Pharmacy in 
LCS (%) 
Total 
(%) 
Regular pharmacy user 23 (82.1) 17 (36.2) 40 (53.3) 
Not regular pharmacy 
user 
5 (17.9) 30 (63.8) 35 (46.7) 
Total 28 47 75 
 
 
4.3 Prescription Data 
Table 4.3 shows that 86% (233/271) of prescriptions in the sample were 
written by GPs during normal surgery hours and 12.2% (33/271) were from 
OOH providers. There were no prescriptions written by nurse or pharmacist 
non-medical prescribers in the sample. 
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Table 4.3 Prescription data 
Prescriber type Number of items % of total 
General Practitioners 233 86.0 
Out of hours’ providers 33 12.2 
Specialist palliative care 
team 
5 1.8 
Non-medical 
prescribers 
0 0 
Total prescriptions 271  
 
Prescriptions were generated as per the methods presented in Table 4.4, 
computer software was used for 90.4% (245/271) of prescription items and 
8.1% (22/271) were handwritten. 
Table 4.4 Method of prescription generation 
Method of prescription 
generation used 
Number of items % of total 
Handwritten 22 8.1 
Computer generated 245 90.4 
Electronic (EPS) 0 0 
Missing data 4 1.5 
Total prescriptions 271  
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The time when prescriptions were presented to the pharmacies was 
classified as either within GP surgery hours or OOHs. OOHs is classified as 
any time after 6pm weekdays, and any time on a weekend or bank holiday as 
well as times when the GP surgery normally closes e.g. on Thursday 
afternoons. As presented in Table 4.5, 28.4% (77/271) of prescriptions were 
presented to pharmacies outside GP opening hours, 42.9% of these (33/77) 
were from OOH providers. The remaining 64.9% (176/271) were presented 
during GP opening hours, in 6.6% (18/271) of forms data on the time of 
presentation was missing. 
Table 4.5 Time prescription presented to pharmacy 
Time prescription 
presented 
Number of items % of total 
Outside GP opening 
hours (OOH) 
77 28.4 
Within GP opening 
hours 
176 64.9 
Missing data 18 6.6 
Total prescriptions 271  
 
In 68.3% of cases (185/271) the medication was needed urgently. Urgent 
medications were indicated by the pharmacy user on the customer survey, or 
were identified by pharmacy staff following a conversation with the pharmacy 
user. Pre-determined categories of urgent items were also identified by the 
researcher so that all items prescribed by an OOH or specialist palliative care 
provider, all handwritten items and those issued as acute prescriptions were 
within the urgent category. Table 4.6 classifies all urgent prescriptions by 
method of generation and Table 4.7 classifies those that were presented 
OOHs by urgency and method of generation.  
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Table 4.6 Urgent prescriptions: method of prescription generation  
Method of prescription 
generation used 
Number of items % of total 
Computer generated 159 85.9 
Handwritten 22 11.9 
Missing data 4 2.2 
Total urgent prescriptions 185  
 
Table 4.7 Urgent Prescriptions: method of generation and out-of-hours 
(OOH) presentation 
Urgency and method of 
prescription generation  
Number of items % of total 
Urgent, computer 
generated, presented 
OOH 
54 70.1 
Urgent, handwritten, 
presented OOH 
18 23.3 
Presented OOH but not 
urgent 
1 1.3 
Missing data 4 5.2 
Total OOH prescriptions 77  
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4.3.1 Analysis of drugs requested 
42.1% (114/271) of items in the sample were for controlled drugs (CDs) in 
schedule 2 or 3 and 49.8% (135/271) were for subcutaneously (sc) 
administered medicines; 24.7% (67/271) of items were for subcutaneous 
CDs. Of the 135 subcutaneous prescription items requested, 90.4% 
(122/135) were formulations on the locally commissioned service (LCS) 
palliative care stock list. Formulations requested not on the stock list included 
diamorphine vials instead of ampoules, midazolam injection in strengths 
other than 10mg/2ml, clonazepam injection 1mg/ml and various sizes of 
water for injection. 
4.3.2 Prevalence of prescription errors 
Legal prescription errors arose in 1.1% (3/271) of prescriptions in the sample, 
all of which did not specify a dose on a subcutaneous controlled drug given 
via a syringe driver. Two of these legal errors were resolved through a legally 
permitted technical change by the pharmacist; one following a telephone call 
to a nursing home to verify the syringe driver prescription administration 
record, which was in the patient records, and the other through using the 
pharmacy PMR to verify the previous dose administered in a prescription that 
was presented outside GP surgery hours. The third legal error required a 
telephone call to the GP to request a new prescription be issued with the 
correct dose instructions. 
Non-legal errors arose in 3% (8/271) of prescriptions due to a variety of 
reasons that have been classified as administrative or clinical errors. 
Administrative errors such as medicine out of stock with supplier, alignment 
of prescription quantities and changing the prescription to an alternative 
strength of an urgently required subcutaneous controlled drug to enable 
supply occurred in 1.1% (3/271) of the sample. Clinical errors included 
information incomplete, wrong dose prescribed, wrong strength prescribed 
and allergy to the prescribed product occurred in 1.8% (5/271) of 
prescriptions.  
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Table 4.8: Prescription errors and method of prescription generation 
Prescription 
generation method 
No error Legal 
errors 
Non-legal errors 
(administrative: clinical) 
Computer generated 237 3 5 (3:2) 
Handwritten 19 0 3 (0:3) 
Missing data 4 0 0 
 
Table 4.8 summarises legal and non-legal errors per method of generation. 
Non-legal errors are categorised further into those that are administrative and 
those that are clinical. There was insufficient evidence of a difference 
between the number of errors and the prescription generation method 
(Fisher’s Exact 2-sided test, p = 0.052). There was insufficient data to 
compare errors between practices or prescribers except all legal errors 
occurred on computer-generated prescriptions from NHS GPs rather than 
OOH GPs. No handwritten prescriptions contained any legal errors. In the 
case of the 8 non-legal errors these occurred across both computer-
generated and handwritten prescriptions as well as NHS and OOH GPs. 
4.4 Promptness of Supply 
The following tables’ present collated data for pharmacies within the LCS 
compared to pharmacies not participating in the LCS to compare promptness 
of supply for:  
• all urgent prescriptions (Table 4.9), this includes drugs on the LCS 
stock list and drugs not on the stock list;  
• subcutaneous medicines (Table 4.10), of which 90% were on LCS 
stock list;  
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• controlled drugs (Table 4.11), which includes enteral and topical 
formulations which are not on the LCS stock list. 
In each case the time taken has been calculated from when the prescription 
is dropped off to the pharmacy dispensary by the pharmacy user or the GP 
surgery to the time when the prescription was completed and ready for 
collection or delivery. Median, minimum and maximum times have been 
calculated as well as upper and lower quartiles. The time taken in each 
scenario is predicated by stock availability in the pharmacy at the time the 
prescription is presented. 
Table 4.9 Urgent prescriptions 
 LCS pharmacies 
(%) 
Non-LCS pharmacies 
(%) 
Total no. urgent 
prescriptions (Px) 
105 (56.8) 80 (43.2) 
No. Px for which time 
data missing 
67 (63.8) 6 (7.5) 
No. valid Px for analysis 33* (31.4) 74 (92.5) 
Minimum time taken 
(hr.min) 
0.03* 0.10 
Median time taken 
(hr.min) 
0.10* 5.00 
Maximum time taken 
(hr.min) 
3.39 47.15 
Lower quartile time taken 
(hr.min) 
0.08* 1.00 
Upper quartile time taken 
(hr.min) 
0.11* 26.30 
*Five urgent prescriptions excluded from analysis where minimum time was 0 minutes where 
user sent to another pharmacy to obtain urgent supplies to prevent skewing results  
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Urgent prescriptions were analysed and compared across pharmacies. There 
were 112 cases, however, five prescriptions were recorded at 0 minutes 
where one of the requested items was not available and the pharmacy user 
had to obtain the prescription elsewhere. Removing these five prescriptions 
left 107 valid cases for analysis across the five pharmacies. The median time 
taken for all urgent prescriptions across all participating pharmacies was 2 
hours with the range between 3 min and 47.15hr.min. The median time taken 
within LCS pharmacies was 10 min and non-LCS pharmacies was 5 hr; an 
independent samples median test was calculated (p=0.002). At a significance 
level of 95% the medians of total time between LCS and non-LCS 
pharmacies are not the same with the time taken within non-LCS pharmacies 
being significantly longer than LCS pharmacies. Due to low numbers of 
prescriptions and missing data no reliable comparison could be made 
between individual participating pharmacies.  
The analysis does not account for confounding variables including time of 
day, prescription numbers, number and type of staff working in the pharmacy 
at the time the prescription was presented. The missing data and presence of 
confounding factors therefore limit interpretation of the results.  
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Table 4.10 Subcutaneous medicines (via syringe driver or anticipatory)  
 LCS pharmacies      
(%) 
Non-LCS 
pharmacies (%) 
Total no. s/c 
prescriptions (Px) 
100 (74.1) 35(25.9) 
No. Px for which time 
data missing  
65 (65.0) 6 (17.1) 
No. valid Px for analysis 30* (30.0) 29 (82.9) 
Minimum time taken 
(hr.min) 
0.03* 0.27 
Median time taken 
(hr.min) 
0.10* 21.18 
Maximum time taken 
(hr.min) 
0.30 146.00 
Lower quartile time taken 
(hr.min) 
0.08* 1.00 
Upper quartile time taken 
(hr.min) 
0.10* 26.30 
*Five urgent prescriptions excluded from analysis where minimum time was 0 minutes where 
user sent to another pharmacy to obtain urgent supplies to prevent skewing results 
Prescriptions for subcutaneous medicines were analysed and compared 
across pharmacies but there were only 59 valid cases for analysis after 
removal of five cases where minimum time was recorded as 0 minutes due to 
prescription items not being available at the pharmacy. The median time 
taken for all subcutaneously administered medicine prescriptions was 27 
mins with a range from 3 min and 146 hours. The median time taken within 
LCS pharmacies was 10 min and non-LCS pharmacies was 21.18 hr.min; an 
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independent samples median test was calculated (p=0.801). At a significance 
level of 95% there is no difference between the medians of total time 
between LCS and non-LCS pharmacies in dispensing subcutaneous 
medicines. Due to low numbers of prescriptions and missing data no reliable 
comparison could be made between individual participating pharmacies. 
Again the analysis does not account for confounding variables at the time the 
prescription was presented limiting the interpretation of the results. 
Table 4.11 Controlled drug prescriptions 
 LCS pharmacies  
(%) 
Non-LCS pharmacies 
(%) 
Total no. CD 
Prescriptions (Px) 
68 (59.6) 46 (40.4) 
No. Px for which time 
data missing  
48 (70.6) 3 (6.5) 
No. valid Px for analysis 18* (26.5) 43 (93.5) 
Minimum time taken 
(hr.min) 
0.03* 0.10 
Median time taken 
(hr.min) 
0.10 23.00 
Maximum time taken 
(hr.min) 
5.45 171.30 
Lower quartile time taken 
(hr.min) 
0.08* 2.30 
Upper quartile time taken 
(hr.min) 
0.10* 26.40 
*Five urgent prescriptions excluded from analysis where minimum time was 0 minutes where 
user sent to another pharmacy to obtain urgent supplies to prevent skewing results  
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Prescriptions for controlled drugs were analysed and compared across 
pharmacies, which resulted in 61 valid cases for analysis after removal of two 
cases where minimum time was recorded as 0 minutes for controlled drugs 
when prescription items not available at the pharmacy. The median time 
taken for all controlled drug dispensed palliative prescriptions was 4.47 
hr.min with a range from 3 min to 171.3 hr.min. The median time taken within 
LCS pharmacies was 10 min and non-LCS pharmacies was 23 hr; an 
independent samples median test was calculated (p=0.0450). At a 
significance level of 95% there is a likely to be a difference in the medians of 
total time between LCS and non-LCS pharmacies in dispensing controlled 
drug items. 
4.4.1 Effect of errors on promptness of supply 
The effect of legal errors on prescriptions for subcutaneous medicines was 
minimal within the sample as these errors were resolved within 10-30 
minutes.  
4.5 Other Interventions 
Only legal, clinical and administrative errors were recorded by the 
pharmacies during the data collection. One administrative error was noted to 
have been corrected through a medicines use review (MUR) to align 
prescription quantities. 
4.6 Customer Survey 
As presented in Table 4.12, 73.3% (55/75) of pharmacy users completed the 
patient/carer survey. In 65.5% of cases (36/55) the pharmacy user was 
collecting a prescription for someone else, 1.8% (1/55) collecting for both 
themselves and someone else and 32.7% (18/55) were collecting for 
themselves. In 21.8% (12/55) of cases pharmacy users stated they were 
referred to the pharmacy by a health care professional. Referrals could 
include a referral to the specific pharmacy or an inter-pharmacy referral when 
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the first pharmacy did not have the requested items. In 72.9% (40/55) 
surveys completed, the pharmacy user indicated that the medication was 
needed urgently and 56.4% (31/55) contained subcutaneous medicines. In 
80% (44/55) of cases patients reported they received all their medicines, this 
increases to 89.1% (49/55) if patients who received a part-supply of their 
medication or reported that the medication was not required urgently are 
included. In 20% (11/55) of cases at least one medicine was not available. In 
54.5% (6/11) of cases medicines were urgently needed but not available. 
Pharmacy users completing the survey had to go to more than one pharmacy 
to get their prescription fulfilled in 18.5% (10/54) cases. 
  
 114 
 
Table 4.12: Customer survey findings 
 Number Percent (%) 
Customers completing 
survey 
55/75 73.3% 
Patient collected own 
prescription 
18/55 32.7% 
Someone else collected 
prescription 
36/55 65.5% 
Customers waiting in 
pharmacy 
34/75 45.3% 
Customer needed to go 
to more than 1 
pharmacy for medicines 
on the prescription 
10/54 
(1 missing data entry) 
18.5% of those 
completing surveys * 
Prescription included 
urgent medicine(s) 
40/55 72.7% 
All medication on 
prescription available 
for supply 
44/55 80.0% 
*The true incidence overall may be as low as 13.3% (10/75) of all observations 
 
Pharmacy users used a variety of methods to collect prescriptions 45.3% 
(34/75) opting to wait in the pharmacy for their prescription while 16.0% 
(12/75) had a delivery service. In 25.3% (19/75) of cases pharmacy users 
could collect their prescription items straight away. This would suggest that 
the prescription items were on a repeat authorisation from the GP and sent 
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directly to the pharmacy for dispensing and collection rather than being 
dropped off by the customer. In 12.0% (9/75) of cases customers chose to 
come back to collect their medicines. 
4.6.1 Descriptive data on customer surveys 
When pharmacy users reported that not all items on the prescription were 
available they were given the option of completing a free-text section to 
explain how they intended to get these items. Tables 4.13 and 4.14 present 
the descriptive and free-text data from pharmacy users where not all 
medicines were available. Information pharmacy users reported is presented 
within quotation marks while pharmacy staff comments are not contained 
within quotation marks. 
Table 4.13: Customer surveys: descriptive data 
 
  
 Number of customers 
reporting 
Percent (%) 
One or more 
prescription items not 
available 
11/55 20.0% 
No supply made and  
urgent prescription item 
5/11 45.5% 
Free-text section 
completed 
6/11 54.5% 
Free-text section left 
blank 
5/11 45.5% 
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Table 4.14: Customer surveys: free-text data 
Prescription 
no. 
Prescription 
Urgent 
Item not available Free-text section 
completed 
(If any items are NOT 
available please explain how 
you will get these) 
2 Yes Diamorphine 10mg vials Left blank 
13 Yes Part supply made ‘collect tomorrow’ 
27 No Zomorph® 30mg caps Left blank 
40 No Butec® 5 patch no stock 
Longtec® part supply 
‘call back at a later date’ 
42 Yes Diamorphine 5mg 
injection 
return tomorrow to 
collect diamorphine 
46 Yes Dexamethasone 
3.3mg/ml injection 
dexamethasone was out 
of stock – collecting 
tomorrow 
62 Yes Midazolam 5mg/5ml 
injection 
Alternative pharmacy 
64 Yes Diamorphine 5mg 
ampoules 
‘Try another pharmacy’ 
68 Yes Unclear as not all items 
specified on form 
Left blank 
72 No Part supply made Left blank 
75 No Part supply made Left blank 
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The customer survey included a question ‘Are there any things that could 
have been improved to make your visit better?’ which was either blank or this 
section was struck through in 76.4% (42/55) of surveys. Customer comments 
made on the remaining 13 surveys are summarised in Table 4.15.  
 
Table 4.15: Customer survey: descriptive data on improving services 
Prescription 
no./s 
What could be Improved 
6, 25 ‘No’ 
4, 11, 40 ‘None’ 
31 ‘No fine’ 
32 ‘No staff were helpful’ 
44 ‘Nothing – excellent and quick service’ 
45 ‘No – very happy with the service provided today’ 
47 ‘Friendly service under difficult circumstances’ 
49 ‘No staff really friendly and helpful. Service was quick 
and efficient’ 
54 ‘Nothing much that would make it better but I phone in 
advance to make sure my items are in stock’ 
64 ‘Keep a stock of all required items’ 
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4.6.2 Use of pharmacy 
Where customers completed a survey they could indicate whether this was 
their usual pharmacy, convenient for them, one of several pharmacies that 
they used or if they were referred to the pharmacy. This data differs slightly to 
the pharmacy reported data presented in table 4.2, which is obtained from 
the pharmacy computer system, since this is reported by customers who may 
not be the patient themselves. 
Table 4.16 summarises the customers’ use of the pharmacy for those 
pharmacies in the LCS and not in the LCS. 
 
Table 4.16: Customer survey reported use of pharmacy 
Use of pharmacy Pharmacy not in 
LCS 
No. (%) 
Pharmacy in 
LCS 
No. (%) 
Total 
Convenient 2 (18.2) 6 (13.9) 8 (14.8) 
Referred to the 
pharmacy 
0 (0) 12 (27.9) 12 (22.2) 
One of several 
pharmacies used 
0 (0) 11 (25.6) 11 (20.4) 
Usual pharmacy 9 (81.8) 14 (32.6) 23 (42.6) 
Total  11 43 54* 
*Missing data on one survey 
  
 119 
 
4.7 Referrals 
In 21.8% (12/55) of the sample, pharmacy users were referred to a pharmacy 
that is not the patient’s regular pharmacy to get their palliative care 
prescription fulfilled. Of the 12 referrals 41.67% (5/12) visited more than one 
pharmacy while 58.3% (7/12) only went to one pharmacy. Table 4.17 
summarises referrals and whether the user had to go to more than one 
pharmacy. 
Table 4.17: Referrals and multiple pharmacy use 
Provider Only 1 pharmacy used 
No. (%) 
More than 1 pharmacy 
No. (%) 
Referrals from GP 
surgery 
3 (42.9) 3 (60) 
Referrals from OOH 
providers 
3 (42.9) 2 (40) 
Referrals from SPCT 1 (14.3) 0 
Total referrals 7 5 
 
There is the possibility that customers who visited more than one pharmacy 
were referred by another pharmacy. This figure could be as much as 8/55 
(14.5%) if all referred customers and those that use several pharmacies are 
included though it is impossible to verify as this data was not specifically 
requested in the survey. 
4.8  Continuity of Care towards the End of Life 
Customers collecting subcutaneous medicines for care near the end of life 
were more likely to visit a pharmacy that is not the patient’s usual pharmacy. 
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Subcutaneous medicines for end of life care were prescribed on 42/75 
(56.0%) of prescription forms in the study and in 34/42 (81.0%) cases these 
were taken to a pharmacy that is not the patient’s usual pharmacy as 
depicted in table 4.18. Of the 55 customer surveys completed 31/55 (56.4%) 
presented prescriptions that contained subcutaneous medicines with 31/31 
(100%) being collected by someone else besides the patient. 
Table 4.18: Subcutaneous medicines at end of life - continuity of care  
 No subcutaneous 
medicines for end of 
life care no. (%) 
Subcutaneous 
medicines for end of 
life care no. (%) 
Regular use of the 
pharmacy 
32 (97.0) 8 (19.0) 
Not usual pharmacy  1 (3.0) 34 (81.0) 
Total  33 42 
 
4.9 Use of SCR/EPS 
SCR was not used for any of the prescriptions in the sample. No 
prescriptions were sent via EPS. At the time of the data collection EPS had 
not been rolled out for controlled drugs in England. 
4.10 Unlicensed Medicines 
The only unlicensed medicine in the sample was clonazepam 1mg/ml 
injection, which was prescribed at an incorrect dose. This injection was 
available in the pharmacy, however, it is unclear what affect the error had as 
the customer survey was not completed and the time completed was missing 
from the data collection form. 
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4.11 Summary of Findings 
The results from the pharmacy data collection demonstrates that a high 
proportion of palliative care prescriptions in primary care are required 
urgently with many containing subcutaneous medicines or coming from OOH 
prescribers. Legal errors on controlled drug prescriptions were more common 
on computer generated prescriptions for subcutaneous controlled drugs, with 
no errors on hand written prescriptions observed. Legal errors did not result 
in significant delays in obtaining medication, however, not having the 
required medicines in stock in the pharmacy did result in delays, which were 
significant in pharmacies not commissioned to provide the palliative care list 
of drugs. There is high compliance with prescribing drugs on the local 
palliative care formulary. Different strengths of midazolam injection caused 
some confusion. Approximately one in five customers had to go to more than 
one pharmacy to get urgently required palliative care medication, with one in 
two customers referred by a healthcare professional needing to go to more 
than one pharmacy. 
In the next chapter, the results from the qualitative interviews with 
pharmacists and other healthcare professionals will be discussed. 
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Chapter 5: Findings from Interviews with Pharmacists and Other 
Healthcare Professionals – Phase 2 Study  
5.1 Introduction 
This chapter presents the qualitative analysis and findings from interviews 
with community pharmacists and other healthcare professionals working in 
the community, in both generalist and specialist roles, to ascertain factors 
causing delays in accessing palliative medicines and determine the scope of 
the community pharmacist’s role in palliative care. The emergent thematic 
framework arising from the analysis following the method set out in chapter 3 
is provided and then verbatim quotes from study participants are used to 
demonstrate the findings. A recap of the aims and objectives in this phase of 
the study will be provided before describing the analysis.  
5.2 Aims 
To identify the barriers and facilitators to obtaining palliative care medicines 
in the community and understand factors that facilitate or limit the community 
pharmacist’s role in palliative care. 
5.3 Objectives 
The specific objectives within the Phase 2 interviews were to: 
• Identify factors from Phase 1 of the study causing delays in obtaining 
palliative medicines. 
• Clarify factors from Phase 1 of the study facilitating or limiting the 
community pharmacists’ involvement in providing palliative care 
services. 
• Determine whether community pharmacies within an enhanced 
palliative care service fulfil more than a supply function. 
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• Explore the pharmacists’ perceptions and experiences in the delivery 
of palliative care services. 
• Explore whether the delivery of palliative care services within 
pharmacies has any effect on community pharmacy staff. 
• Explore the future role of community pharmacists in palliative care 
according to the views of other healthcare professionals 
5.4 Definitions  
To support data analysis and interpretation participants have been organised 
into one of three specific groups as defined below. This protects individual 
participant’s anonymity and confidentiality whilst aiding interpretation across 
professional groups. Each group contains between three and eight 
individuals as specified in the parentheses as follows: community 
pharmacists (5), general practitioners (GPs) (3) and community healthcare 
professionals (cHCPs) (8). The group “community healthcare professionals” 
comprised of district and community nurses, specialist palliative care team 
members, both medical and nursing, as well as a pharmacist working in the 
intermediate care team. 
5.5 Data Analysis 
Data analysis was conducted using the Framework method (Gale et al. 2013) 
where initially transcripts were reviewed by the researcher to familiarise 
themselves with the content. Data were then manually labelled and coded by 
annotating in the left-hand margin of the transcript and highlighting significant 
sections of the text. The initial labels used a combination of ‘a priori’ labels 
based on the objectives of the research as well as ‘emergent’ concepts using 
both an inductive and deductive approach allowing any unexpected 
experiences to be captured (Gale et al. 2013). These codes were then 
organised into a framework using overarching themes based on the research 
questions. Sections of the text were summarised into the framework with 
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codes down each column and cases across each row. The framework was 
developed on an excel spreadsheet with separate pages within the 
spreadsheet for each overarching ‘a priori’ theme. Two of the community 
pharmacist interviews were used to develop the initial framework with 
categories within each overarching theme changed iteratively in order to 
bring similar coded concepts together. Once the initial framework was 
developed this was then used for coding one of the healthcare professional 
interviews to ascertain how codes aligned with the framework. 
Codes that did not fit within the framework were put in an ‘other’ category for 
discussion with supervisors. Once an initial framework was developed this 
was discussed with academics, researchers and postgraduate students at a 
meeting of the University of Bradford Medicines Optimisation Research 
Group (MORG), a cross faculty research group, as well as with two 
supervisors experienced in qualitative methods. 
The initial thematic framework tree diagram can be found in Appendix T 
(Framework A: Jan 2017). The classification system presented problems 
since there was some overlap in the categories; for example, 1.9 and 2.4 
both contained the need to have skilled and trained support staff in the 
pharmacy. Supervisors suggested fewer themes to categorise the data and 
to consider sub-levels within each category indicating whether a positive or 
negative consequence was experienced. Further to this MORG members 
suggested utilising a theoretical framework such as COM-B (Michie et al. 
2011) to categorise themes to support interpretation and make 
recommendations on changing practice and processes. It was felt by the 
researcher that COM-B or another theoretical framework such as the 
theoretical domains framework (Michie et al. 2005) were more relevant to 
interventional studies rather than systems and processes addressed in this 
study. On reflection it was felt an inductive approach led by the data, the 
research questions and literature would help to explain the findings rather 
than a pre-existing framework and ensure the researcher was open to 
exploring the data in full.  
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A revision of the thematic framework was made to look at a smaller number 
of themes namely: timely access to palliative care medicines; current and 
future community pharmacist’s role in palliative care; and healthcare 
professional relationships with an ‘other’ category.  Sublevels within 
categories indicated codes with a positive or negative impact, which were 
highlighted in either red (negative impact) or green (positive impact), within 
the framework. At this point the “other” category included access to 
information and records, knowledge and training issues, IT systems, 
integration with CCG, judgements and risks as can be seen in the thematic 
framework in Appendix T (Framework B: April 2017). 
At this point all 16 interviews were recoded and code labels were added onto 
electronic copies of the transcripts. Sections of data were then summarised 
into the revised framework adding a cross reference to the transcript line 
number so this could be traced back to the original data. The revised 
framework was further refined to bring together all categories relating to 
timely access across all professional groups thereby removing ‘healthcare 
professional relationships’ and ‘other’ themes (Appendix Q, framework C: 
May 2017). Electronic interview transcripts were recoded against the new 
framework again ensuring codes were copied and pasted into the revised 
categories. A process of comparing and contrasting cases and professional 
groups was used to ensure the framework was complete, this included 
looking for deviant cases and cells with no data by going back to reassess 
the original data to ensure nothing was missing. Where the ‘other’ category 
was used the original transcript was reread to understand the essence of 
what was being said and assess whether this should be recoded within the 
framework. For instance, the category specialist palliative care was removed, 
data recoded and added to integrated working, personal relationships and 
collaborative working or multiplicity of prescribing depending on the context. 
In order to support explanation, higher order abstraction of themes was 
developed, compared and contrasted across professional groups. Categories 
of data relating to the community pharmacists’ role were brought together in 
a separate overarching theme; this topic being less well defined with 
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contribution coming mainly from community pharmacists themselves. The 
complete process of data analysis took approximately five months allowing 
immersion in the data and used an iterative, inductive and reflective process 
utilising support from supervisors. This approach helped to make sense of 
the interconnected data and as explained by (Holliday 2016) helped form the 
argument for the written findings that follow. The resulting themes and 
subthemes arising within the framework are represented in figure 5.1. 
Figure 5.1: Framework analysis themes and subthemes  
 
The final overarching analytical framework was further broken down into sub-
categories as shown in table 5.1.  
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Table 5.1: Final Thematic Framework (July 2017) 
1. Timely access to palliative care medicines  
1.1 Environment and resources 
1.1.1 Forward planning, anticipation and being resourceful 
1.1.2 Stock availability in the pharmacy 
1.1.3.1 Locally agreed formulary list 
1.1.3 Accessing specialist palliative care medication 
1.1.4 Transporting medications to the patient’s house  
1.1.4.1 Family involvement 
1.1.4.2 Pharmacy delivery service 
1.1.5 Obtaining correctly written prescriptions  
1.1.6.1 GP computer systems  
1.1.6.2 Effects of CD regulations 
1.1.6 Responding quickly 
1.2 Communication and Collaboration 
1.2.1 Understanding role  
1.2.1.1 Professional role and identity 
1.2.1.2 Confidence and experience 
1.2.2 Community Pharmacist relationships with other healthcare 
professionals 
1.2.3 Communication within and across teams/care settings  
1.2.4.1 Decentralisation/isolation 
1.2.4.2 Information sharing 
1.2.4.3 Integrated/collaborative working 
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1.3 Skills/knowledge and training 
1.3.1 Pharmacists knowledge, skills and experience 
1.3.2 Community pharmacy team knowledge, skills and experience 
2. The Community Pharmacist’s role in palliative care 
2.1 Talking with, supporting and referring patients and their carers 
(counselling and compliance) 
2.2 Clinical review of prescription and checking safety 
2.3 Providing advice and information, working with GPs and other 
healthcare professionals  
2.4 Continuity of medicines supplies 
2.5 Supervision of medicines disposal and pharmacy processes 
2.6 Pharmaceutical care 
 
To refine the community pharmacists’ role further and support explanation it 
was necessary to determine those codes within the individual community 
pharmacist’s sphere of practice compared to those situated within the 
pharmacy corporate body or managed by the pharmacy business. The open 
labelled codes were examined and reviewed with a community pharmacist 
working in palliative care to further refine these into each of the categories as 
described in figure 5.2.  
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Figure 5.2: Thematic codes in relation to community pharmacist, 
pharmacy and pharmacy corporate bodies 
 
 
In preparation for interpretation, emergent themes were checked across 
cases and across professional groups to understand the similarities, 
differences and diversity across and between groups of healthcare 
professionals (Ritchie et al. 2014). 
Quotes from participants have been coded to identify which group of 
healthcare professional they belong to whether; community pharmacist, GP 
or other community healthcare professional (cHCP) as well as the interview 
code. Where there is a risk of disclosure and it is not possible to use the 
quote, the identity has been removed and only the text quoted to ensure 
confidentiality and anonymity are not broken where professionals could be 
identified within the local context or where sensitive issues are discussed. 
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5.6 Findings 
5.6.1 Demographics 
Of the sixteen participants five were community pharmacists (who had also 
participated in the Phase 1 data collection). Eleven were other healthcare 
professionals: three were general practitioners (GPs), five were district or 
community nurses not specialising in palliative care, two were specialist 
palliative care team members (one doctor and one clinical nurse specialist), 
and one was a pharmacist working in intermediate care. The sampling frame 
of participating healthcare professionals is provided in table 5.2. Participants 
were considered to be representative of both generalist and specialist roles in 
palliative care. 
All interviewees participated in an in-depth one to one interview lasting for 
approximately 51 minutes (median time of community pharmacist interview) 
and approximately 18.5 minutes (median time for cHCP and GP interviews) 
respectively. The cHCP and GP interviews were of a shorter duration due to 
time restrictions but all interviews except one covered all questions within the 
topic guide. One cHCP interview was terminated due to running over time. 
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Table 5.2: Sampling frame criteria and numbers of participants 
 Sampling frame 
criteria 
Total number of 
participants 
Discipline District or Community 
Nurse 
5 
 Pharmacist 6 
 GP 3 
 Specialist palliative care 
nurse 
1 
 Specialist palliative care 
doctor 
1 
Length of time since 
registration 
1-3 years 1 
 >3 years 15 
Gender Female 6 
 Male 10 
Completed palliative 
care training 
Community 
Pharmacists 
4 
 Healthcare 
Professionals 
6 
If nurse / pharmacist Extended prescriber 
V150 or NMP 
4 
with another 2 in 
training 
If GP / pharmacist 
 
Experience of GP 
Pharmacist role3 
4 
  
                                                          
3 The Sheffield Primary Care Pharmacy Programme provides one session of community pharmacist 
time in local GP practices each week as part of the GP Access Scheme (formerly Prime Ministers 
Challenge fund) 
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Following the data analysis two over-arching themes emerged from the data 
namely:  timely access to palliative care medicines and the community 
pharmacist’s role in palliative care, each of these will be considered in turn. 
5.6.2 Timely access to medicines 
Three subthemes were identified from the analysis: environment and 
resources; communication and collaboration; and skills and knowledge, with 
a number of categories and subcategories identified within each that are 
explored in more detail below. 
The themes from the analysis on timely access to palliative care medicines 
have been incorporated into a schematic diagram to aid interpretation in 
figure 5.3.
 
Figure 5.3: Schematic diagram of timely access to palliative care 
medicines  
User 
experience -
timely access 
to palliative 
medicines
Environment 
and Resources
Communication 
and 
Collaboration
Skills and 
Knowledge
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5.6.2.1 Environment and Resources 
There was agreement that being able to secure rapid supply of medicines at 
times of changing needs, supported timely symptom management. 
…if you get that prescription right and get it into the house quickly 
then that’s going to help symptom control (Community Healthcare 
Professional, cHCP9) 
The data showed the critical importance of planning in advance through pre-
emptive or anticipatory prescribing, local commissioning policies, 
development of GP computer systems, and digital transmission of 
prescriptions. I will go on to discuss these in more detail. 
5.6.2.1.1 Forward planning, anticipation and being resourceful 
Healthcare professionals were aware of the need to plan ahead and 
anticipate the need for palliative care subcutaneous medicines in advance for 
those patients who may deteriorate. It was also recognised that healthcare 
professionals, in particular nurses, working in the community needed to have 
the skills to do this.  
…we all need to get a bit better with palliative care. So, we need 
to be pre-empting further ahead of time…but I think that comes 
with the skillsets in community (Community Healthcare 
Professional, cHCP4) 
It was recognised that although GPs may be happy to prescribe pre-emptive 
medication they cannot prescribe a syringe driver ahead of time so such 
prescriptions would always need doing urgently.  
…a GP won’t prescribe a syringe driver ahead of time…but that 
means we are always being [sic] having to do it now not in a 
more considered way (Community Healthcare Professional, 
cHCP4) 
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Where patients were already on subcutaneous medication in a syringe driver 
the community nurses perceived it was their role to ensure sufficient 
medication had been ordered and was in the patient’s house before the 
weekend and described a pre-weekend checking process. This was because 
fewer nurses worked on the weekend and it would not be possible, for 
example, to send staff to collect medications from a community pharmacy. 
…whoever goes in on a Thursday or a Friday morning double 
checks that the drugs are there that we are not going to be 
needing anything, we go through them with a fine-tooth comb 
(Community Healthcare Professional, cHCP5) 
Sometimes it was possible to make a syringe driver with what was available 
in the house ensuring timely symptom management by being flexible and 
resourceful with what is available.  
…I tend to look at what’s available in the house…then order the 
stuff in for the next day…otherwise it can delay that patient 
getting a syringe driver (Community Healthcare Professional, 
cHCP11) 
Pharmacists and other healthcare professionals described how anticipation 
and forward planning impacted on their practice. Quantities on prescriptions 
were often perceived as a problem as illustrated by cHCP11 and cHCP6. The 
quantity of hyoscine butylbromide prescribed was not enough and 
pharmacies did not keep large quantities of medicines in for patients on 
syringe drivers.  
…they might have a few of those [hyoscine] but then not enough, 
[be]cause you only get 10 in a box, and then that’s not enough for 
a few days (Community Healthcare Professional, cHCP11) 
Other healthcare professionals perceived that pharmacies should be 
expecting the prescription and have the medication available where patients 
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had previously been on a syringe driver and the medicines remained the 
same.  
…if someone’s on a syringe driver…for quite a while…and their 
regular pharmacy can’t get certain medications in even though it’s 
expected for them to be on that… (Community Healthcare 
Professional, cHCP6) 
A deviant case was recalled where a nurse said the local community 
pharmacist intuitively spotted a trend of increased oxycodone use in a 
syringe driver and made a judgement to order additional stock in before the 
weekend. 
…there was one particular patient who was on oxycodone huge 
doses, massive doses and I didn’t ever have to say…I need 
enough to get me over the weekend he’d already spot the trend 
and he’d get enough in to cover me over so that was a really 
positive experience and showed how it can work well (Community 
Healthcare Professional, cHCP4) 
Contrary to this community pharmacist P5 perceived that phoning ahead for 
large quantities would be helpful. 
…if a nurse was to phone up to say I’m going to ask for a 
prescription for 20 ampoules will you have the stock, ‘no but I’ll 
get it by 4 o’clock’… (Community Pharmacist, P5) 
Insufficient quantities had consequences for staff resources taking them 
away from completion of tasks and this could adversely impact on the 
management of the patient’s symptoms. 
…I just remember having to go [to the pharmacy] in the middle of 
doing a [syringe] driver because there weren’t enough drugs 
(Community Healthcare Professional, cHCP8) 
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…I went to review a patient…they were on pre-emptives and I 
called out-of-hours and say this patient needs a syringe driver 
now…they’ll write it up, syringe drivers done and they’ll 
leave...and you [sic] been thinking oh we haven’t got any of these 
and we haven’t got enough (Community Healthcare Professional, 
cHCP6) 
…the community pharmacy are [sic] forever doing owing’s [for 
CDs] …so we then phone the pharmacy ‘oh yeah we owe him 
some’ and they’ve not thought that’s important enough to send on 
[deliver to the patient’s house] (Community Healthcare 
Professional, cHCP1) 
Pharmacists, on the other hand, explained a number of practical, non-clinical 
issues they had to take into account. These applied particularly in the case of 
controlled drugs. They could not send controlled drugs back to the 
wholesaler due to the rules and guidance for the licensing of pharmaceutical 
distributors (MHRA, 2017). This could cause consequences for the pharmacy 
and could affect the pharmacist’s attitude as witnessed by cHCP5. 
…we’ve only got very small CD cabinets…the more controlled 
drugs you keep the more issues you are going to have 
(Community Pharmacist, P1) 
…by the time you get a prescription sorted out they might not 
need it anymore in which case you face a storage problem…I 
can’t just put it on a shelf (Community Pharmacist, P5) 
…we did have a patient who needed some ASAP took the script 
she [pharmacist] ordered them in the next thing the patient 
passed away and she [pharmacist] was not happy… (Community 
Healthcare Professional, cHCP5) 
Pharmacies’ limited storage space for controlled drugs combined with 
their attempts to predict the quantities of stock that might be needed 
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sometimes led to an inability to fulfil prescriptions. The pre-weekend 
prescribing on Fridays could exacerbate an already challenging 
situation. 
…we don’t have an ability to be able to keep a lot [controlled 
drugs] and so we have a particular issue with the quantities that 
they write on the prescriptions sometimes which can impact on 
the next patient… (Community Pharmacist, P4) 
…once there was three people…all wanting palliative care things 
all on the same Friday afternoon… (Community Pharmacist, P5) 
There was some evidence of healthcare professionals informing 
pharmacies to check their stock levels and to keep more stock of 
particular drugs in when a regular supply was needed for instance when 
a patient was expected to continue on a syringe driver. 
…this person is on this…they are going to be on it for a while it 
would be good if you could have a mind to your stock levels 
(Community Healthcare Professional, cHCP9) 
So, there was a patient…discharged from the hospital…and their 
local pharmacy didn’t normally have methadone in but the 
pharmacist …picked that up…and said you know we’ll make sure 
we’ve always got some…some [pharmacists] take that on 
themselves…other people might need prodding or directing 
towards it (Community Healthcare Professional, cHCP9) 
5.6.2.1.2 Stock availability in the pharmacy 
Stock availability in the pharmacy was a key issue to ensure timely access 
for patients with data occurring across all interviews. Factors contributing to 
stock availability in the pharmacy are depicted visually in figure 5.4. 
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Figure 5.4 – Factors contributing to stock availability in the pharmacy 
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It was recognised by other healthcare professionals that pharmacies could 
not stock everything and may only have a limited quantity in stock. They also 
understood that in exceptional circumstances more than one prescription 
could be presented on the same day for the same items so the stock is not 
available. 
…I can understand that they can’t stock everything and they 
might have to work hard to get them… (GP, HCP10) 
Other healthcare professionals said they wanted more pharmacies to stock 
what they considered to be the very ‘basic’ palliative care medicines such as 
diamorphine, midazolam, haloperidol and hyoscine butylbromide, though 
others presumed most if not all pharmacies held stock of these drugs. 
…they all hold some, but I know some don’t hold specific ones or 
quantities (Community Healthcare Professional, cHCP7) 
…I tend to assume that they stock morphine, diamorphine, 
oxycodone and then the usual antiemetics…midazolam… 
(General Practitioner, HCP10) 
Many of the interviewees highlighted differing strengths of midazolam, 
oxycodone injection and sizes of water for injection to be issues. 
…the big problem is midazolam…so many strengths…volumes of 
ampoules…the GPs just pick one… (Community Pharmacist, P3) 
…such a palaver getting hold of water for injection. The 
pharmacist rang me 5 times about water for injection…it wasn’t 
available (Community Healthcare Professional, cHCP11) 
A pharmacist pointed out that even if pharmacies are open longer hours they 
still have the same cut off times for ordering drugs from the wholesalers so if 
the drugs were not available longer pharmacy opening hours did not help. 
…wholesalers don’t work longer opening hours so…if stock 
needs to be ordered the timescale for ordering that stock remains 
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the same. So, 100-hour pharmacies will still have the same cut 
off time for placing orders and…the same delivery schedules as 
pharmacies who are open much less hours…if the stock’s there 
it’s great, but if the stock’s not there it doesn’t improve things just 
because they are open longer hours (Community Pharmacist, P1)  
Most healthcare professionals - GPs, members of the palliative care team 
and community pharmacists - were aware of current and past national issues 
affecting availability of diamorphine and haloperidol, both commonly used 
palliative care medications, which had caused difficulty. It was pointed out 
that stock problems consume a lot of time both knowing when something is 
not available and when it becomes available again. 
Its [stock problems] one of the biggest I think irritating problems 
that we’ve had in the last year or two and is growing …it just 
consumes so much time…I guess with palliative we are just a bit 
more cautious to make sure the availability is there (General 
Practitioner, HCP3) 
I’d…be enquiring what medicines were available…I might know 
what I want to prescribe but there’s no point if it’s not there and 
it’s going to lead to a delay (General Practitioner, HCP2) 
Some community pharmacy computer systems had issues passing controlled 
drug orders between wholesalers when the usual wholesaler was showing 
that the product was out of stock. In some cases, pharmacy staff ended up 
ordering the controlled drugs as both a manual order in addition to a 
computer- generated order on the pharmacy computer system to ensure the 
medication arrived. This could result in double quantities of controlled drug 
stock arriving that could not be sent back. 
We use electronic systems to order drugs so we actually did it as 
a manual order as well, so we actually ended up having double 
lots [of controlled drugs] in (Community Pharmacist, P3) 
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There could also be issues with the pharmacy computer system when 
ordering expensive or special items where the computer-generated order did 
not automatically replace stock issued against a dispensing label. This meant 
that pharmacy staff had to take care in ordering particularly sensitive items 
like palliative care medications to ensure stock was available in the pharmacy 
when expected. 
…if there is a product which is particularly expensive it [pharmacy 
computer system] won’t automatically order it…if it’s on the 
computer menu but it’s a special it will let you do the label but it 
won’t order it…so with something that is particularly sensitive like 
palliative care [drugs] we look at the computer information…but it 
doesn’t proffer the information you have to go looking for it…it 
might say ‘regret no stock or out of stock’ …you will try your third 
line wholesaler or try an adjacent pharmacy or you go back to the 
doctors (Community Pharmacist, P5) 
a) Locally agreed Formulary List 
Use of a limited list or formulary of palliative care medicines was seen to 
support availability of palliative care medicines in urgent situations. This was 
evident even in pharmacies not part of a formal commissioned service who 
had worked with local GPs to instigate their own local list of palliative care 
medicines as well as those within the formal commissioned service. 
…I have had conversations with the surgery to establish what I 
should keep…I gave that [a palliative care list] to the surgery and 
I said …which ones shall I keep… (Community Pharmacist, P5) 
…we went to them [GPs] and said, what are the most common 
drugs you would prescribe in palliative care for patients and they 
[GPs] came back with a list…so we would try to keep the stock in 
for what they specified (Community Pharmacist, P3) 
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Even though such a formulary list was well established for commissioned 
pharmacies (see Appendix R), healthcare professionals in the community 
were not aware of the list’s existence, which pharmacies kept the drugs or 
what drugs were on the list. 
…relatives who are running right left and centre trying to get hold 
of these meds…there is a commissioned service…but we don’t 
know who they are… (Community Healthcare Professional, 
cHCP1) 
Instead CHCPs relied on local knowledge or rang ahead to check whether 
the pharmacy had the necessary medication. 
I don’t know who’s commissioned we just basically know which 
ones we go to that are more likely to have it… (Community 
Healthcare Professional, cHCP4) 
It was suggested that a citywide bulletin would help ensure everyone knew 
the formulary so pharmacies who were not commissioned to provide the 
service still had the option of keeping the drugs in. Interviewees thought that 
a bulletin would provide information to ensure a smoother supply of drugs. 
…making sure we that we all work from a standardised formulary 
in palliative care and sharing that formulary with the pharmacies 
as well, at least then the pharmacists’ have the opportunity to 
decide oh I’ll keep that stock in or not…something like a CCG 
wide letter…like a formulary or just a bit of help with regards to 
obtaining the drugs… (Community Pharmacist, P3) 
…it’s easy from my point of view to solve it, you send out the 
formulary drugs to every GP…and you tell everyone this is the 
drugs…stick to these (Community Pharmacist, P4) 
It was also identified that this can prove difficult to achieve. 
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…we have a list of drugs…I’m absolutely sure has been 
disseminated to everybody but getting clinicians to a) read 
it…and then retain it and remember …that’s the particular one 
that they need to pick is very, very difficult (Community 
Pharmacist, P4) 
Some interviewees from non-commissioned pharmacies perceived that the 
commissioned pharmacies were being paid extra to stock drugs but were not 
providing anything different to the universal NHS contractual obligation to 
supply drugs with due promptness. 
…it’s not like a specialist service…you’re being paid to hold a set 
amount of stock…you’re not offering anything above and beyond 
from what I understand… (Community Pharmacist, P1) 
…it doesn’t really make any difference…whether it’s someone 
wanting vitamin capsules…or diamorphine ampoules…I’m under 
the same expectations to provide with due promptness…that’s 
the contractual obligation (Community Pharmacist, P5) 
...we’re talking about things that might…cost £5 to £10 it’s no big 
deal and for the difference it makes to the patient that’s not much 
money at all (Community Pharmacist, P5) 
For most pharmacies if they did not have the stock in or for commissioned 
pharmacies when the item was not on the commissioned list then it would 
invariably be ‘next day’. Several staff raised this as being a problem. 
Healthcare professionals may not know what the cut off time is for the 
pharmacy when ordering medications for same day delivery. 
… [The pharmacy] say ‘oh it won’t be in till tomorrow’ 
…sometimes that’s a bit too late really (Community Healthcare 
Professional, cHCP1)  
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…I could go in now and say, ‘I need these drugs’ ‘Oh I can get 
them in for 11 o’clock tomorrow morning’ [exasperated laugh] it’s 
like that’s not really very helpful, I need them now (Community 
Healthcare Professional, cHCP7) 
We can normally order things for the same day, if it’s before 
midday we can get them [medicines] for 4 o’clock that 
afternoon… (Community Pharmacist, P2) 
5.6.2.1.3 Accessing specialist palliative care medicines 
Prescribing of non-standard formulations of some drugs and specialist 
palliative care medicines posed challenges. Methadone for example, in tablet 
or injection form was rarely a core stock item in most community pharmacies. 
Patients prescribed methadone for pain relief were usually under the 
palliative care team who then had to plan ahead and issue prescriptions well 
in advance of a patient running out. 
…nobody’s sure that they are on methadone or never mind who’s 
prescribing it or dispensing it (General Practitioner, HCP2) 
…like methadone you can’t really get your hands-on methadone 
[injection] from an average pharmacy… (Community Healthcare 
Professional, cHCP6)  
Difficulties in accessing other ‘specialist’ drugs for complex patients were 
reported, for example dexamethasone and clonazepam injection, which were 
not even on the commissioned service drugs list. In the case of clonazepam 
injection, healthcare professionals and some pharmacists were not aware 
that it is not licensed in the UK and had to be imported. 
…we quite often use clonazepam in the syringe drivers…if you 
take it [prescription to the pharmacy] …and ask them to order it in 
I will undoubtedly get a phone call to say it’s not available, they 
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can’t get hold of it… (Community Healthcare Professional, 
cHCP11)  
These disconnections in the supply chain sometimes had dire consequences 
for a patient. A case was reported where a patient at risk of a seizure, who 
could not swallow, had a long turnaround time to access dexamethasone 
injection. 
…dexamethasone…for a patient with a brain tumour…we 
requested it at about 12 o’clock…by the time the district nurses 
had then got to the patient to make up the [syringe] driver it was 
10pm (GP, HCP2) 
5.6.2.1.4 Transporting medications to the patient’s house 
The location of the pharmacy, the distance to the patient’s house and 
transporting the medication to the patient’s house were also key factors that 
affected timeliness of accessing medication. Family involvement and 
pharmacy delivery services were identified as prominent sub-categories. 
a) Family involvement 
Community healthcare professionals perceived there was a significant 
burden for family caregivers who were involved in obtaining medications for 
patients near the end of life; nevertheless it was accepted that family 
caregivers should provide support in this area. This normally required having 
access to a vehicle. 
…you know they can end up getting a lot of prescriptions and 
they are back and forth to the pharmacy…sometimes…that 
involves getting someone to do it for them or going in the car and 
that’s hard but that’s the nature of looking after someone with a 
terminal illness (Community Healthcare Professional, cHCP9) 
…if they haven’t got a car it’s sometimes a bit tricky…in other 
pharmacies which are potentially more isolated…if you didn’t 
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have a car it was particularly difficult to get to pharmacies that 
were perhaps larger, open longer hours and held more of the 
stock (Community Pharmacist, P1) 
In some cases, the stress for family caregivers was recognised and 
Healthcare Professionals “went the extra mile”:  
[the pharmacy] can be miles away from…the patient…they may 
not have transport and it’s a huge stress [with emphasis from 
cHCP11] on families…to…pick up these medicines they get so 
frustrated…sometimes we have to...take that burden off them… 
(Community Healthcare Professional, cHCP11) 
Even though family caregivers were cited as being valuable in supporting the 
process of collecting the medication it was also recognised that this may 
affect community nursing response time. In some cases, nurses were doing 
all the work to collect drugs and start the syringe driver taking an appreciable 
amount of time and resources away from care of other patients to ensure 
timely access. 
…quite often it is doing the full package…if you are relying on 
other people to do that [pick up medications] it could take a lot 
longer (Community Healthcare Professional, cHCP11) 
…we’re getting the phone calls…you need to pick up…the family 
can’t get ‘em…I just feel sometimes that the pressure is on us to 
get it done (Community Healthcare Professional, cHCP5) 
…you have to get the family involved or delivery it’s just that short 
amount of time of getting it done… (Community Healthcare 
Professional, cHCP6)  
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b) Pharmacy delivery services 
Pharmacy delivery services were generally felt to be helpful. However, other 
healthcare professionals were not necessarily aware that the NHS does not 
fund pharmacy delivery services or the terms and conditions for when 
delivery services were offered. It was also noted that ‘…not all community 
pharmacies do deliver. I think a lot of them have to now; otherwise they 
would lose business’. 
…feedback I get from patients is that pharmacies are very helpful 
and they do delivery services…so I’ve had lots of good positive 
feedback whether the patient says ‘oh that’s fine they always 
deliver that’s not going to be a problem, they’ll sort it out’ 
(Community Healthcare Professional, cHCP9) 
I think the most useful thing would be delivering medicines to a 
patient’s house…I’m not sure…they are contractually obliged to 
do it or if that is something they do as a bit of a favour seems to 
be a bit of variation as to how freely that happens and some 
chemists…do charge if its certain times of day or something. I 
don’t quite know what the rules are. [GP, HCP10] 
In cases where acute, urgent supplies of medication were ordered from a 
pharmacy that was not the patient’ usual pharmacy there may be a charge 
applied for a delivery. Healthcare professionals were embarrassed that some 
pharmacies were charging families five pounds per delivery for medications 
at the end of life.  
...is kind of awkward to ask the family to pay…especially when 
they…get medicines delivered almost every day… (Community 
Healthcare Professional, cHCP11) 
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5.6.2.1.5 Obtaining correctly written prescriptions 
Prescriptions were not seen as a barrier since most prescriptions were 
computer generated or where minor typographical errors were present the 
community pharmacists were able to amend these due to changes in CD 
regulations (Home Office 2015a). 
…we don’t generally have hand writing issues anymore. A lot of 
prescriptions are computer generated; we don’t generally have 
that issue (Community Pharmacist, P4) 
…I think the prescriptions are written well particularly the 
computer-generated ones…I think most scripts come and go 
without too many problems (Community Pharmacist, P2) 
Very rarely did pharmacists need to contact the prescriber or OOH service to 
issue a new prescription. Most pharmacists preferred not to contact the OOH 
service due to the slow process and because the GP on duty OOHs had 
limited knowledge about the patient. 
…I don’t think I’ve ever…contacted the out-of-hours GPs in 
Sheffield. Mainly because it’s a bit of a protracted process. 
(Community Pharmacist, P4) 
…you’ve got to ring the out-of-hours doctor to get a new 
script…they probably don’t know any more about the patient, [or] 
have access [to] much more [information] than we’ve got and we 
are just asking them to write a script for a different strength that 
we have in stock (Community Pharmacist, P2) 
There was no evidence reported by interviewees of community nurses 
sorting out prescription queries before taking prescriptions to the pharmacy 
though one nurse commented: 
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…it’s not you guys it’s the prescription that’s not done or it’s the 
wrong prescription, it’s not enough what they [the patient] need… 
(Community Healthcare Professional, cHCP6) 
Another nurse commented that the prescriptions should be sorted between 
the GP and community pharmacist and were not for the nursing team to get 
involved with. 
a) GP Computer Systems 
GPs stated that the computer was helpful for enabling them to generate a 
legal prescription. There was an auto-consultation for pre-emptive medication 
pre-loaded onto SystmOne a general practice clinical computer system that 
supported this and covers nearly 80% of practices in Sheffield. 
…we now have an auto-consultation for pre-emptive 
prescribing…that seems to be helping cut down mistakes it just 
generates a standardised set of prescriptions (GP, HCP10) 
Some pharmacists reported instances where the GP clinical system was not 
so helpful and the wrong product was chosen leading to a delay in the patient 
obtaining the medication. 
…we have a particular issue with incorrectly written prescriptions, 
and it’s always midazolam. They always pick the one [on the 
computer] that’s not on formulary…legally there’s no problem with 
it but it’s not formulary, it’s not a regular stocked item (Community 
Pharmacist, P4) 
Community pharmacists mentioned that development of EPS should relieve 
problems with accessing correct prescriptions and be quicker too. 
…obviously faxing is illegal whereas with an electronic 
prescription that would relieve that whole problem and probably 
speed things up…I think that would make a big difference 
(Community Pharmacist, P2) 
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No EPS delivered prescriptions were reported in the study though it was 
noted that there could be a potential issue with EPS prescriptions coming in 
two parts since controlled drug prescriptions could not yet be issued on EPS 
due to the need for technical updates to GP clinical system prescribing 
software (HSCIC, 2017). 
…electronic prescriptions…could potentially be an issue…I don’t 
know if it happens with palliative…they’ll [GP] send down 
electronic prescriptions for all the non-CDs…but…there’s a CD 
script still at the surgery that we might not know about… 
(Community Pharmacist, P2) 
b) Effects of CD Regulations 
Doctors and nurses were generally unaware of the affect CD regulations had 
on the pharmacist except GPs were aware of the need for legal prescriptions. 
Pharmacists all raised the limitations of the legal framework especially where 
this caused an ethical dilemma like the supply of medications at the end of 
life where they recognised they had a duty of care to the patient. All of the 
pharmacists could relay stories from the past where they had issued an 
illegal prescription where this was in the best interests of the patient ‘So, I’ve 
done prescriptions that are illegal and then sorted those out afterwards 
because you don’t want to delay treatment for these patients’. ‘[The] GP had 
phoned up…and said if they faxed us across [a prescription] can we get it to 
the patient…[we] handed it out before I’d even got the prescription in my 
hands.’ The pharmacists also felt their hands were tied by the legal 
framework that was very specific in what was allowed and considered they 
would be inviting trouble if they did not comply with the legal requirements. It 
was recognised this would be particularly difficult when the prescriber could 
not be contacted, if the pharmacist did not know the prescriber or for locum 
pharmacists who would be relying on pharmacy staff and the pharmacist the 
next day to resolve the issue. Where an illegal prescription could not be 
dispensed this could impact on timely access to the medication for the patient 
and necessitate a trip back to the GP or a call to the GP OOH service to 
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access a legal prescription. Whilst some pharmacists felt ethically they could 
justify their decision to ‘bend the law’ and issue medications on an illegal 
prescription at the end of life they also understood there was no option to 
‘break the law’. ‘…if someone came to me at closing time, and said he’s out 
of MST tablets… I send them to somewhere where they can get more tablets 
because I’ve got absolutely no option on that, if it’s somebody who if I can 
bend the law without breaking it I will do but there’s somethings where 
it…might be well intended but you can’t do it’. 
A further problem identified by community pharmacists was the inability to 
alter legal prescriptions where they could not supply the requested product. 
‘…we haven’t got the 10mg in stock but we’ve got 20[mg], I think I would be 
more than capable of changing that…having to go back to the doctor to get 
the script changed isn’t a good use of anyone’s time particularly if this poor 
patient needs their diamorph[ine].’ This was further compounded when GPs 
had difficulty choosing the correct formulation from their computer’s palliative 
care list as described in section a) above. This was noted particularly for 
midazolam and oxycodone. 
…we’ve got three different strengths of oxycodone injection, and 
they [GPs] prescribe all three, and you might not have one, you 
might have the other…it’s just so frustrating…you don’t want to 
delay treatment for what is a really difficult time for the patient 
and the family…but unfortunately our hands are tied by the 
legislation and our ability to be able to alter any of these 
prescriptions (Community Pharmacist, P4) 
5.6.2.1.6 Responding quickly in the community setting 
All healthcare professionals expressed time pressures in their day to day 
work that affected their ability to co-ordinate and respond quickly to patient 
needs, this was particularly heightened where patients’ and carers’ 
expectations were not managed after discharge from an inpatient setting 
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where they were expecting the same quick response to relief of symptoms in 
the patient’s home. 
…we are not the 4th emergency service but when people come 
out here [in community] to die we can’t respond like you can in 
[name of organisation] but patient’s relatives don’t like that part of 
it and we literally …drop everything to do the drugs…it’s just too 
much pressure sometimes for us to do it all (Community 
Healthcare Professional, cHCP5) 
There was recognition that pharmacies are a busy environment with chasing 
stock availability and Monitored Dosage Systems (MDS) issues consuming a 
lot of time. It was recognised that MDS or Nomad® boxes made it difficult to 
titrate drugs and respond quickly to the patient’s symptoms. 
Nomads are just growing exponentially with the aging population 
massive, massive burden for pharmacists (GP, HCP3) 
Patients that have Nomads there was quite a lot of liaison with 
the pharmacist and it could get a bit complicated because it was 
really hard to titrate things when people have got Nomads 
because you are back and forth and back and forth [to the 
pharmacy] you’d go back the week after and the new drug hadn’t 
been put in [the Nomad] (Community Healthcare Professional, 
cHCP11) 
Community healthcare professionals expressed the opinion that if 
pharmacies just had the basic stock of palliative drugs available this would 
enable a quicker response to the patient’s symptoms and avoid delays. 
…I think if just more chemists had the bog-standard stuff in… 
[Community Healthcare Professional, cHCP11] 
…simple things like keeping a stock in for me of all the regularly 
used drugs…there [a locality] I would get a [syringe] driver up in 
an hour [for a patient], because I knew worst case scenario down 
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the hill into there [pharmacy], back out again. Whereas a lot of 
the pharmacies around here don’t even keep the drugs in. So 
that’s a delay… [Community Healthcare Professional, cHCP4] 
5.6.2.2 Communication and Collaboration 
Under the subtheme of communication and collaboration the categories are: 
understanding role, community pharmacist relationships with other 
healthcare professionals and communication within and across teams with a 
further number of subcategories within these. Further details of these 
categories and subcategories are explained further below. 
5.6.2.2.1 Understanding role 
Within the category of understanding role there were two sub-categories: 
professional role and identity; confidence and experience. 
a) Professional role and identity 
Community pharmacists had a simplistic view of their professional role within 
palliative care that was limited in scope to providing what the doctor ordered; 
a traditional dispensing role. 
…but the important thing is to just recognise your role is trying to 
provide what the doctor wants and what the nurses want for that 
patient, because they’ve assessed the patient personally and 
they consider this to be the best treatment… (Community 
Pharmacist, P5) 
…most of the decisions have already been taken, for example 
dosing (Community Pharmacist, P3) 
Nevertheless, community pharmacists identified they had an important role 
acting as a go-between for the patient or the patient’s representative and the 
GP practice in sorting out prescription issues. Some community pharmacists 
who had experience of working in GP practices had gained an understanding 
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of how practices worked. ‘I think the GP practice has given me a greater 
understanding of what goes on in a GPs day to day life, and how many 
queries they do get’. This then reflected in their behaviour for instance when 
contacting the practice from the community pharmacy ensuring practice staff 
were aware they had a palliative query so this could be prioritised. 
There was also consideration of extending the pharmacists’ role in palliative 
care but there were barriers to be overcome: 
In terms of what we could do, it’s all about our ability to be able to 
fit those things in…you could change the whole system if it wasn’t 
for the classification of the drugs… we’re really restricted in terms 
of time that we have to do anything else in community pharmacy 
and do anything outside of the four walls of the community 
pharmacy and the legal framework that defeats our ability to 
change from what’s on the prescription (Community Pharmacist, 
P4) 
There was the opinion that community pharmacists could have more of a role 
in palliative care. 
I don’t think there is a consistency of involvement of community 
pharmacy with patients [in palliative care], it definitely feels like 
something that could make a difference if it could be formalised 
more and proved… (Community Healthcare Professional, 
cHCP9) 
Nurses knew little about the community pharmacists’ role beyond dispensing. 
…nurses just see pharmacists as people who dispense drugs 
they don’t see pharmacists as the person who can actually make 
suggestions of drugs… (Community Healthcare Professional, 
cHCP4) 
It’s probably a case of not having knowledge of what else you –
[pharmacists] do apart from dispensing medications we need for 
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the patient if there is any other service they provide I’m not aware 
of that [laughs] (Community Healthcare Professional, cHCP6) 
Interestingly, although a nurse might consult a pharmacist for their own 
treatment, within palliative care they would always go to the GP. 
You know for myself, going off subject, a lot of the time I go 
straight to the pharmacist rather than the GP first. I don’t know 
why I don’t in this instance [both laugh] (Community Healthcare 
Professional, cHCP8) 
Many healthcare professionals had a distinct lack of knowledge of community 
pharmacy services both nationally contracted and locally commissioned 
services as well as services provided by the local pharmacies themselves, 
which had an impact on how they viewed and utilised community 
pharmacists. For instance, healthcare professionals did not understand the 
term and conditions around delivery of medicines relying on local knowledge 
about where to go to access palliative care medicines. 
GPs were aware of some of the nationally contracted services such as MURs 
but noted they had not experienced these services being provided to 
palliative patients. 
Generally, the [community] pharmacists do medication reviews 
for us occasionally but that doesn’t tend to be the case with 
palliative patients. For instance, with other patients they would 
check if all the medications were needed…but I don’t think that 
tends to happen with palliative as much (GP, HCP3) 
b) Confidence and experience 
Pharmacists’ confidence and experience in palliative care was mostly 
obtained after registration and relied on the pharmacist’s own motivation. 
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…I’ve done the CPPE [training] pack…I think I had just qualified, 
because they scared me a bit palliative care scripts (Community 
Pharmacist, P2) 
…depending on your training and experience, there is definitely 
psychological support you can give…depending what you 
specialise in…talking to someone going through this stage in their 
life…there is the pharmaceutical side…being proactive rather 
than trying to be reactive does play a big role… (Community 
Pharmacist, P3) 
Other healthcare professionals contrasted their own experience of seeing 
dying patients and feeling responsible for their care: 
I think it’s a question of people [pharmacists] feeling responsible 
or competent so just you go into a local pharmacy and the 
pharmacist in there is not going to feel they are responsible for all 
the palliative patients on their patch or they may not feel they 
have the specialist skillset (Community Healthcare Professional, 
cHCP9) 
…if you’ve not seen lots of patients close up and you’ve not got 
much clinical experience of seeing patients with symptoms with a 
palliative nature everyday then I suppose it’s a training/ 
experience barrier (GP, HCP10) 
5.6.2.2.2 Community Pharmacist relationships with other healthcare 
professionals 
Communication between community pharmacists and GPs varied from close 
working relationships within co-located facilities, to good relationships in 
small neighbourhoods, to more professional relationships across several 
practices. 
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…I’m not sure if we’ve got an exceptionally good relationship with 
ours [pharmacist] or not but I would have thought most GPs do 
(GP, HCP3) 
…my relationship with the GPs is not as solid as it was with the 
previous surgery…you’ve got loads more GPs in your radar, so it 
makes it difficult (Community Pharmacist, P3) 
Pharmacists in pharmacies that were not co-located with a GP practice 
tended to talk directly to GPs less often and conversations were more likely 
to be initiated by the GP on the telephone than co-located pharmacies who 
initiated more face to face conversations with GPs.  
…there was an on-site pharmacy…I could go to them with 
questions because they were literally in the same building (GP, 
HCP2) 
Relationships between GPs and pharmacists were positive both ways with 
GPs stating they found pharmacists to be very accommodating. GPs did not 
mind pharmacists querying things though this was seen as giving 
reassurance to the pharmacist for example, when a potential drug interaction 
is flagged up on the pharmacy computer system. 
They’re very good the local pharmacists and I never mind them 
querying things…they’re never wasting my time…they do 
occasionally pick errors up. I mean most of the time it’s just 
reassurance…but it’s an extra safety net for us (GP, HCP3) 
Relationships between pharmacists and other healthcare professionals 
tended to be very limited or non-existent. 
…I don’t really have a great deal to do with the pharmacy. I can’t 
tell you the last time I ever spoke to a pharmacist about any 
prescribing or any drugs for palliatives (Community Healthcare 
Professional, cHCP5) 
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…we have district nurses…across the way from the 
pharmacy…we don’t necessarily have those relationships with 
the nurses…we don’t have that close collaboration with the 
District Nurses (Community Pharmacist, P4) 
Where cooperative relationships between GPs and pharmacists existed this 
resulted in a positive patient experience where GPs communicated intentions 
to prescribe palliative medicines in advance with the pharmacist. 
So, the surgery down the road...one GP…rang us and said well 
what have you got in stock and what can you get, which I found 
really, really useful because as the prescription came in the stock 
came in and this thing was completely seamless (Community 
Pharmacist, P3) 
Nurses also held the view that closer integration with pharmacists would help 
patients though this appeared to be difficult to enact on the ground. Nursing 
staff favoured more personal relationships needing to meet someone face to 
face and they worked well with pharmacists who were ‘part of the team’ 
where they had built trusting relationships. 
When we were down at [previous community nurse location] 
…there was a pharmacy next door so…if we had any quick 
questions, we would go and talk to them…they were more like 
part of the team (Community Healthcare Professional, cHCP7) 
…so sometimes by sharing knowledge with pharmacists I think 
we could get better results for patients (Community Healthcare 
Professional, cHCP4) 
Trust was an important part of developing personal relationships and was 
regarded as necessary when dealing with palliative care whether they were 
professionals or patients and their family caregivers. 
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…I knew the GP and I had an existing relationship with them and 
I knew they would fulfil their end of the agreement (Community 
Pharmacist, P1) 
…you’re just someone to speak to. Quite often they’ve [the 
patient’s family] been to see the doctor, they’ve been to see a few 
and it’s almost just like they want to see what you have to say 
about this and it’s just supporting them in the best way you can 
and signposting them where appropriate (Community Pharmacist, 
P2) 
 
5.6.2.2.3 Communication within and across teams and care settings 
Under the category of communication there were two sub-categories: 
decentralisation and isolation of teams and information sharing including 
access to records. 
a) Decentralisation/Isolation 
Community healthcare professionals said that decentralisation of community 
nursing teams to locations away from GP practice and community pharmacy 
hubs had made it more difficult to pop into a pharmacy unless passing or 
collecting medicines and nurses only tended to call pharmacists on the 
telephone to source urgent medication. 
When we were down at [previous community nurse location] 
…there was a pharmacy next door so…if we had any quick 
questions, we would go and talk to them…they were more like 
part of the team (Community Healthcare Professional, cHCP7) 
…they’ll phone up and say…have you got the following stock 
because I’m going to ask for a prescription from the doctor 
(Community Pharmacist, P5) 
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…I do contact them [pharmacies] and say, ‘have you got this in 
stock’ ‘yes I do’ ‘well expect a prescription and can you get it 
ready for a family to collect in an hour’…they will always try to 
accommodate I think because they know it’s a necessity… 
(Community Healthcare Professional, cHCP6) 
Likewise, pharmacists did not feel that they worked closely or collaboratively 
with nursing teams. There also appeared to be limited contact with specialist 
palliative care in all except one pharmacy. 
…no, I’ve never had any interaction with them [specialist 
palliative care team] at all (Community Pharmacist, P4) 
Community pharmacists were often viewed by other healthcare professionals 
as being detached and working in isolation, however, they also found 
pharmacists to be accommodating and professional in trying to resolve any 
issues especially in the context of end of life. 
…community pharmacy are [sic] a bit detached sometimes 
(Community Healthcare Professional, cHCP1) 
…pharmacists are behind a counter…they don’t tend to go out 
into patients’ houses… (Community Healthcare Professional, 
cHCP4) 
Community pharmacists felt isolated from other members of the primary care 
team due to the necessity to remain in the pharmacy arising from the 
responsible pharmacist regulations. This was compounded by the geography 
of primary care, the city itself and the many GPs who the pharmacist could 
potentially encounter. 
…we’re really restricted in terms of the time that we have to do 
anything else in community pharmacy and do anything outside of 
the four walls of the community pharmacy… (Community 
Pharmacist, P4) 
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…the logistics of community and primary care don’t support that 
[multidisciplinary working] as well with regards to the 
geographical locations of these people and with things like 
responsible pharmacist regulations… (Community Pharmacist, 
P1) 
My relationship with the GPs is not as solid as it was with my 
previous surgery… you’ve got loads more GP surgeries in your 
radar, so it makes it difficult… (Community Pharmacist, P3) 
This was exacerbated further by a lack of involvement in GP practice clinical 
meetings. One GP had not considered the involvement of community 
pharmacists in their palliative care team meetings and expressed practical 
considerations that would probably make it difficult for a pharmacist to attend. 
(GP, HCP3) …they don’t for instance come to our palliative MDT 
meetings. 
(Researcher) Would they be invited? 
(GP, HCP3) No. 
(Researcher) No. 
(GP, HCP3) No, I’ve never really thought about it. It’s hard 
enough getting everybody together anyway without additional 
people… 
One pharmacist suggested the use of new technology to facilitate their 
involvement in meetings. 
…it would be great if there was some way, perhaps using modern 
technology facilitating the involvement of a pharmacist in these 
sort of [practice clinical] meetings (Community Pharmacist, P1) 
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b) Information sharing and access to records 
There was caution in communicating information with pharmacists hindered 
by participants’ views on confidentiality and information sharing with 
pharmacists and pharmacy teams. Dispensers and other staff in the 
pharmacy often lived in the area and it was felt inappropriate that information 
on palliative patients and their families could be shared with these staff. 
I do have some slight reservations about them [pharmacists] 
knowing all those ins and outs…I’m not sure how wide that circle 
is in there [pharmacy]…I’d prefer it …on just a case by case 
basis…to an identified clinician… (General Practitioner, HCP10) 
…but you’re limited by what you can tell them [pharmacists] 
obviously from a confidentiality point of view… (Community 
Healthcare Professional, cHCP11) 
Healthcare professionals did not see the need to share information with 
community pharmacists’; they did not see what information would be of use 
to pharmacists. They also did not see a reason to inform the pharmacist that 
the patient is palliative instead they would rather let them work this out 
intuitively from the prescription. 
(Researcher) Is there any information that you or your team 
could share with pharmacists to improve the care of 
palliative care patients? 
(Community Healthcare Professional, cHCP6) I can’t think of 
anything, no. 
…we don’t communicate with them [community pharmacist] what 
the problem with the patient is we just prescribe the drugs… 
sometimes they can obviously work it out… (GP, HCP3) 
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In some cases where the researcher prompted the question some healthcare 
professionals considered it may be helpful for the community pharmacist to 
have this knowledge if it supported patient care. 
…it’s an interesting point that’s only just occurred to me as we 
mentioned it…I think maybe it would be useful for them to know 
[the patient is palliative]. I mean they get to know if we ring up to 
check if drugs are available (GP, HCP3) 
Maybe we should have better meetings say like [if] a palliative 
[patient] did come on [the nurse’s caseload] would it be a good 
idea to inform them [community pharmacist] that they are on [the 
nurses caseload] and that there may be issues that we need to 
address and keep in close contact. Other than that I can’t really 
see any call for it [sharing information with the community 
pharmacist] (Community Healthcare Professional, cHCP5) 
 
(Researcher) What kind of information do you think you or 
your team could share with community pharmacists to 
improve the care of palliative care patients? If anything? 
(Community Healthcare Professional, cHCP7) Well obviously 
from my lack of communication and usage maybe more 
integration with them  
(Researcher) In what way do you think that might help 
palliative care patients? 
(Community Healthcare Professional, cHCP7) Just maybe they’re 
getting the right drug at the right time for the right length of time 
and it gets changed more appropriately, the dose is more 
appropriate. 
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Some pharmacists stated that access to patient clinical records on SCR, 
though this had not often been used in palliative care, had helped resolve 
queries with prescriptions and managing conditions in the pharmacy. There 
was concern due to frequent medication changes and multiplicity of 
prescribing in palliative care that SCR may not be complete or up to date yet 
there was general agreement that having access to information meant that 
the pharmacist was better able to help the patient. 
I use Summary Care Records…[if]… the CD dose changes 
particularly the opioids I’ve used SCR to check if have they had 
this before or have they had a lesser strength before…some of 
them can be scarily high so you’d hope to see something on this 
[SCR] (Community Pharmacist, P2) 
…having more access to that [referral letters on SCR] will help 
speed things up particularly out-of-hours…I think palliative care 
would be an area that [SCR] has one of the biggest effects 
on…the more information we can get as community pharmacists 
the better able we are to deal with it and help the patient. 
(Community Pharmacist, P2) 
Even though it was considered that access to electronic patient records might 
help community pharmacists in their role there was still some concerns about 
sharing this information with them. 
…that would definitely help [having access to electronic records] 
… we share this information with the out-of-hours teams so 
actually having the chemist formally aware rather than just 
picking up because they have received a prescription for 
diamorphine… [however] I’ve not become aware of where it’s 
been a problem…I’ve never heard a chemist saying well I’m sorry 
I wasn’t willing to issue this… because I was not aware they were 
palliative. (GP, HCP10) 
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5.6.2.2.4 Integrated/Collaborative Working 
There was some evidence where there was high quality communication 
between the professionals looking after palliative care patients and the 
pharmacy team there was higher co-ordination of care. 
…the doctors would be there writing the scripts, the nurses would be 
there…we would work very closely and collaboratively (Community 
Pharmacist, P4) 
… [the District Nurses] …they would come in and ask for advice…and 
say what have you got in, what can I prescribe (Community 
Pharmacist, P3) 
I’m very open to suggestions and conversations, and they [District 
Nurses] appreciate that and I encourage them to keep in touch…new 
nurses are given this list [of palliative care medications] and I say look 
this is what I do…if you want me to modify that [list] do tell me…the 
greater the level of dialogue, not just the quantity but [with] the 
different professionals involved, you do liaise better if you talk to each 
other a bit more often which kind of seems obvious but there’s nothing 
worse than hitting a snag which could have been 
resolved…(Community Pharmacist, P5) 
Ongoing discussions between a pharmacy and the palliative care team to 
allow access to more specialist drugs were being considered on an informal 
basis ‘…one of the pharmacists did stop me and asked…if we drew up a list 
of drugs we would like them to have, then they would be happy to stock 
those for us…’ 
5.6.2.3 Skills and Knowledge 
Categories included pharmacists’ knowledge, skills and experience and 
community pharmacy team knowledge, skills and experience. 
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5.6.2.3.1 Pharmacist’s knowledge, skills and experience 
Community pharmacists acknowledged that palliative prescriptions can be 
difficult and can take a little more concentration. 
…you have really got to concentrate and make sure you’re… 
checking them right…they’re difficult (Community Pharmacist, 
P2) 
It was clear from the healthcare professionals that some of the pharmacists 
they encountered were not familiar with pre-emptive prescribing or 
understood the urgency of needing the drugs near the end of life. 
I got the impression [the pharmacist had] probably never done 
pre-emptives before because she rang me, she wasn’t happy for 
the family to take them because she wanted to be clear that they 
weren’t going to be giving them and if she needed to give the 
family any counselling about how to use them and I was…that’s 
not the point of pre-emptives the family don’t use them at all so 
you’re fine to give it to them and they haven’t got anything in the 
house that they could use them for so they couldn’t draw them up 
(Community Healthcare Professional, cHCP11) 
…community pharmacy don’t [sic] really understand how urgent 
these kinds of things are… (Community Healthcare Professional, 
cHCP1) 
An example of the unfamiliarity meant that a patient was turned away when 
they presented a controlled drug prescription from a non-medical prescriber. 
‘not that long ago, a patient took one of my prescriptions in [to the pharmacy] 
and because it had a controlled drug on [the prescription] the pharmacist 
refused to do it and sent them [the patient] away [be]cause it was a purple 
form’. 
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There may have also been unfamiliarity around the term ‘palliative’ with 
pharmacists focusing on those people in the terminal phase though it was 
defined for the interview as anyone in the last year of life. 
It’s been the experiences of people bringing in prescriptions 
for…all sorts of medication that might go in a syringe driver 
or…that’s administered by injection for end of life care 
(Community Pharmacist, P1) 
Another example was concerning a ‘living with and beyond’ cancer scheme 
developed in partnership with Macmillan, a national cancer charity, available 
in Sheffield community pharmacies. People who had been referred to the 
pharmacy for symptomatic treatments relating to their cancer treatment were 
considered ‘pre-palliative’. 
…it’s probably not at the palliative stage, it tends to be dealing 
more with the effects of [cancer treatment] …if say they’ve got a 
dry mouth…we can help make that easier for them… (Community 
Pharmacist, P2) 
Training in palliative care had been completed by four of the five community 
pharmacists. The training was provided by CPPE, a nationally accredited 
pharmacy training provider, encouraged within professional development 
networks and by the CCG commissioned service for providing palliative care 
medicines (although some of the pharmacists not commissioned to provide 
the service had also completed it). Some community pharmacists had also 
completed a Postgraduate Clinical Diploma, which included a module on pain 
control. Training was knowledge based with pharmacists identifying a lack of 
experience and skills in more specific areas of palliative care. 
Syringe drivers…I don’t know a great deal about them 
practically…I know the doses…but I’ve never actually seen a 
syringe driver in use or come across one (Community 
Pharmacist, P2) 
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One of the pharmacists had completed the advanced practitioner framework 
for a company chemist in liaison with a cancer charity, which had given 
specific skills in supporting patients with cancer. ‘You get an insight into what 
people’s lives are like when they have cancer…you get a sense of what the 
families go through, the dynamics changing’. 
Pharmacists acknowledged their lack of experience in palliative care that 
meant that besides screening prescriptions for error they did not consider 
their role extended to questioning other healthcare professional’s choice of 
treatment. Pharmacists thought it would be difficult to use a supplementary or 
independent prescribing qualification in this area of practice. 
…beyond screening their prescriptions and their choices of 
treatment for error I don’t think I shall be telling patients what I 
have unless I did that as a supplementary prescribing role in 
palliative care, that’s a possibility but not in general practice 
community pharmacy. I don’t see enough of it to become good at 
it, not at that level of detail (Community Pharmacist, P5) 
This sentiment was shared by some healthcare professionals who 
understood the generalist nature of community pharmacy and the need for a 
specialist skillset in looking after palliative care patients. ‘…a pharmacist 
working with general practice is more of a generalist role…but there comes a 
point where it becomes more specialist palliative care…and it’s above and 
beyond the generalist issues’ 
Specific difficulties for locum and relief pharmacists existed since they may 
not know what palliative care medications are in stock, may have difficulty 
engaging in local education and lack knowledge of locally commissioned 
services meaning they may not be able to provide the same level of service 
compared to a regular pharmacist. Locum or relief pharmacists would be 
unlikely to take a risk in dispensing an illegal prescription that was required 
urgently if this meant leaving an unresolved query for the pharmacy team and 
pharmacist to pick up the next day. ‘not only are they [the locum] entrusting 
their place on the register and their place out of prison, potentially anyway, to 
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a GP…they don’t know…but it is about the trust they have put in 
the…pharmacy team and the trust they put in the pharmacist that they may 
have never met’. Unlike pharmacy managers and regular pharmacists, locum 
pharmacists may not have the same support networks or relationships with 
an Area Manager or Superintendent Pharmacist to enable them to discuss 
any difficult ethical issues or to summon a second opinion. 
5.6.2.3.2 Community pharmacy team knowledge, skills and 
experience 
Having skilled and competent pharmacy support staff was crucial in releasing 
the pharmacist to take on additional roles in the pharmacy. Within the context 
of palliative care, skilled support staff could resolve many prescription queries 
before they reached the pharmacist. This was not a common scenario with 
most palliative prescriptions passing directly to the pharmacist in the majority 
of pharmacies. ‘Where I worked before the pharmacist would tend to deal 
with all of palliative care…whereas here we’ve got a number of technicians 
who know all about it and are more than capable.’ 
In the next section, findings related to the theme of the pharmacists’ role in 
palliative care according to figure 5.5 are discussed in more detail. 
 170 
 
5.6.3 The Community Pharmacist’s role in palliative care 
Figure 5.5: Tree diagram of thematic framework for pharmacist’s role 
 
 
 
 
 
 
 
 
 
 
 
 
 
The Community Pharmacist’s 
Role in Palliative Care 
Talking with, supporting and referring 
patients and their carers 
Clinical review of prescriptions and 
checking safety 
Providing advice and information – 
working with GPs and other healthcare 
professionals 
Continuity of medicines supplies 
Supervision of medicines disposal 
Pharmaceutical care 
 171 
 
5.6.3.1 Talking with, supporting and referring patients and their 
carers 
Pharmacists showed they were highly concerned and paid attention to the 
customer’s needs whether it was the patient, their family caregivers or other 
relatives. This was demonstrated through their professional responsibility, 
being accommodating, helpful and having consideration for others.  
…if you recognise…what these prescriptions are for you 
accept…when you speak to people they will be upset… we will 
take some responsibility for that prescription…explain to them 
what we’ve got to do and why… you approach it sensitively then 
you can normally come up with an acceptable resolution for them 
(Community Pharmacist, P2) 
In contrast, there were also experiences where it was felt by other healthcare 
professionals that the pharmacist was not helpful for instance where people 
were turned away from a pharmacy and told to go elsewhere when they 
required urgent medications for someone near the end of life and were not 
given any direction of where to go or when a prescription did not fulfil legal 
requirements leaving the pharmacist in a difficult position. 
…one bloke got into a bit of a fight with the pharmacist because 
he was so anxious about getting the medication back in time for 
the syringe driver and the pharmacist wouldn’t give him the 
medication because he [the pharmacist] didn’t know what dose 
(Community Healthcare Professional, cHCP11) 
Pharmacists stated that pharmacies were busy places but they all had private 
consultation areas that could be used to sit with patients and talk about their 
medication. Time constraints meant it was not always possible to sit in a 
consultation room but it helped to ask patients how they were getting on with 
their medications when issuing them as people tended to talk about things 
that they were not so sure about, which would indicate if they had any 
difficulties. Pharmacists also emphasised their role in explaining medicines to 
 172 
 
patients and their family caregivers, telling them what the medication is for, 
checking their understanding and advising on safe storage. 
…pharmacies are really, really busy…it depends on the patient; if 
they’ve got time to sit down and have a chat that’s fine, it also 
helps when you hand out the prescription…you can ask ‘do you 
have any problems with these, or is there anything you’d like to 
know about these’…yes I am comfortable to be able to sit down 
with the patient and go through the use of a patch for example 
(Community Pharmacist, P3) 
There could be difficulty in pharmacists achieving the above since palliative 
patients may be unable to visit the pharmacy needing or opting to have their 
medicines delivered instead. 
…if patients are being delivered to then…they [only] ever come 
into contact with the [delivery] driver and the pharmacist doesn’t 
know whether the patients are getting on alright with their 
med[icine]s [be]cause they never really speak to them 
(Community Healthcare Professional, cHCP1) 
This appeared to be a gap in service provision as noted by other healthcare 
professionals. 
…sometimes you go into people’s houses and they’ve got a 
whole sideboard full of medicines and they don’t really know what 
they are taking and actually getting that sorted out is sometimes 
incredibly difficult because it’s whose responsibility is it… 
(Community Healthcare Professional, cHCP9) 
Having had conversations with people diagnosed with cancer or those on a 
‘living with and beyond cancer’ local scheme enabled pharmacists to support 
and signpost people. Often those patients talking with the pharmacist would 
say that their specialist had mentioned this but they had forgotten the details 
discussed at the consultation due to the shock of the diagnosis or results 
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given. Pharmacists said that sometimes patients just wanted a second 
opinion or wanted reassurance and were just trying to sort things out in their 
head. 
…depending upon your training and experience, there is 
definitely psychological support you can give…being able to 
signpost and just putting people in touch with people so they get 
the proper support they need (Community Pharmacist, P3) 
…you get a few upset patients and sometimes they just want to 
tell you about it… Quite often they’ve been to see the doctor, 
they’ve been to see a few and it’s almost just like they want to 
see what you have to say…it’s just supporting them in the best 
way you can and signposting them where appropriate 
(Community Pharmacist, P2) 
Another aspect was supporting the general public for example a bereaved 
neighbour or those who were self-medicating who were putting off going to the 
doctor. 
All the pharmacists were versed in making referrals to other pharmacies to 
source palliative care medications at the end of life including to a competitor 
pharmacy, putting the patients need for timely symptom management above 
commercial interests. 
In the context of palliative care, the community pharmacist’s default referral 
was to the GP. This was also the pathway used by community nurses 
whenever they had any query or concern about a patient or their medication. 
5.6.3.2 Clinical review of prescription and checking safety 
The checking of safe and appropriate doses was a consistent theme across 
pharmacists, GPs and other healthcare professionals who identified the 
pharmacists’ role in patient safety especially in dispensing what are 
potentially dangerous drugs and interactions with other medication. 
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…I think the safety net of double checking regarding interactions 
and dosages is very important (General Practitioner, HCP3) 
…a good pharmacist becomes that safety net…I think GPs do a 
fantastic job but they don’t understand drugs the same way that 
pharmacists do …pharmacists are much better at picking up the 
subtle differences between different drugs and the subtle 
interactions…that sometimes GPs don’t see… (Community 
Healthcare Professional, cHCP7) 
This recognises the specific skills and knowledge of pharmacists beyond just 
merely supplying the drugs. It was acknowledged that although the pharmacist 
screens the prescription to ensure it is appropriate for the patient they may not 
actually have a specific dose on the prescription for instance if the medication 
is to be used in a syringe driver and is prescribed ‘one as directed’. 
Nevertheless the pharmacists could pick up prescribing errors such as strange 
doses or volume errors. 
It is not uncommon to have doctors putting milligrams when they 
meant mls…when you phone up and say ‘that’s a rather strange 
dose do you mean?’ ‘Yes I do’...you’re building these safe 
practices…not [to] assume that the doctors got it right, they 
probably have…but they definitely appreciate the second pair of 
eyes looking at it. (Community Pharmacist, P5) 
From the pharmacists’ point of view, they were involved in ensuring safe and 
appropriate opioid conversions and screening choices of treatment for error 
in addition to ensuring the prescription was safe and complies with legal 
requirements. 
What we would do is look at the [opioid] conversion charts with 
the patient, ask the patient what they’ve been on and doing the 
conversion and then feeding this back to the GP surgery 
(Community Pharmacist, P3) 
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There was a situation a couple of years back when…a doctor 
made a mistake and tried to increase their [patient’s] morphine 
equivalent dose to something equivalent to 100 fold…So 
pharmacists we know we are good at calculations we’re good at 
doing [opioid] conversions and making sure that, not only 
…people aren’t scaled up too much but also making sure 
that…prescribers aren’t being too cautious to a degree 
(Community Pharmacist, P1) 
GPs and one other doctor identified that the pharmacist may be able to 
advise on mixing drugs in a syringe driver but it was also noted that the 
pharmacists are not always given the syringe driver chart and would not be 
aware of what was being mixed together from an FP10 prescription form. 
No, they don’t get the pink card [syringe driver record] …they 
simply get the prescription (GP, HCP3) 
…I might only need say, extra diamorphine, so that script might 
only say diamorphine whereas I might be using midazolam and 
haloperidol which were prescribed previously but I’ve still got a 
supply of those, so they don’t always know what’s in the [syringe] 
driver (Community Healthcare Professional, cHCP4) 
5.6.3.3 Providing advice and information - working with GPs and 
other healthcare professionals 
GPs noted that there was excellent communication between GPs and 
pharmacists and all healthcare professionals identified the need for more 
communication around medications especially those dispensed in Monitored 
Dosage Systems. 
One of the biggest problems…is Nomads because drugs are 
changing all the time and once you go to palliative mode Nomads 
can be a real nuisance and sending Nomads backwards and 
forwards and giving drugs outside of the Nomad on a prn [as 
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required] basis can be quite challenging…so they’re 
[pharmacists] …helpful with that. So, we do discuss Nomads a lot 
(GP, HCP3) 
GPs would seek advice from the pharmacist but this would usually be 
specific for example stock availability or choice of formulation for someone 
with swallowing difficulties. Pharmacists described an increased involvement 
with medical trainees and training practices. 
I worked at a GP practice [as]…a trainee and there was an on-site 
pharmacy…so I could go to them with questions because they were 
literally in the same building (GP, HCP2) 
I actually get more questions from the F2s than the majors…we had a 
patient prescribed…co-danthramer and one of the F2s was unsure of 
whether [they] could use it…so [they] came and spoke to us in the 
pharmacy…they want advice rather [than] just an exchange in 
information (Community Pharmacist, P4) 
Local collaboration was evident where pharmacists had worked with local GP 
practices on stocking a list of palliative care medicines, though this 
discussion was usually initiated by the GP. Furthermore, pharmacists co-
located with GP practices had more opportunities for joint working and 
described a range of ‘spin offs’ that helped foster closer relationships 
between professional groups. 
‘I get these doctors, the F2 level and when they start at the 
practice I’ll spend an hour with them, they’ll get sent next door 
into the pharmacy…and I’ll say to them if you know what you 
want medicine wise but the patient’s not going to take it phone 
me and I’ll tell you alternative drugs or alternative brands or 
formulations…’ (Community Pharmacist, P5) 
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‘…when trainee nurses and trainee healthcare assistants join at 
the medical centre, they usually get sent to me [pharmacist] for 
an afternoon…’ (Community Pharmacist, P5) 
‘…we have an open door…so, if I have an issue or they have an 
issue, they’ll [GPs] come into the pharmacy, I’ll go to their 
rooms…I also have SystmOne access within the surgery…so 
anything that they want to know they can ask’ (Community 
Pharmacist, P4) 
Other community healthcare professionals described instances where 
community pharmacists’ advice could be helpful for patient care but tended to 
not utilise community pharmacists. 
I don’t think we utilise community pharmacy as much as we could 
do (Community Healthcare Professional, cHCP1) 
I think that I underuse…the skills of the community 
pharmacist…we tend to go with the GP (Community Healthcare 
Professional, cHCP7) 
5.6.3.4 Continuity of medicines supplies 
Community pharmacists in their supervisory role in the pharmacy ensured 
continuity of medicines supplies for patients and often had an eye on what 
was going out and what was needed. Pharmacists could refer patients on to 
obtain medicines when necessary. 
…sometimes…specials can cause a problem…I phoned the hospital 
and they explained where the stock [of the special] was …I called [the 
patient] and said [name of hospital] will arrange a prescription for you 
to collect… (Community Pharmacist, P5) 
The pharmacist picked that up and…said you know we’ll make sure 
we’ve always got some [name of medicine] …in now while [the 
patient’s] on it (Community Healthcare Professional, cHCP9) 
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There could be a sense of ‘failure’ within the team where supplies of the 
requested medication could not be made. 
I think not being able to supply the medicine would be an issue 
because I think most of my team, the dispensers take pride in their 
work and if they can’t supply they would feel a little bit let 
down…(Community Pharmacist, P3) 
…when the prescriptions arrived in the pharmacy there wasn’t enough 
time to order any if you didn’t have them [medications] (Community 
Pharmacist, P5) 
5.6.3.5 Supervision of medicines disposal and pharmacy 
processes 
When prompted by the interviewer pharmacists and other healthcare 
professionals confirmed the pharmacies role in the safe disposal of unwanted 
and out of date medicines including the safe disposal of opioids after 
bereavement. This point was not referred to spontaneously by interviewees 
without prompting though is a core service by all pharmacies. The 
pharmacists identified their role in supervising this process and the need for 
pharmacy staff to show empathy to bereaved relatives. 
…you can either see they’re upset…they don’t want to drag it out, 
they just want to give you these medicines and go…we get quite 
a lot of medicines back, we’re used to dealing with that 
(Community Pharmacist, P2) 
… [pharmacy] staff deal with it very well in terms of legal needs, 
to establish what’s in the bag…and being sympathetic to that 
patient’s carer’s/relatives situation (Community Pharmacist, P4) 
Though pharmacists were used to dealing with disposing of medicines there 
was an underlying current of inconvenience, this was noticeable when large 
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quantities were returned or if the drugs were returned to a place different to 
the issuing pharmacy. 
…we really don’t like that [disposing of medicines] but it has to be 
done…everywhere I’ve ever worked…it never seems to be the 
medicine that you’ve dispensed that people bring back in, it’s 
always well ‘why don’t you use your own pharmacy’, you’d never 
say that…but we’re all thinking it I guess (Community Pharmacist, 
P1) 
5.6.3.6 Pharmaceutical Care 
Pharmaceutical care aims to optimise drug therapy and minimise risks to the 
patient utilising the pharmacist’s knowledge and skills (RPS, 2016) and within 
this context applies to evidence of any pharmacist led clinical activity beyond 
the essential nationally contracted pharmacy services. 
Community pharmacists who had completed postgraduate pain modules 
tended to consider their role included pain control and managing other 
symptoms; ‘[I’d be] optimising their pain relief and any other symptoms 
they’ve got’. In contrast, some community healthcare professionals and GPs 
suggested that symptom control was not the pharmacist’s role.  
…I don’t see that as their [pharmacist’s] particular role…I’m not 
sure I would expect a community pharmacist to start getting into 
symptom analysis and diagnosis and suggesting treatments 
myself (GP, HCP10) 
I do… speak to…. pharmacists…if we are trying to source 
[medications] …but not so much about symptoms… (Community 
Healthcare Professional, cHCP11) 
Though nurses didn’t speak to pharmacists about symptoms one nurse did 
acknowledge that pharmacists could support nurses in this area. 
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I think we could be more open about patients and their symptoms 
and symptom management…by sharing knowledge with 
pharmacists I think we could get better results for patients 
(Community Healthcare Professional, cHCP4) 
There was recognition of the pharmacist’s role in supporting patient 
concordance in medication taking through their unique relationships with 
patients and carers and through providing information or rationalising 
therapy. 
…the reason why people don’t take their medicines…is because 
there [are] lots of unresolved issues that weren’t addressed in a 
consultation and if it’s not addressed by the doctor then the last 
line before…the patient is the pharmacist… (Community 
Healthcare Professional, cHCP1) 
Sometimes carers find themselves out of their depth with 
medication and possibly the GP doesn’t recognise that whereas 
the pharmacist might (GP, HCP3) 
 ‘…a community pharmacist could really help with that medicines 
reconciliation and rationalisation of medicines and looking at: they 
are taking these three things how much of their side effects is 
from those…I think we could work with community pharmacy 
more on that than we do’ (Community Healthcare Professional, 
cHCP9) 
Little mention was made of the nationally contracted services such as MURs 
being used in palliative care; mainly because patients had to be present and 
provide consent for it to be considered an MUR. 
…we don’t seem to have medicines usage reviews…they don’t 
seem to happen [in palliative care patients] (GP, HCP10) 
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…if you’re going to do an MUR for a patient, they’ve got to be 
there, they’ve got to consent to it, you’ve got to explain it to them 
and that obviously can’t happen with a carer. We do what would 
probably be an MUR for a patient…external to that patient for no 
remuneration because that’s the right thing to do… (Community 
Pharmacist, P4) 
Pharmacists considered their role included educating patients and carers, 
which would be done on a more ad-hoc basis. 
…whether you do a medicines use review or not I think it’s good 
practice just to try and engage patients…just ask them ‘how are you 
getting on with your medicines… any headaches, dizzy spells, 
stomach ache?’…with time constraints you might have to let it 
go…hoping that you’ll catch them eventually (Community Pharmacist, 
P5) 
There was discussion by the community pharmacists taking part in a local 
Living with and Beyond Cancer Programme that they could advise and 
support patients going through cancer treatment on symptoms such as dry 
mouth or eyes. 
You get a lot of people who need some simple advice; if…they’ve 
got a dry mouth…we can make that easier for them… 
(Community Pharmacist, P2) 
 
…they might have dry eye syndrome off chemo[therapy] or…they 
might be overdoing it with the hypromellose and getting sore eyes 
because there’s too much preservative …they quite often 
appreciate the conversation, the fact that you’re interested… 
(Community Pharmacist, P5) 
Although community pharmacists described ‘providing pharmaceutical care’ 
to palliative care patients they also had the opinion that treatment decisions 
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had already been made so it would be difficult to have any extended role or 
influence in this area. 
 
…most of the decisions have already been taken, for example 
dosing…. and obviously MURs aren’t very clinical…so it’s about 
the decision that has already been made…the MUR could 
possibly help discussing the medication…but…if it’s palliative 
care, you might not always see the patient…we can do house 
visits…but arranging something like that takes quite a while to do 
(Community Pharmacist, P3) 
 
In the next chapter, the results and findings from each phase of the study are 
brought together and discussed in the context of relevant literature making 
recommendations on improving the pharmaceutical care of palliative care 
patients and processes for obtaining urgent palliative care medication. 
   
 183 
 
Chapter 6: Discussion 
In this chapter, findings from the quantitative and qualitative phases are 
discussed and evaluated in relation to the research objectives to assess 
whether these were met. Further to this, the findings are compared and 
contrasted with other available research to assess the outcomes. After the 
objectives from each phase are appraised, the collated results are integrated 
and discussed in the context of other published literature and the purpose of 
the study (Creswell and Plano Clark 2011). Finally, the strengths and 
limitations of the research will be evaluated. 
6.1 Recap of Research Aims 
The aim of the research was to explore timely access to palliative care 
medications in the community and the community pharmacist’s role in 
palliative care. This aim was achieved through utilising a sequential mixed 
methods approach with a quantitative phase followed by a qualitative phase. 
In the initial quantitative phase, sequential palliative care prescriptions were 
examined from five participating community pharmacies in Sheffield; two of 
which take part in a local commissioned service providing access to palliative 
care medicines, and three comparators not in the commissioned service. The 
purpose of this phase was to explore factors leading to a delay in accessing 
palliative care medicines in the community pharmacy setting and the time 
taken for accessing urgent palliative care medications. In the second, 
qualitative phase the researcher conducted semi-structured interviews with 
sixteen healthcare professionals including community pharmacists (n=5) who 
had participated in the quantitative phase, GPs (n=3), community nurses 
(n=5), members of the specialist palliative care team (n=2), and a member of 
the intermediate care team (n=1). The interviews explored the participants’ 
views, perspectives and experiences in accessing timely palliative care 
medication and the community pharmacist’s role in palliative care.  
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6.2 Findings from Phase 1: Data Collection in Community 
Pharmacies 
This section considers the findings from the data collected from the five 
participating pharmacies within the parameters of the study objectives. 
Findings will be discussed in the context of other published and unpublished 
data. 
6.2.1  The prevalence and nature of prescribing errors  
The objective was to investigate the prevalence of prescribing errors on 
palliative care prescriptions and explore whether the error rate varied 
according to practice, prescriber status or the nature of the prescription. The 
results of this study demonstrated that legal prescription errors, which did not 
meet the statutory CD prescription requirements, occurred in 1.1% of the 
sample of palliative care prescriptions. In all three cases of legal error, the 
prescription did not specify a dose on a subcutaneously administered 
controlled drug given via a syringe driver. Non-legal errors including clinical 
and administrative errors occurred in 3% of the sample. There was 
insufficient data owing to the low level of prescription errors to ascertain 
whether errors varied due to the prescriber or nature of the prescription. No 
handwritten prescriptions contained errors and there were no EPS delivered 
or NMP prescriptions in the sample. All legal errors occurred on prescriptions 
from NHS GPs on computer-generated prescriptions; there was no pattern to 
clinical and administrative errors; which occurred on handwritten and 
computer-generated prescription forms, NHS GPs and OOH providers. 
In this current study, there was a lower level of incorrectly written 
prescriptions and legal errors compared to previously reported unpublished 
studies. In an unpublished audit of 850 CD prescriptions from 61 pharmacies 
in Scotland by Stuart (2013), an error rate of 12.5% was reported; 10.7% of 
which were legal errors and 1.8% being clinical errors. A further unpublished 
audit in Scotland by the NHSGGC Controlled Drugs Governance Team in 
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2009, reported in Stuart (2013), found an error rate of 7.6% for 991 CD 
prescription items from 50 pharmacies; however, the authors did not specify 
whether these were legal or clinical errors or both. MacRobbie et al. (2015) 
reported a legal error rate of 3.7% in an audit of 695 CD prescription items 
from three pharmacies and four dispensing GP practices though it was noted 
there was a high prevalence of errors on handwritten prescription forms as 
hospital doctors did not have cause to write these very often. In a study by 
Lucey et al. (2008), community pharmacists reported that 31.5% of delays in 
supplying palliative care medications in the community were due to 
incorrectly written prescriptions but the study did not record actual 
prescription data or specify whether incorrectly written prescriptions 
contained legal or other errors. In the PRACtlCe study (Avery et al., 2012), it 
was reported that there were eight legal problems within 6,048 prescriptions 
during a retrospective review of GP clinical prescribing systems but it is not 
possible to ascertain if this data is comparable as there is no information on 
what the legal problems were or whether these occurred on CD or palliative 
prescriptions.  
 
Some of the differences in the legal error rate between my study and 
previous studies could be due to the scale of the study, study location and 
local prescribing practice. The study by Stuart (2013) covered a population of 
over a million with approximately 19% of pharmacies taking part whilst 
Sheffield has a population of over half a million (ONS 2011) with 
approximately 4% of pharmacies taking part. Both studies have a similar 
percentage of hand-written prescriptions, but more prescriptions were 
generated by OOH GPs in my study compared to the study by Stuart (2013); 
12% compared to 5% respectively. In contrast the study by MacRobbie et al. 
(2015) had no OOH prescriptions, which may be due to the remote location 
and low demand to provide a local OOH service. Despite the higher 
proportion of OOH GP prescriptions in Sheffield, there was a significantly 
lower error rate in prescriptions from OOH GP providers in Sheffield 
compared to those in Stuart’s study. Furthermore, handwritten prescriptions 
in Sheffield had fewer errors than in Stuart (2013) or MacRobbie et al. 
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(2015). The difference could be related to the structure of the OOH services 
with one main provider supporting Sheffield compared to one central hub and 
ten OOH bases within the study by Stuart (2013) as well as IT support within 
the Sheffield OOH service supporting computer generated prescriptions. 
 
There were no prescriptions electronically transmitted via EPS release 2 
(EPSr2) in my study or in previously published or unpublished studies on 
palliative care prescriptions; so it is not possible to ascertain the effect of 
EPSr2 on the prevalence of prescribing errors. A systematic review reporting 
the effect of electronic prescribing systems on medication errors suggests 
electronic systems reduce errors significantly; however, the authors note that 
studies varied in quality and reporting was poor, which could increase the risk 
of bias (Ammenwerth et al. 2008). 
 
Moreover, it was not possible to ascertain whether prescriptions written by 
non-medical prescribers (NMPs) had more or fewer errors since there were 
none in either my study or previous studies. Prescriptions written by 
specialist palliative care team members, approximately 2% of the sample in 
my study, had no legal or non-legal errors. All of the specialist palliative care 
prescriptions were handwritten. No previous reported studies could be found 
on specialist palliative care team prescribing errors and this may be worthy of 
further investigation in future research. 
 
In both my study and Stuart (2013), errors were four times more likely for 
injectable products compared to non-injectable products,4 and in Sheffield all 
of these errors occurred on computer-generated prescriptions from NHS GPs 
though this should be interpreted with caution due to the small sample size. 
In MacRobbie et al. (2015) injectable products had a greater proportion of 
errors compared to tablets with half of all prescriptions for injectable CD 
products having an error. Legal errors relate to the statutory CD prescription 
                                                          
4 Figures within the Stuart (2013) include both legal and clinical errors whilst only legal errors 
occurred on subcutaneous injection prescriptions in my study. 
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writing requirements in the Misuse of Drugs Act 1971 and the Medicines Act 
1968 that specify that the prescription must include a specific dose. This 
means it is permissible to state ‘one ampoule as directed’ but it is not legal to 
specify ‘according to the syringe driver chart’ or ‘as directed’. Prescriptions 
written for drugs at end of life to be administered in a syringe driver may 
change dose frequently as the patient deteriorates; so prescribers can be 
reluctant to include a specific dose on the prescription in case this 
subsequently caused error or confusion if the specific dose to be given on the 
community syringe driver chart differed to that on the pharmacy dispensed 
label. The continuation of legal errors on subcutaneous prescriptions in both 
my study and in Stuart (2013) and MacRobbie et al. (2015) suggests a 
review of the legal requirements should be undertaken as it is questionable 
whether legal requirements set in 1971 are relevant to clinical practice today 
with increasing use of syringe drivers. The error rate may in fact be related to 
the constraints of an out-dated law (Stuart 2013). Another consequence of 
prescribing ‘one ampoule as directed’ is this limits the pharmacist’s 
interpretation of whether a dose is safe since pharmacists do not necessarily 
have access to syringe driver records or patient records to know what dose is 
to be given or what drugs are being mixed together. Exceptions would be 
patients in care homes where they could contact care home nursing staff for 
this information. 
 
The analysis of prescribed preparations compared with the palliative care 
formulary showed that issues relating to the choice of product were low with 
only one in ten not on the commissioned list. The main deviations were 
different strengths of midazolam injection, size of water for injection 
ampoules, and use of unlicensed clonazepam injection5. In palliative care, 
only midazolam 10mg/2ml injection is recommended with other strengths 
                                                          
5 Sheffield has a local informal agreement to hold stock of unlicensed clonazepam injection 
in a pharmacy even though this is not on the commissioned list. As this arrangement is not 
formalised it is not taken account of in the formulary figure. 
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being too dilute to give subcutaneously. Using data from a pilot study 
(Tsoneva 2011), it was possible to calculate and compare the percent of non-
formulary items based on the current stock list with approximately 11% of 
non-formulary items being prescribed in 2011. This current study may 
indicate a slight improvement in adhering to the commissioned list. In 
comparison, Stuart (2013) reported prescribing of inappropriate strengths of 
midazolam was 30%, significantly higher. 
6.2.2  The effect of prescribing errors on timely access to medication 
Data from pharmacists’ prescription logs showed that legal errors had a 
negligible impact on the timeliness of supply of urgent palliative care 
medicines from participating pharmacies in this study since all prescriptions 
with legal errors were available within 10-30 minutes.  Considering the 
median waiting time for urgent palliative care medicines was ten minutes 
compared to five hours for commissioned and non-commissioned 
pharmacies respectively; other factors besides legal errors had a greater 
impact on timely access to palliative care medicines. Where legal errors did 
occur on a prescription, some of these could be resolved through a permitted 
technical change by the pharmacist using the PMR or by contacting the care 
home nursing staff. 
 
In 2006, changes were made to the Misuse of Drugs Regulations 2001 to 
allow pharmacists to make minor typographical amendments to prescriptions 
for schedule 2 and 3 controlled drugs where there is a spelling mistake or 
where the total quantity is specified in words or figures but not both (Home 
Office 2015). This change has, as intended, permitted better access to 
palliative care medications. In an audit by the NHSGGC Controlled Drugs 
Governance Team in 2009, reported in Stuart (2013), pharmacists made 
amendments to 15% of CD prescription errors whilst in Stuart’s own audit 
across NHSGGC nearly four years later, pharmacist changes were made to 
8% of CD prescriptions (including both legal and clinical errors). In the study 
by Stuart (2103), resolution of errors took 15 minutes if they occurred during 
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surgery hours but over an hour OOHs possibly reflecting the higher error rate 
during this time as well as the difficulties in contacting the prescriber. The 
time to resolve a prescription error was noted by Stuart (2013) to be less 
where the pharmacist dispensed against the illegal prescription but made 
arrangements for a new prescription to be issued. This was suggested to be 
more likely where the pharmacist was manager of a shop than if the 
pharmacist was a locum (Stuart 2016: pers. comm., 2 December). In an audit 
reported in MacRobbie et al. (2015) 55% of legal errors were resolved in less 
than 15 mins, 28% within an hour, and one took up to 24 hours, though was 
not needed urgently.  In their study only one pharmacist chose to amend the 
prescription accordingly to the permitted regulations. In other circumstances 
the pharmacists chose to dispense from the original prescription once contact 
had been made with the prescriber, which was thought by the authors to try 
and avoid delay to the patient. 
 
Although all legal errors in my study were on urgently required prescriptions, 
it is likely the time to resolution for an illegal CD prescription that is not 
required urgently will be much longer. In such situations, the pharmacist 
would not be placed into making an ethical decision on the urgency of patient 
need against the illegal prescription and would more likely require the 
prescription to be rectified to meet legal requirements before dispensing took 
place. An audit by the NHSGGC Controlled Drugs Governance Team in 
2009, reported in Stuart (2013), stated that 0.5% of CD prescription errors 
took one day or more to resolve but there is no information on the urgency of 
the prescription. 
 
Pharmacist access to SCR was not used to resolve any urgent medication 
queries in the current study; however, having access to up to date 
information on SCR may support resolution of prescription queries when a 
prescriber cannot be contacted. Although having access to SCR may help for 
clinical queries where such information is included on SCR, is updated and 
the pharmacist has access, it would not resolve the need for the pharmacist 
to obtain a legal prescription prior to dispensing.  
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6.2.3 Waiting times for palliative care medicines in a community 
pharmacy 
The maximum waiting time for accessing urgent palliative care medicines in 
the community pharmacy setting was more than four times longer in the non-
LCS commissioned pharmacies in the study (47hr 15min). For subcutaneous 
medicines either given as a bolus or via a syringe driver, median waiting time 
was almost 24 hours and maximum waiting time was nearly 100-fold longer 
in non-LCS pharmacies compared to LCS pharmacies. No other published 
studies have reported on waiting times for palliative care medications in a 
community pharmacy setting and the researcher was unable to find any 
published studies of waiting times for other medicines in a community or 
retail pharmacy. The time taken to dispense medications is predicated by the 
availability of stock in the pharmacy and confounding factors such as time of 
day, number and type of staff and prescription numbers were not taken 
account of within the analysis. The results are furthermore limited by missing 
data particularly in the LCS pharmacies where one or both times were 
missing on the data collection form. Even so, the results demonstrate that 
pharmacies commissioned to provide access to palliative care medicines in 
the study were able to supply medication quickly, prioritising urgent and 
subcutaneous prescriptions in comparison to pharmacies not commissioned 
to provide such a service since they were more likely to have the necessary 
medicines in stock. All medications on the palliative care list were available 
within 30 minutes of a prescription being presented at a commissioned 
pharmacy. A quick response makes it more likely that a patient’s symptoms 
can be managed in a timely manner where professional staff are available to 
administer the medication. There is however an assumption that all 
subcutaneous palliative care medicines are needed urgently unless the 
customer has completed the customer survey to the contrary. The researcher 
is unclear of the actual timeframe in which the supply was required and this 
may have a bearing on the results from non-commissioned pharmacies, 
which may be more likely to receive a non-urgent prescription.  The influence 
of this in addition to the confounding factors mentioned above means the 
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results should be interpreted with caution and used as the basis for further 
studies that control for these variables and their effect on promptness of 
palliative medication supplies. 
Furthermore, the small number of participating pharmacies makes it more 
likely that some pharmacies could have skewed the data, e.g. large numbers 
of subcutaneous medicines from pharmacies that are open outside regular 
hours or pharmacies with small numbers of data collection forms. The three 
pharmacies that were not LCS providers and therefore not commissioned to 
hold stocks of palliative care medications took longer to supply than LCS 
pharmacies. One of these skewed the results with significantly longer times 
to supply palliative care medicines, which could be because the pharmacy 
does not hold large amounts of CDs on site, preferring to order these in when 
a prescription is received. The other two had minimum times similar to the 
LCS pharmacies. It was noteworthy that the pharmacists in both of these 
pharmacies had worked with local GP surgeries to draw up a list of 
medication they would hold for urgent palliative care prescriptions in 
advance, and the GPs were aware of what stock was available. This may 
suggest that working in collaboration with GPs may be more advantageous 
than just commissioning a pharmacy service. If feasible, it would be helpful to 
complete similar time audits with other commissioned and non-commissioned 
pharmacies in the UK to provide comparative data including the timeframe for 
which the drugs were required and controlling for other confounding factors. 
There were no electronically transmitted prescriptions using EPSr2 within this 
study; so it was not possible to judge the effect this could have on waiting 
times. As at July 2017, even though legislation to allow transmission of 
schedule 2 and 3 controlled drugs via EPSr2 was passed in 2015, there have 
been no CD prescriptions transmitted this way in England (NHS Digital, 
2017). GP prescribing system suppliers must update clinical systems, and 
these need to be tested and piloted before full access to CDs via EPSr2 is 
available (NHS Digital, 2017). As at June 2017, 63.7% of prescriptions in 
England were claimed using EPSr2 (NHS Digital, 2017). In other countries 
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where electronic prescriptions are available, pharmacists have reported 
quicker dispensing times (Hammar et al. 2010; Timonen et al. 2016), and 
studies in England with EPSr2 suggest quicker dispensing times with better 
workflow overall (Garfield et al. 2013; Harvey et al. 2014); however, these 
studies were general and not specific to palliative care medicines. 
6.2.4 Referrals to obtain palliative care medicines 
One in five of the 55 people completing a customer survey in my study stated 
they were referred to the pharmacy to obtain palliative care medicines. 
Furthermore, one in five customers had to go to more than one pharmacy to 
obtain palliative medicines; increasing to nearly one in three when the 
prescription included subcutaneous medication. Other people supported the 
patient in collecting subcutaneous medicines near the end of life with all 31 
participants surveyed obtaining the medicines on behalf of the patient. 
Customers who used the pharmacy but had home deliveries did not take part 
in the customer survey so it is unclear what effect having a pharmacy home 
delivery might have had on accessing timely medication. 
There appeared to be some evidence of referrals from GP OOH providers, 
though fewer pharmacies are open OOHs and many of these may have 
access to palliative care medicines. However, 40% of survey respondents 
coming to a community pharmacy from the OOH GP service had to go to 
more than one pharmacy. This finding suggests the OOH GPs may not have 
directed them to a pharmacy providing palliative care medicines nor did they 
ring ahead to check the pharmacy had the requested items. There also 
appeared to be some evidence of inter-pharmacy referral with between 9-
16% of customers potentially going to their usual pharmacy first before going 
to another community pharmacy to obtain palliative care medications. 
The high number of people needing to go to more than one pharmacy is of 
concern as this suggests there is no systematic way of referring relatives to 
the pharmacies that are commissioned to hold the palliative medicines and 
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the approach is ad-hoc. This was similar in OOH providers with a higher 
proportion of OOH attenders needing to go to more than one pharmacy. This 
suggests healthcare professionals or providers may not be aware of the 
commissioned pharmacies, relatives are not being directed where to go or 
cannot access the pharmacy, or the commissioned pharmacies have not got 
the necessary stock. A baseline audit across a Birmingham network of 
community pharmacies commissioned to hold palliative care stocks reported 
only one pharmacy out of nineteen held all palliative care items and some 
pharmacists were not aware that the scheme was still active (Aslett and Wall-
Hayes 2015). This may have been due to a lack of monitoring of pharmacies 
within the scheme by the former commissioning body (Wall-Hayes 2016: 
pers. comm., 12 July). Monitoring of such local schemes appears to be 
deficient and though an electronic system for recording and monitoring 
service provision exists, the researcher was unable to obtain any information 
on access to palliative medicines schemes from the system provider 
PharmOutcomes (Stotesbury 2016: pers. comm., 12 July). Further 
investigation in Phase 2 of my study suggests that some healthcare 
professionals may indeed be unaware of the local palliative care scheme 
from community pharmacies; however, as no OOH GPs were interviewed, it 
is not possible to substantiate this. Further investigation of referral patterns 
and close monitoring of the scheme may improve referral patterns and the 
caregivers’ experience. Specifically a future study should interview OOH 
GPs. 
Access pathways for patients on subcutaneous medication near the end of 
life appear to change when patients are unable to visit the pharmacy 
themselves and need to call on the support of others to help them with the 
task of collecting medication. It is also possible that they request or are 
offered a home delivery by the pharmacy. Customers collecting medicines 
may use a different pharmacy or several pharmacies that may not be the 
patient’s usual pharmacy, thereby disrupting continuity of care of the patient 
at this stage of their life. This may have important safety and quality 
implications for patients (Kripalani et al. 2007; NICE 2016). No published 
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research could be located on patient or caregiver experience related to 
changes to continuity of care with pharmacy providers near the end of life but 
this may warrant further examination. 
6.2.5  Discussion of other findings from pharmacy data 
collection 
One of the original statistical objectives was to undertake a stepwise logistic 
analysis to determine whether there was a relationship between time delay 
and legal prescription errors, and any other significant variables from the 
analysis. This detailed analysis could not be achieved as there were few 
legal errors in the sample and these errors were not associated with a time 
delay. Insufficient data was collected with no significant factors identified to 
input into a regression model. 
 
Only one MUR was reported by the pharmacists suggesting advanced 
services within the community pharmacy contractual framework may be 
infrequent within this patient group. A similar lack of MURs was reported in 
cancer patients by Savage et al. (2012). This must be seen in the context of 
the national priority for MURs within the national pharmaceutical contract, 
which does not include cancer patients, palliative care or analgesic 
medications. It also needs to be seen in the context of this study where a 
high proportion of prescription items (56%) contained one or more 
subcutaneous medications for symptom management near the end of life and 
so it is unlikely a patient would be present in the pharmacy at the time of 
collecting such items. 
Compared to the previous pilot study conducted in Sheffield (Tsoneva 2011) 
and NHS prescription data (HSCIC 2014), there was an unexpectedly low 
number of palliative care prescriptions recorded by the pharmacists in the 
study. This could be due in part to the small number of pharmacies 
generating the data of which three were not part of the commissioned 
service; so were perhaps likely to have lower levels of palliative care 
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prescriptions but also could relate to the rarity of such prescriptions and 
variation in practice. It could also be due to increasing numbers of these 
drugs are supplied pre-emptively on discharge from hospital and inpatient 
units with specialist palliative care team involvement thereby reducing 
primary care prescribing. In some cases, pharmacies only recorded 
information on opioid prescriptions with no other medicines on the data 
collection form for other conditions. This may be due to some pharmacies 
separating prescriptions, e.g. prescriptions for opioids may be on a separate 
form to other usual medicines that go into an MDS, or the pharmacists were 
unclear on the need to include all items on the data collection form or had 
insufficient time to do this. Another explanation could be that not all palliative 
care prescriptions were identified. Subcutaneous medication prescriptions 
made up 56% of the sample, which may suggest that pharmacists saw these 
as ‘palliative’ even though the inclusion criteria included oral morphine, 
oxycodone and opioid patches but fewer prescriptions for these were 
included. It could be that where palliative patients were on a mix of oral and 
subcutaneous medications, these were on separate prescription forms. 
Identifying that someone is palliative compared to someone who is 
housebound with chronic pain may be difficult for pharmacists who are not 
informed if someone is palliative and need to establish that intuitively or find 
out in an ad hoc way. Pharmacists had no reliable way of finding out a 
patient’s cancer diagnosis and determining whether they had cancer pain in a 
study by Savage et al. (2012). Communicating such issues with pharmacists 
can be productive since pharmacists, who learn about a patient’s palliative 
nature and are engaged with the process, are more likely to stock the 
necessary items in advance (Tait and Swetenham, 2014). In their study, Tait 
and Swetenham state that 21% of pharmacists were informed of a patient’s 
palliative care status from another healthcare professional, which suggests, 
as with Savage et al. (2012), that community pharmacists are not usually 
involved in these conversations. 
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In the customer survey, respondents reported high satisfaction for the service 
they received from pharmacies with most either not commenting or providing 
positive comments. One customer commented that the pharmacy should 
keep the necessary palliative care medications in stock. Another customer 
reported they always ring up in advance to order their CD medication 
allowing the pharmacy time to order this in. 
6.2.6  Summary of key findings from Phase 1 study 
In summary, there is no evidence from this study that errors on prescriptions 
for palliative care medicines lead to a delay in obtaining medication in 
comparison to other factors. Further investigation of patient referrals and the 
effect of electronic transfer of palliative care prescriptions may be warranted, 
in particular when CD prescriptions can be transmitted electronically, to 
assess whether this speeds up timely access to palliative care medication. 
There was a statistically significant difference in the time taken to obtain 
urgent and subcutaneous palliative medication between commissioned and 
non-commissioned pharmacies with the latter less likely to keep the 
requested drugs in stock. However, those pharmacies that had worked with 
local GP surgeries to draw up their own list of palliative care medications to 
keep in stock had similar minimum times for accessing medication as LCS 
pharmacies suggesting that when pharmacies are involved and informed of 
decisions they are able to provide timely access. Future analysis into timely 
access to palliative medicines should control for confounding variables 
between pharmacies within the analysis. 
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6.3 Findings from Phase 2: Interviews with community pharmacists 
and other healthcare professionals 
This section presents a discussion of the findings related to the qualitative 
Phase 2 study presented for each of the two themes emerging from the 
qualitative analysis: timely access to palliative care medicines and the 
community pharmacists’ role in palliative care. Following this, the objectives 
within Phase 2 are reviewed to assess whether these were achieved. 
6.3.1 Factors causing delays in obtaining palliative care medicines 
Obtaining timely access to medication emerged as a major theme within the 
qualitative study with all groups of healthcare professionals raising concerns 
leading to poor access to palliative care medications, particularly 
subcutaneous medicines near the end of life. The data arising from the 
analysis on factors causing delays has been classified into two sub-themes: 
environment and resources, and communication and collaboration. 
6.3.1.1 Environment and Resources 
Other health professionals recognised that pharmacies cannot hold stocks of 
all medications; however, community and specialist palliative care team 
nurses expressed significant frustration at trying to obtain palliative care 
medications towards the end of life. It was felt by community nursing staff 
that a considerable amount of nursing resource was required for advanced 
planning to ensure medications were in place, which put community nursing 
staff under intense pressure. In some scenarios, due to national stock 
shortages and the difficulties experienced, GPs were more cautious and rang 
the pharmacy in advance to check on pharmacy stock availability before or 
while writing the prescription. Nurses felt that if more pharmacies held a basic 
stock of palliative care drugs, this would help. Maintaining stock availability 
by using a network of pharmacies has been done in Northern Ireland, 
Scotland, and in England (Bennie et al. 2012; Armstrong 2017; PSNC 
2017b); to ensure a pharmacy in the locality is designated as a ‘palliative 
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care pharmacy’. Sheffield has a list of nineteen pharmacies providing access 
to palliative care medicines but interview data suggests this is either not 
widely known by GPs and nurses, or pharmacies do not maintain the stock. 
Community pharmacists working in the LCS commissioned pharmacies were 
aware of the CCG agreed list of palliative care medicines and made efforts to 
ensure stock was available, though in exceptional circumstances, they were 
not able to supply when more than one prescription was received on the 
same day or the quantity in stock was insufficient to cover the prescription. 
Having an agreed list of palliative care drugs allowed the pharmacies to 
maintain the agreed stock levels to cover most circumstances. Core palliative 
care medicine lists have been established in other areas (Bennie et al. 2010; 
Akram et al. 2012; Tait et al. 2014; PSNC 2017b) as a way of supporting 
access to palliative care medicines near the end of life. Interestingly, two 
pharmacists working in pharmacies not part of the commissioned service had 
worked with local GP surgeries to instigate their own local palliative list to 
resolve the problem of stock availability in the pharmacy. Similarly in Savage 
et al. (2012), two pharmacies held an extended range of palliative care 
medicines without being funded by a commissioned service. 
GPs and other community healthcare professionals were unaware of the 
CCG approved list of medicines in palliative care and those pharmacies who 
were commissioned to hold the medication in stock. Instead, GPs relied on 
an inbuilt prescribing auto-consultation template within SystmOne, which the 
CCG Medicines Management Team and IT services had developed, to 
ensure they prescribed the correct products. A similar system using an EMIS 
template has been used successfully in NHS Scotland GGC (Bennie et al. 
2013a). Research suggests that the use of a restricted ‘formulary’ of palliative 
care drugs helps to reduce prescribing errors, aids prescriber familiarisation, 
supports stock control resulting in less delays (Akram et al. 2012; Avery et al. 
2012; Savage et al. 2012). This suggests that strategies using the GP clinical 
system can be effective in ensuring the correct product is selected, making it 
more likely to achieve timely access to medicines near the end of life. 
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GPs said they found the general practice clinical computer system helpful in 
generating a prescription meeting legal requirements, though results from 
Phase 1 suggest that legal prescription errors on computer generated 
prescriptions still happen occasionally. GPs did not routinely check resources 
such as the British National Formulary (BNF) to write a CD prescription and 
one GP was a little confused as to the legal requirements. Legal errors on 
CD prescriptions have caused ethical dilemmas for community pharmacists 
(Akram et al. 2012; Bennie et al. 2012; Savage et al. 2012; Stuart 2013), 
though it is reported that computer-generated prescriptions have reduced 
these problems (Savage et al. 2012). Legal prescription errors may cause 
delays that could impinge on patient care depending on the pharmacist’s 
method of resolution (Bennett et al. 2009; Akram et al. 2012; Stuart 2013); 
however, such errors were not generally seen to cause a problem in my 
study. Often minor typographical errors could be amended by the pharmacist; 
also noted to support access for a small proportion of CD prescribing errors 
in other studies (NHS Greater Glasglow and Clyde (NHSGG&C) Governance 
Team 2009: cited in Stuart (2013):76; Stuart 2013). The regulatory 
framework for controlled drugs was considered a barrier where the 
prescriber’s intention was clear but the prescription was illegal, and the 
pharmacist was unable to amend the prescription or receive a fax, leaving 
the pharmacist with an ethical dilemma of whether to dispense from an illegal 
prescription (Home Office 2015b). This may not be as much of an issue in 
future with the provision of EPS delivered CD prescriptions that may allow 
quicker resolution of CD prescription errors (NHS Digital 2017). The findings 
from this section corroborated the results from the Phase 1 prescription 
analysis on prescription errors and time delays. 
Community pharmacists expressed difficulties around the storage of CDs 
since some pharmacies had small CD cabinets that did not provide enough 
space to store and hold large amounts of CDs. Where pharmacies ordered 
CDs in error, these could not be returned to the wholesaler leaving the 
pharmacist with a storage and regulatory issue until a further prescription 
was received, or the stock expired and could be destroyed by an authorised 
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witness. GPs and nurses seemed to be unaware of this issue and expected 
most pharmacies to keep a small amount of palliative care medicines in 
stock. For some pharmacists, it was pointed out that CDs were not stocked in 
the pharmacy, for example, if the pharmacy was not commissioned to hold 
palliative care drugs, and the pharmacist relied on receiving a prescription in 
advance of making a supply. Regular repeat CD medicines did not cause 
problems as often a patient or their caregiver would ring to request the CDs 
from the pharmacy when requesting the prescription from the GP. When 
pharmacies were not informed in advance to expect a palliative care CD 
prescription, it would often result in the healthcare professional being told it 
would be the next day before it would be available. Healthcare professionals 
felt this would be too late for the patient, and the pharmacist and pharmacy 
staff felt as if they had ‘failed’ because they could not supply the drugs. Such 
difficulties have been expressed in other studies (Savage et al. 2012; Faull et 
al. 2013; Tait et al. 2013; Tait and Swetenham 2014) and have been 
mitigated by transferring medication between pharmacies, referring the 
customer to a pharmacy with the requested items, or contacting the 
prescriber (Akram et al. 2012; Bennie et al. 2012; Tait et al. 2013; Tait and 
Swetenham 2014). 
Prescriptions of specialist medicines for patients managed by the specialist 
palliative care (SPC) team required forward planning to ensure they were 
prescribed in advance to avoid delays to treatment. SPC team members 
expressed how they had learnt through experience to contact the pharmacy 
when they were going to prescribe something unusual that may not be kept 
in stock. Also the SPC team were mindful of being resourceful, utilising 
medications available in the home until any necessary medication could be 
ordered in. 
Transporting the medications from the pharmacy to the patient’s house could 
also prove difficult and could cause a delay unless the family caregivers or 
friends could support this process. Not all pharmacies provide a delivery 
service and since pharmacy delivery is not an NHS funded service, there 
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may be certain restrictions and conditions for when a delivery service is 
offered. Customers may be charged, for instance, if the patient does not get 
their regular items dispensed from that pharmacy, even though the items are 
for end of life care. Healthcare professionals were unclear on the terms and 
conditions for pharmacy delivery services as such services were not 
universally available. In a study by Akram et al. (2012), a taxi protocol was 
available to collect or deliver urgent medications between pharmacies or the 
patient’s home free of charge; however, this system was viewed to be 
‘bureaucratic’ with some pharmacists preferring to deliver the medicines 
themselves. 
 
6.3.1.2 Communication and Collaboration 
Healthcare professionals identified that planning or ‘pre-empting’ in advance 
of need towards the end of life supported good symptom management and 
ensured timely access to palliative medicines also identified by others 
(Wowchuk et al. 2009; Wilson and Seymour 2017). This often involved the 
patient’s community nurse or palliative care team liaising with the patient’s 
GP to review the patient and instigate plans; however, community 
pharmacists were generally not part of this process, and GPs did not inform 
the pharmacist that the patient was palliative at the time or in advance of any 
decisions being made. The first time the pharmacist may be aware is when a 
prescription is presented to the pharmacy or if a nurse or GP contacts them 
to ascertain availability of medicines at the time of or soon after the 
prescription writing process. Nurses identified cases where supply of 
medication for palliative patients had worked well in the past, often where the 
pharmacist was proactive or where good communication pathways existed 
between GPs, the nursing team and pharmacy staff. Tait et al. (2013) found 
that only 21% of pharmacists were informed of a patient’s palliative care 
status from another healthcare professional, though 87% of those surveyed 
knew at least one palliative patient or carer using the pharmacy. They also 
observed that pharmacies informed of a patient’s palliative care status were 
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statistically more likely to keep a larger range of medicines from the palliative 
care list than pharmacies that were not informed, indicating that greater 
communication between healthcare professionals supports more timely 
access to palliative medicines (Tait et al. 2013). 
Communication from commissioning organisations to healthcare 
professionals and providers on accessing palliative care medicines appears 
to be not effective since GPs and nurses did not know which pharmacies 
stocked palliative care medication or the existence of a list of drugs, instead 
relying on GP clinical systems and local knowledge to guide choice. By 
contrast, pharmacies in the commissioned service were aware of the list and 
managed stocks accordingly with pharmacists considering locally 
commissioned pharmacy services being well integrated. An unpublished 
audit in Birmingham suggests that a lack of clarity on local commissioning 
may be more of a widespread problem with pharmacists in a local scheme 
reportedly being unaware of a service being commissioned from the 
pharmacy (Aslett and Wall-Hayes 2015). Also a review of LCS/LES schemes 
on the PSNC website shows that a number of these are not on updated NHS 
contracts with schemes being commissioned by a variety of organisations 
suggesting the PSNC information is out of date or schemes are not actively 
being reviewed and monitored. This could be due to NHS structural changes 
in 2013 when primary care trusts (PCTs) were abolished and replaced by 
CCGs with many of the former LCS contracts under PCTs not being updated. 
Some schemes are being regenerated and retendered under the new 
contracting arrangements, and this may include arrangements for 
commissioners to monitor these schemes in future (Bunn 2017: pers. comm., 
8 March). There could also be resource implications as monitoring of such 
schemes requires dedicated time and a co-ordinator to facilitate this 
(Armstrong 2017: pers. comm., 15 March). 
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6.3.2 Factors facilitating or limiting community pharmacist’s 
involvement 
Healthcare professionals gave positive feedback on their experience and 
interactions with community pharmacists stating how helpful, accommodating 
and resourceful they were. There was a feeling of goodwill in their 
interactions particularly for patients at the end of life. There were a number of 
factors facilitating or limiting the pharmacist’s involvement that are discussed 
further under the sub-headings of: skills, knowledge and training, and 
collaborative relationships. 
 
6.3.2.1 Skills, knowledge and training 
Healthcare professionals saw community pharmacists as having limited 
experience in palliative care and they felt that some pharmacists may not be 
familiar with the use of pre-emptive medications at the end of life. A lack of 
experience in the specialist area of using syringe drivers was cited by one of 
the community pharmacists, though all the participating pharmacists had 
experience of palliative care prescriptions and most had completed additional 
education. GPs and some other healthcare professionals identified the 
pharmacist’s knowledge as being helpful in advising on alternative 
formulations when patients could not swallow or when products became 
unavailable due to national stock shortages and some pharmacists were 
utilised in training and educating GP trainees and nurses new in practice. 
GPs thought it might be helpful for pharmacists to advise on mixing drugs 
given via a syringe driver; however, this would be difficult noting the 
pharmacists’ lack of practical experience and training in syringe drivers but 
also because the community pharmacist does not usually have access to the 
syringe driver record chart, which is kept in the patient’s home or in a care 
home. Community pharmacists in a Scottish programme were nevertheless 
able to advise on mixing of drugs though received specific training and 
support for this (Bennie et al. 2012). 
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Having skilled pharmacy support staff who can deal with prescription queries 
was crucial in releasing the pharmacist to attend to professional roles. In 
most pharmacies palliative scripts would be left to the pharmacist but there 
was the potential for support staff to resolve queries and manage stocks. In 
Scotland, Macmillan Pharmacist Facilitators have supported and trained 
pharmacy technicians, dispensing assistants and counter-staff to manage 
prescription queries thereby releasing the pharmacist’s time (Bennie et al. 
2012). Likewise, pharmacists have identified the need to train pharmacy 
counter-assistants and locum pharmacy staff to better identify palliative care 
prescriptions and avoid delays (Akram et al. 2012). 
Studies have focused on the need for additional training for pharmacists 
(O'Connor et al. 2011a; O'Connor et al. 2011b; Jiwa no date) and for 
pharmacy support staff (Bennie et al. 2015; MacRobbie et al. 2015) including 
communication skills, palliative care symptoms and signposting to other 
services. Though the pharmacists in my study had completed additional 
training including CPPE training in palliative care and were aware of being 
empathetic with patients and family caregivers it is unclear what information 
they have to direct patients and their caregivers to other national and local 
support services or whether they had undertaken additional communication 
skills training not included in the CPPE palliative care pack. Pharmacists 
cited work with a national cancer charity as supportive in signposting to other 
services; however, not all palliative patients will have a cancer diagnosis and 
pharmacists may not have access to the patient’s clinical record to ascertain 
this. Furthermore since the Living with and Beyond Cancer Programme is not 
universally provided, signposting beyond those involved in the scheme may 
be ad-hoc (NHS Sheffield CCG 2016). The lack of communication and the 
potential for pharmacists to be isolated from the rest of the primary 
healthcare team makes this a cause for concern as it makes it more difficult 
for pharmacists to get involved with palliative care patients and their families, 
which has also been highlighted in previous studies (Ise et al. 2010; 
O'Connor et al. 2011a; Savage et al. 2012). The South Yorkshire and 
Bassetlaw Sustainability and Transformation Plan (STP) provides some 
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encouragement as it plans to ‘improve signposting to services and support 
people with education to help them manage their medicines and pain control’ 
(Cash 2016: 30). The need to undertake advanced communication skills 
training has been highlighted in other studies (Bennie et al. 2010; O'Connor 
et al. 2011a; O'Connor et al. 2013; Jiwa no date) 
 
6.3.2.2 Collaborative relationships 
In my study, community nurse’s preferred face to face relationships based on 
trust; also reported in other studies (Savage et al. 2012; Faull et al. 2013; 
Wilson and Seymour 2017). Yet, nurses had limited opportunities to network 
or build relationships with pharmacists’ due to work pressures and in some 
cases decentralisation of their nursing teams away from GP and pharmacy 
hubs. Faull et al. (2013) highlight the importance of effective relationships 
and team working within and across organisational boundaries and crucially 
personal links between professionals in the process of advanced care 
planning and anticipatory prescribing. In my study, interviewees relayed 
stories of positive working relationships between nursing teams and 
pharmacies that supported patient care, timely access to medication and 
reduced nursing time in accessing palliative care medications. The 
advantages of collaborative and interdisciplinary working in palliative care are 
well reported in the literature (Hearn and Higginson 1998; Meier and 
Beresford 2008; Goldsmith et al. 2010; Oishi and Murtagh 2014) requiring 
pharmacists to actively participate and collaborate in the interdisciplinary 
team (ASHP 2002; Gilbar and Stefaniuk 2002; Hussainy et al. 2011; 
O'Connor et al. 2011b; Cortis et al. 2013; Pruskowski 2017); so improved 
collaboration between healthcare professionals in primary care including 
pharmacists should be beneficial. Indeed, den Herder-van der Eerden et al. 
(2017) report in their study of continuity of care within integrated palliative 
care across five European countries that patients’ experience relied on a 
small group of trusted health care professionals who shared information and 
worked collaboratively with all health care professionals in the patients’ care 
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network. New technologies and remote working including teleconsultation, 
telehealth, and shared digital records may support streamlined working 
practices in future but are not universally available at present. Examples of 
practice such as those being taken forward within NHS Vanguard sites as 
part of the general practice forward view technology transformation fund 
(NHS England 2017a), remote clinical pharmacy services to rural areas of 
Alaska (Perdew et al. 2017), and remote palliative care services within Wales 
(RPS Wales 2016) and Scotland (Inch et al. 2017) may support further 
integration of pharmacists within patient’s palliative care networks. 
GPs and community nurses were unclear on any extended role for 
community pharmacists in palliative care and considered pharmacists 
provided a traditional role of dispensing medication promptly and checking 
the safety of medication doses. Though evidence suggests that community 
pharmacists’ interventions in community palliative care are beneficial 
(Needham et al. 2002) in this study, there appears to be a lack of clarity of an 
extended role that pharmacists currently do or could provide in the future for 
patients with palliative care needs. There was a willingness from the 
pharmacists to do more; however, a variety of barriers existed including the 
terms and remuneration within the current pharmacy contract, the 
responsible pharmacist regulations, the lack of integration within the primary 
care team, lack of access to patients’ electronic records, and limited access 
to palliative patients where they are unable to attend the pharmacy. The lack 
of integration and payment systems have also been noted by (Jiwa no date) 
in their feasibility trial of a community pharmacist home medication review 
service. In Scotland, the use of a nationally contracted Chronic Medication 
Service (CMS), which includes the development of a pharmaceutical care 
plan in palliative care, together with national resources has supported an 
extended role for the community pharmacy team in palliative care 
(MacRobbie et al. 2009; Bennie et al. 2012). 
Where there was an existing relationship between community pharmacists 
and GPs, the GP was more likely to consult or involve the pharmacist on a 
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specific case by case basis. Local collaboration with GP practices through 
participation in the GP Access Fund supported development of such 
relationships; however, concerns remained on appropriate sharing of 
information with pharmacists and pharmacy teams with both GPs and 
members of the specialist palliative care team. These concerns meant that 
GPs and healthcare professionals did not communicate whether a patient 
was palliative with the pharmacist, instead leaving them to work this out 
intuitively from the prescription or requiring the pharmacist to proactively 
have this discussion with the GP. Considering the potential lack of contact 
with other primary care team members and the lack of information that is 
shared with community pharmacists, there is a risk that patients may not 
have effective symptom control, and in the worst case scenario could 
experience a patient safety incident relating to the use of medication such as 
opioid analgesics. Lack of access to clinical information by pharmacists has 
been reported previously (Akram et al. 2012; Avery et al. 2010; Savage et al. 
2012), which limits the pharmacist’s ability to detect medication errors (Avery 
et al. 2010), but poor information transfer between professionals could also 
result in not meeting patient’s and caregiver’s needs (den Herder-van der 
Eerden 2017). Information from the National Survey of Bereaved People in 
England found that only 19% of people stated that pain was relieved 
‘completely, all of the time’ in the community; figures were much higher in 
hospitals (39%), care homes (46%) and hospices (63%) (ONS 2014). Whilst 
some of this will be reflective of the care setting and the staff available to 
support patients, it also suggests that there is room for improvement in 
managing symptoms such as pain in the community and the potential role of 
community pharmacists within the primary care team. 
GPs tended to view community pharmacists as providing mostly a supply 
function and supporting compliance in medication taking for patients in 
palliative care, and did not feel pharmacists should get involved in the more 
complex issues facing palliative patients and their families. This was also 
noted by (Jiwa no date) where GPs did not recognise an extended role for 
community pharmacists in palliative care. By contrast, community 
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pharmacists described a range of activities that were provided to ‘palliative 
users’ including the provision of psychological support to those not in the 
immediate family. A local scheme developed with a national cancer charity 
had enabled community pharmacists to get more involved in symptom 
management for certain cancer patients going through or recovering from 
treatment as well as providing psychological support. Though not viewed as 
‘palliative’ by the pharmacists, this has enabled better access to treatments 
for symptomatic relief closer to the patient’s home and is likely to reduce the 
need for hospital visits in future (Macmillan and NHS Commissioners 
Working Together, 2016). The researcher is aware of a further project on the 
role of the community pharmacist in breast cancer services that is being 
completed as part of a PhD (Nottingham University, 2017) that may be able 
to provide further evidence on an extended role for community pharmacists in 
this area in future. There, however, continues to be inequity of access to 
palliative care services for patients with conditions other than cancer (Oishi 
and Murtagh, 2014) and the community pharmacist’s accessibility may 
provide an avenue for expanded provision of services across all diagnoses. 
In my study, there appeared to be limited time and resources for pharmacists 
to have a proactive approach to collaborating, meeting and working with 
other healthcare professionals and also limited opportunities for other 
healthcare professionals, to meet with community pharmacists, making it 
difficult for collaborative networks to flourish. The provision of joint training 
events and sharing of practice across professional groups could be explored 
both at a local and city-wide level to provide opportunities for joint working. 
The next sub-sections review findings against the Phase 2 study objectives. 
 
6.3.3 Do community pharmacies within the LCS provide more than a 
supply function? 
Within the study, there was little evidence that the LCS provided more than a 
supply function; however, this is not surprising as the LCS is designed for 
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quick access to palliative care medicines and there are no additional services 
within the LCS. Participating pharmacists discussed the processes in place to 
check and reorder palliative care medicines prior to the weekend 
phenomenon. There was also discussion within one of the LCS pharmacies 
to provide further specialist palliative care stock medicines, beyond the LCS 
local palliative stock list, which should be explored further by commissioners 
within a pharmaceutical needs assessment. 
 
There was little evidence in this study of pharmacists providing additional 
clinical services and support to patients and carers. It is likely that medication 
support is provided ad-hoc relying on the pharmacist’s skills and training, 
time availability and resources such as support staff, and whether the patient 
or carer came into the pharmacy proactively requesting advice. 
6.3.4 Pharmacists’ perceptions and experiences in the delivery of 
palliative care services 
Pharmacists mostly experienced palliative care as requests for prescription 
medications near the end of life. Sometimes they were asked for advice on 
choice of alternative products when patients had swallowing difficulties but 
they rarely interacted with community nursing or specialist palliative care 
teams except on availability and supply of palliative care medicines. 
Two pharmacists working in pharmacies that were not within the palliative 
LCS had the perception that keeping some basic palliative care medications 
in stock was inconsequential compared to the difference it would make to the 
patient. In both pharmacies, there had been a past experience where they 
were unable to supply medication when this was needed urgently. This 
experience seems to have had a significant impact on their decision to keep 
a limited number of palliative care medicines in stock. A different pharmacist 
working in a non-commissioned pharmacy trivialised the service as a stock 
and supply function and justified being less likely to hold palliative care 
stocks since another pharmacy in the locality was already commissioned to 
provide these.  
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6.3.5 Does the delivery of palliative care have any effect on community 
pharmacy staff? 
It was not possible to fully answer this objective as the views of pharmacy 
staff were not established directly since only community pharmacists were 
interviewed in the study and sometimes they felt unable to comment on the 
effect the provision of palliative care had on pharmacy support staff. This has 
been considered a limitation of the study and is discussed in more detail in 
section 6.7.2. 
Pharmacists considered pharmacy support staff were accustomed to a wide 
demographic of people who visited the pharmacy and staff showed sensitivity 
and empathy in the context of palliative care and bereavement. In some 
smaller localities, pharmacists expressed the concern that pharmacy staff 
may know families of the bereaved and this may cause some distress. The 
perspective of the pharmacists was that close working conditions in the 
pharmacy, and the fact that many people may visit the pharmacy and be 
upset for a variety of reasons, meant most pharmacy staff were able to cope 
with the emotional issues of working with bereaved relatives and were able to 
support both relatives and each other. The pharmacists felt that suitable 
support networks and referral processes were available both inside and 
external to the pharmacy. This would need to be substantiated with the views 
of pharmacy staff directly. 
6.3.6 What is the community pharmacist’s current and future role in 
palliative care? 
The evidence presented in the study shows that most healthcare 
professionals did not know what community pharmacists did or what input 
they could have for palliative patients, which is not surprising when there 
appeared to be limited opportunities to work with pharmacy teams. Despite 
the national direction to extend the role of the community pharmacist, other 
healthcare professionals lacked insight into what community pharmacists do 
beyond a traditional role of supplying medication, which also meant the 
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national vision for a role in palliative care was not enacted on the ground. 
This could be due to the evolution of the ‘clinical’ pharmacist role that has 
seen the pharmacist move from a scientific role manufacturing items on a 
prescription to a healthcare role working in collaboration with patients and 
other healthcare professionals and the resultant ‘re-professionalisation’ not 
understood by others in the primary healthcare team (Hughes and McCann 
2003; Bush et al. 2009; Latif 2012; Blondal et al. 2017). In developing the 
thematic analysis framework for this study, it was noted that some of the 
coding labels emerging from the interviews with other healthcare 
professionals included themes for pharmacy services provided by pharmacy 
corporate bodies not within the pharmacist’s control, for instance, delivery 
services (which are specified within the pharmacy corporate body 
guidelines). Other healthcare professionals had a lack of understanding of 
community pharmacists as well as the pharmacies they work in and the 
services they offered potentially causing a feeling of mistrust through 
corporatisation of pharmacy bodies and a target driven culture (Bush et al. 
2009; Mitchell 2016). This is not unique to my study with others also reporting 
lack of clarity on the pharmacists’ role (Smith et al. 2013; Davies et al. 2014; 
Jiwa no date). Pharmacists and pharmacy corporate bodies could provide 
more information on pharmacy services to healthcare professionals but also 
potentially to patients as advised by Bennie et al. (2012) to show what 
services they provide to support patients and their family caregivers. GPs are 
open to involving pharmacists more in the patient’s clinical care where they 
have expertise and no conflict of interest (Kelly 2016; Primary Care Sheffield 
(PCS) 2016; Blondal et al. 2017) 
The community pharmacists’ role in clinically reviewing the prescription 
against legal regulations, and checking safe and appropriate doses was a 
consistent theme across professional groups; however, it was acknowledged 
that the pharmacist is not always aware of the specific dose for medications 
administered via a syringe driver as this could not always be determined from 
the FP10 prescription form. Core service functions for community pharmacies 
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have been described by Bennie et al. (2012) including the clinical 
assessment of prescriptions to ensure safe doses. 
Talking with patients and their carers was seen by community pharmacists to 
be an important role but time constraints, the fact that the patient may not 
come into the pharmacy and remuneration of nationally contracted pharmacy 
clinical services were identified as barriers to achieving this in palliative care. 
Davies et al. (2014) report on a time audit suggesting that only 10% of the 
community pharmacists’ time is spent on counselling patients attending the 
pharmacy. Pharmacists were highly concerned and paid attention to 
customer’s needs, showing empathy at what was perceived as a difficult 
time; however, there was also the perception from healthcare professionals 
that pharmacists were reluctant to see patients as their responsibility, and 
were detached seeing their job as only to sort the prescription. This could be 
related to the community pharmacist’s freedom to act within the constraints of 
professional organisation, regulatory and pharmacy group policies 
(Svensberg et al. 2015) as well as workload pressures. 
The provision of pharmacy clinical services such as MURs and NMS was 
seen to be minimal in my study and in palliative care generally as many 
barriers existed, for instance, patients do not visit the pharmacy, and 
pharmacists felt unequipped to deal with the emotional issues (Savage et al. 
2012), and palliative care, cancer and analgesics were not within the target 
groups for the MUR or NMS service (PSNC 2017a). Furthermore, the patient 
would normally need to be present in the pharmacy for it to be considered an 
MUR, negating the benefit of discussing medication with the patient’s carer 
who may be involved in supporting the patient’s medication-taking at this 
time. Where a pharmacist obtains patient consent to undertake an MUR by 
telephone or off the pharmacy premises, the pharmacist must request prior 
permission from the local NHS England team to receive the MUR payment. 
Since palliative patients may deteriorate rapidly or suddenly, it may not be 
feasible to request prior permission. Another issue is that when a pharmacist 
leaves the pharmacy premises, they must do so in accordance with the 
 213 
 
responsible pharmacist regulations, which only allow for them to be absent 
for a maximum of two hours in a day. Whilst away from the pharmacy, all 
dispensing and supervised pharmacy sales cannot take place, which has 
been reported to have a negative impact on patients (Blenkinsopp et al. 
2007; Urban et al. 2008; Latif et al. 2013). Pharmacies are paid a flat fee for 
each MUR whether the MUR occurs in the pharmacy, in a patient’s home, or 
via telephone and there is no provision to pay for transport costs. Other 
barriers such as lack of time, lack of staff resources, and increased workload 
factors have been reported in the literature (Bradley et al. 2008; Latif and 
Boardman 2008; Gidman et al. 2012). Although MURs are not clinical 
reviews, there may also be difficulty in accessing the patient’s current 
medication list due to multiplicity of prescribing across different settings, for 
example, specialist prescribing of oral chemotherapy or treatment for 
pulmonary fibrosis. All together there is no incentive for community 
pharmacists to undertake MURs within the palliative care population and it is 
uncertain what, if any, clinical pharmacy support palliative care patients and 
their family caregivers receive. This was identified as a gap within my study 
for housebound palliative patients who may be on a lot of medication and by 
GPs who thought that carers would benefit from more support and 
information on managing medications. This has also been reported within 
studies, including bereaved carers managing medications near the end of life 
(Payne et al. 2015), barriers to post discharge MURs for housebound 
patients, those with carer support (Ramsbottom et al. 2016), and focus 
groups of palliative care patients and their carers (Bennie et al. 2013b) who 
wanted more face to face contact with a pharmacist. There is  evidence that 
community pharmacists in a multidisciplinary environment can provide more 
support to domiciliary patients as demonstrated in a Sheffield pilot scheme 
(Alton 2015); however, this required additional local funding, was time limited 
and it is unclear whether it was economically cost-effective. 
It was identified by some pharmacists, they may have a role in symptom 
management, for example, for patients undergoing or living with the effects of 
chemotherapy or radiotherapy in the community. Participating GP and 
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pharmacists recognised that supporting patients to take their medication 
through concordant conversations, and making changes to formulations or 
suggesting alternate drugs where patients had swallowing difficulties may 
also support symptom management in the palliative patient and for which 
community pharmacists could have a role. 
The suggested continuity of care offered by community pharmacy has been 
incorporated into a model developed by RPS Wales as part of its strategic 
vision for pharmacy. This model shows how people may access pharmacy 
over the whole of their life from health and wellbeing support through to 
palliative and end of life care. Interactions between the patient, the 
pharmacist and pharmacy staff build trusting relationships, thereby further 
enhancing patient centred care. 
Figure 6.1 Patient interactions with pharmacy along their care journey 
from Your Care, Your Medicines (RPS Wales 2014). With kind permission. 
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6.3.7 Discussion of Phase 2 study results 
Participating community pharmacists reported they were aware of the 
existence of a ‘network’ of pharmacies commissioned by the CCG to provide 
palliative care medicines, though in contrast most other healthcare 
professionals did not appear to be aware of this. The researcher thinks this 
could be explained by a proactive LPC that has supported community 
pharmacy involvement in commissioned services, having commissioned 
thirteen local services in 2015/16 (CPS 2016). Another possible explanation 
could be that participating GPs and other healthcare professionals were the 
ones not aware; however, this explanation seems unlikely since participants 
came from different areas and practices across the city and had a significant 
number of years of experience between them. Furthermore, members of the 
specialist palliative care team were unaware, suggesting a more systemic 
lack of knowledge of a ‘network’ of pharmacies. Information on the 
pharmacies commissioned to provide the LCS needs to be reviewed and 
disseminated widely to capture all healthcare professionals and contractors 
involved with palliative care patients. Furthermore, this must be an ongoing 
process of communication embedded across all local organisations to 
capture staff changes. 
In my study, most healthcare professionals had found community 
pharmacists to be accommodating and helpful particularly when informed the 
patient was end of life; however, there were also examples expressed by 
other healthcare professionals where pharmacists seemed detached and 
less helpful. Reasons for this could include the community pharmacist not 
being aware of the commissioned service or there may be a large turnover of 
staff or locum staff working in the community pharmacy who are not aware of 
local services, also observed in (Smith et al. 2013). Some healthcare 
professionals suggested community pharmacists may not feel responsible for 
patients in their area since patients are free to go to any pharmacy, not 
having to register with a community pharmacy as happens with GP practices. 
This is noted as one of the strengths of community pharmacy, which allows 
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access at a place and time convenient for the customer (Thornley et al. 
2017), though perhaps this could also disrupt continuity of care especially 
towards the end of life when patients rely on family caregivers and friends to 
fetch medication for them, and who may not access the patient’s regular 
pharmacy. This division between the patient’s regular pharmacy and a 
‘palliative pharmacy’ can cause resentment where the regular pharmacy has 
built up a relationship over a number of years (Armstrong, 2017 pers. comm. 
March 13). This could manifest as friction from pharmacies not 
commissioned to hold palliative care medicines as seen in my study and 
resistance to hold palliative care medication where another pharmacy in the 
area provides this service. The availability of a ‘network’ of pharmacies 
holding palliative care medicines is a model used in other areas (Bennie et al. 
2012; Armstrong 2017: pers. comm., March 13) and often pharmacies 
provide services OOHs but this was also noted by (Armstrong 2017: pers. 
comm., March 13) to cause some friction. The patient’s regular pharmacy 
should be supported to provide continuity of care close to the patient’s home, 
reducing the time for the patient’s carer away from the house and 
transportation. Pharmacies should be encouraged to work with GP practices 
and consider providing services to meet their customer’s needs. Patients 
should be encouraged to register for EPS and other pharmacy services to 
support their long term care needs.  
GPs and other healthcare professionals generally held a very traditional view 
of the pharmacists’ role in supplying and dispensing medication promptly, 
and were unaware of what other support or services the pharmacists could 
provide, also observed in (Jiwa no date). GPs and other healthcare 
professionals’ contact with the pharmacist were mainly in connection to 
medication supply, also witnessed in Savage et al. (2012). GPs identified the 
pharmacists’ role in completing a clinical screen of the prescription, checking 
the safety of the medication, and checking for interactions between 
medications. GPs and a doctor in the specialist palliative care team identified 
the community pharmacists’ role in clinically screening the prescription, and 
suggested they could provide advice on mixing and the compatibility of 
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medicines given in a syringe driver. Then again, they also understood that 
the community pharmacist may not be aware of the specific dose to be 
administered by injection or those drugs that were to be mixed together in a 
syringe driver since that information was not always available on the FP10 
prescription form. Such information was available on the community 
medicines administration record but the community pharmacist did not 
always see this. 
Integration of community pharmacists with GPs and primary care teams did 
happen but not on a widespread basis, and was more likely in small localities 
with a single GP practice or where the community pharmacist worked in the 
GP practice. In some cases pharmacists described hardly ever speaking to a 
GP on the phone, and GPs would not discuss palliative care patients unless 
requesting specific advice. A facilitator to the integration of pharmacists 
within primary healthcare teams was proximity to the GP practice with high-
street and town centre pharmacies or those with several GP practices on 
their radar feeling that their relationship with GP practices was not as strong. 
Previous research on integrating community pharmacists into the primary 
health care team within local pharmaceutical service (LPS) pilots reports that 
co-location of pharmacies and GP practices facilitates integration (Bradley et 
al. 2008) with decentralisation of nursing teams away from primary care hubs 
causing challenges in communication (Wilson and Seymour 2017).   In my 
study GPs, community pharmacists and community nurses described good 
working relationships when they were working in close proximity with each 
other., Formal palliative care team meetings such as those within the Gold 
Standards Framework (GSF) support joint decision making in primary care 
(Amass 2006; Clifford et al. 2016) but GPs and community pharmacists in 
this study stated that community pharmacists are not invited to GSF 
meetings, and it would be difficult logistically to enable this to happen, such 
practicalities also noted by Akram et al. (2012).  Attendance at palliative care 
meetings has been suggested as a way of enhancing the community 
pharmacist’s contribution in palliative care (Akram et al. 2012; Savage et al. 
2012) and has been achieved within networks in Scotland (Bennie et al.) One 
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pharmacist suggested the use of technology to support remote attendance. 
Such strategies using remote technology to allow multidisciplinary team 
working in palliative and end of life care are envisaged within Wales (Royal 
Pharmaceutical Society (Wales) 2014). 
Integration with community nursing teams was also hindered for a number of 
reasons in this study, including a lack of knowledge of what pharmacists do 
and the pharmacy services they offer. Nursing staff favoured face to face 
relationships with GPs and pharmacists in my study, also seen in (Wilson 
and Seymour 2017); however, there appeared to be little opportunity to 
interact with community pharmacists. Geographical proximity and having face 
to face access to other healthcare professionals develops trust and supports 
an understanding of each other roles in the primary care palliative team 
(Wilson and Seymour 2017). Where close working relationships existed, this 
had enhanced care for palliative care patients, for instance, pharmacists in 
my study not commissioned to hold palliative care medications made 
arrangements to keep some palliative care stock in, and there were reports 
where pharmacists enabled a fast turnaround time for medications to go in a 
syringe driver or sufficient stock was available for over the weekend. Despite 
this, there appeared to be few examples of community pharmacists working 
with other healthcare professionals in the context of palliative care except in 
terms of stocking and supplying medication. There was a case where a 
pharmacist had worked with the local nursing team and GP practice in 
proactively providing education to new nursing staff and GP trainees in the 
pharmacy. Such schemes are likely to improve knowledge and 
understanding of each other’s professional roles and have been suggested 
as a way to learn about other professions, support building personal 
relationships and multidisciplinary working (Micallef et al. 2017). 
Nursing staff also overlooked pharmacies and pharmacists in respect to 
queries on medicines within my study, preferring instead to contact the GP or 
the specialist palliative care team. Nurses never thought of contacting the 
pharmacist in a professional role, though it was identified by a nurse that this 
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would happen for medicine issues in a personal context outside of work. This 
could be explained by the nurses having a lack of awareness of community 
pharmacist training, roles and pharmacy services or a preference for the 
advice of the GP in relation to palliative care issues. It could also be 
explained by professional isolation and a lack of a personal relationship with 
any pharmacist. The issue of personal trusting relationships in and between 
teams is cited as centrally important to achieving anticipatory prescribing by 
Faull et al. (2013) as well as for integrating pharmacists into primary care 
teams (Jorgenson et al. 2014). Previous research on contact between nurse 
prescribers and community pharmacists noted that more than two-fifths of 
community pharmacists did not have any regular contact with nurses (While 
et al. 2005) but this could have been related to low nurse prescribing rates in 
the study. The authors suggest increased contact and understanding of roles 
would be needed to support team working between nurses and community 
pharmacists. With GPs under increased pressure and a workforce crisis 
(NHS England 2016), they are open to letting other healthcare professionals 
such as district nurses and specialist palliative care teams lead on areas 
within palliative care potentially to the point where GPs are only observed to 
be involved, with the prescription of the drugs (Payne et al. 2015). Answering 
queries on medicines is an area where community pharmacists could get 
involved thereby reducing the number of queries hitting the GP practice. In 
Sweden, dispensing pharmacists, added to palliative care teams, have been 
valued for answering queries on medicines and improving medicines 
management (Norrström et al. 2010), and pharmacists incorporated into 
palliative care teams have answered queries and significantly improved 
nurses medication related knowledge (Hussainy et al. 2011). 
Concerns raised by other healthcare professionals on sharing confidential 
information with the pharmacy team, a potential lack of trust and an 
understanding of how this information could support patient care suggests a 
much greater barrier to be overcome before pharmacists can be integrated 
into primary healthcare teams to provide more support to palliative care 
patients and their caregivers. This may be reflective of public trust in 
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pharmacy services per se making it improbable that the public will access an 
extended role for pharmacists in a high risk area such as palliative care 
without an existing trusting relationship with the community pharmacist and 
the support of their GP (Gidman et al. 2012). Developing relationships 
between cancer patients and their community pharmacist through a local 
‘Living with and beyond cancer’ may be a positive step in the right direction 
providing evidence for new models of care whilst helping patient symptom 
management but such schemes are not universally provided at present. 
Community pharmacists appear to have a limited role in palliative care due to 
the current infrastructure in community pharmacy that does not support an 
extended role in providing additional services to this group of patients. Where 
patients and their family caregivers are given additional pharmaceutical 
support by community pharmacists, this is often ad-hoc and done without 
remuneration as a result of the pharmacist’s own motivation, skills and 
professionalism. Pharmacists in the study reported this was more likely to 
happen within pharmacies with an additional pharmacist or upskilled support 
staff and less likely in pharmacies with only one pharmacist where there are 
increased time pressures. A lack of organisational support and constraints of 
the pharmacists workload in undertaking MURs has been reported elsewhere 
(Rosenbloom and Graham 2008; Latif et al. 2011; Latif 2012). There is 
concern that housebound patients with a high degree of symptomatic burden 
may have limited access to a community pharmacist or any pharmaceutical 
care in the community with family caregivers often taking on the burden of 
managing their medicines, which can cause difficulties due to complexity in 
the medicines regime, concerns on giving opioids and “as required” 
medication (Savage et al. 2012; Payne et al. 2015). In their study of 
bereaved relatives, Payne et al. (2015) highlight that family carers need more 
information to manage medicines and suggest community pharmacists could 
advise on the safe management, storage and disposal of medications. A 
proactive approach whereby community pharmacists provide medicines 
information to older palliative care patients and their carers is also suggested 
as a way to give reassurance and advice (Bennie et al. 2013b), and is likely 
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to build relationships and trust between pharmacists and their customers. 
However, the pragmatic difficulties of how to achieve this within the current 
community pharmacy infrastructure without adequate processes for patient 
consent and remuneration to support this remain. Although community 
pharmacists in my study were willing to do more to support palliative care 
patients, they stressed such constraints as workload, time and responsible 
pharmacist regulations were major barriers in allowing them to undertake 
extended roles or to leave the pharmacy unless additional staff were 
available and specifically trained to take on more ‘traditional’ tasks. 
It was suggested by other healthcare professionals in my study that 
community pharmacists may lack confidence in counselling palliative patients 
and be unfamiliar with pre-emptive medication. Furthermore, they may have 
difficulty in identifying a patient as ‘palliative’ due to a lack of access to 
patient clinical records and not being informed when someone is on a 
palliative care register by the primary care team. Both of these issues may 
substantially limit the pharmacists’ ability to do more to support symptom 
management and provide a clinical service in the pharmacy. Access to 
patient records including read and write access to SCR has been highlighted 
as being critical to ensure effective communication and co-ordination across 
the multidisciplinary team when providing high quality, responsive palliative 
and end of life care (RPS England 2016). In my study pharmacists felt as if 
the treatment decision had already been made by the GP and nurse prior to 
the palliative care prescription coming to the pharmacy. Since syringe drivers 
could not be pre-empted and prescriptions were often presented urgently, 
there was no time to discuss treatment alternatives unless the prescribed 
choice was not available or could not be obtained. The pharmacists’ reactive 
role in only responding on presentation of a prescription, having limited 
access to patient records and minimal time to have impact has already been 
discussed elsewhere (Rosenbloom and Graham 2008; Avery et al. 2012). 
Community pharmacists need to be proactive and involved earlier in the 
patient care pathway to improve care and utilisation of medicines, and not 
just at the end of the supply chain. 
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6.4 Integration of findings from quantitative and qualitative phases of 
the research 
Creswell and Plano Clark (2011) state, using an explanatory sequential 
design, uses the qualitative results to help explain the quantitative results of 
the study. Using mixed methods helps provide a fuller picture of the issues 
and triangulate the data (Bryman 2012; Ritchie et al. 2014). The purpose of 
this study was to identify factors associated with a delay in supplying 
palliative care medicines and understand factors that facilitate or limit the 
community pharmacists’ contribution to palliative care. In this section, I 
examine where two or more sources of data are in agreement or contrast 
with each other to help explain the quantitative results of the study. 
The findings from the interviews with community pharmacists corroborated 
with the evidence that prescription errors, in particular, legal errors on 
handwritten prescriptions for CDs were very infrequent now. When legal 
prescription errors did occur they could often be resolved through a permitted 
pharmacist technical change and did not cause a significant delay in contrast 
to Stuart (2013) and MacRobbie et al. (2015). Interestingly, the community 
pharmacists interpretation of ‘prescription errors’ included instances where 
the item prescribed was not the strength or form specified on the local 
palliative care medicines list while such errors were classified as 
administrative errors within my study as the prescriptions complied with legal 
requirements. As with Stuart (2013), my study suggests changes to CD 
requirements for syringe driver prescriptions may be required or future 
improvements through the use of electronic transmission of prescriptions, -
which are on the horizon for controlled drugs using EPS r2 (NHS Digital 
2017)-may allow quicker resolution of incorrectly written prescriptions.  
The number of people needing to go to more than one pharmacy as recorded 
in the customer survey could be explained by the poor awareness of the 
commissioned palliative care pharmacy service by GPs and other healthcare 
professionals, and the assumption by GPs that most pharmacies keep some 
palliative care drugs in stock; so GPs do not necessarily contact the 
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pharmacy in advance or direct the patient as to where to go when needing 
urgent medicines. This is reinforced by half of those referred to the pharmacy 
had to go to one or more pharmacies to access urgent palliative medications. 
Having the stock in the pharmacy was the main facilitator for quick access 
meaning pharmacies participating in the LCS monitoring stock levels or those 
pharmacies working in collaboration with GPs to stock a few basic palliative 
medicines were more likely to provide quicker access. Even though there 
was a lack of awareness of the CCG list of palliative care drugs in the 
interviews with GPs, the fact that there was a high adherence to the 
formulary list can be explained by embedded use of IT prompts within the 
SystmOne GP clinical prescribing system used in many practices. 
The low number of queries and MURs recorded in the pharmacy could be 
explained by a lack of communication and referrals from others in the primary 
healthcare team regarding palliative care patients, often due to concerns on 
sharing confidential patient information, as expressed by the GP and nurse 
interviews. Furthermore, the perceived barriers to conducting additional 
services in this patient cohort, who may not be present in the pharmacy, was 
illustrated by the community pharmacists. 
SCR was not used within the pharmacy data collection with the community 
pharmacist interviews confirming that, though SCR can be helpful in many 
circumstances in the pharmacy such as emergency supplies, it may not 
always be up to date where frequent dose changes have occurred or where 
there is multiplicity of prescribing, which could be the case for palliative care 
patients. Some pharmacists in the study explained that working in the GP 
practice and having access to the full patient clinical record was used in 
preference for palliative care queries compared to SCR. There is a concern 
that not having access to full clinical records or a specific dose on a syringe 
driver prescription means that the clinical safety check performed by 
community pharmacists can be jeopardised potentially putting patients at risk 
of inadvertent medication errors. The higher percentage of prescriptions for 
patients who are not regular users of the pharmacy as well as OOH 
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presentation make this a high risk area for community pharmacists. Having 
read and write access to SCR, which includes up to date letters and referrals, 
would give pharmacists the ability to record discussions and therapy 
suggestions, updating patient’s medical records back through to GPs and 
other healthcare professionals involved in the patient’s care (Andalo and 
Sukkar 2015). In addition, having read and write access to SCR would 
improve interdisciplinary working, increase the quality of care improve patient 
safety and support continuity of care especially OOHs (PSNC 2017). 
The high proportion of medicines given by subcutaneous injection in the 
pharmacy data collection may be explained by the pharmacists 
understanding of palliative care, viewing this as end of life care, in addition to 
the lack of communication from others in the primary healthcare team when a 
patient is added to the GP palliative care register. This view was also 
conveyed in the interviews where pharmacists described patients as ‘pre-
palliative’ when taking oral medicines or managing their symptoms well and 
being more mobile. Furthermore, other healthcare professionals questioned 
the pharmacists’ understanding of palliative and pre-emptive prescribing. 
An interesting finding from the qualitative interviews with other healthcare 
professionals is the lack of sharing of information with the pharmacist and 
pharmacy team when the evidence suggests that planning in advance and 
informing the pharmacy would make it more likely for pharmacy teams to 
keep items in stock. This would also have implications for nursing resources, 
patient carers who need to travel long distances by car to access medication, 
and potentially provide quicker symptomatic relief for patients. The need to 
have robust systems to share information is essential so that GPs and 
community nursing staff feel able to share patient confidential information 
securely with the pharmacist or pharmacy team, where this is lawful and 
necessary as part of delivering good patient centred care (NHS England 
2016). 
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Data from both parts of the study corroborates the fact that community 
pharmacists currently have limited input into care of palliative care patients 
with the focus mostly on the supply of medicines from the pharmacy. GPs 
and other healthcare professionals limited understanding of the community 
pharmacists’ professional role and the services they could provide that may 
be of benefit to palliative patients does not support early involvement and 
limits the pharmacists input. It also means they are not the preferred route 
when nurses have medicines queries; not utilising the pharmacist’s specialist 
skills and knowledge. This lack of knowledge and integration was also noted 
by Jiwa et al. (no date). In Australia and in Scotland, development of specific 
services for chronic disease management and home medication reviews 
have allowed pharmacists to have greater input into the care of palliative care 
patients (Jiwa et al. 2011; Bennie et al. 2012; Jiwa no date) suggesting that 
external factors such as contracts and reimbursement policies can support 
pharmacists to have an extended role in this area. 
Near the end of life, family caregivers and friends were involved in collecting 
medication for the patient with many of them going to a pharmacy that is not 
the patient’s usual pharmacy. Changes in continuity of care could be 
explained by the urgent nature of the prescription, the chosen pharmacy 
being easier for the relative to reach or the fact they have been directed or 
referred to the pharmacy from an OOH provider, GP, a member of the 
nursing or specialist palliative care team or another pharmacy. This finding 
around referrals appears to be novel with no other reported research found in 
this area. Changes in continuity of care highlight the need for advanced care 
planning to be effective and for all healthcare professionals to be aware of 
the LCS so they can direct family caregivers appropriately.  
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6.5 Generalisability of Findings 
This study was not intended to be generalisable as it was set in the specific 
context of a locally commissioned service in Sheffield; with a wide community 
pharmacy network, an active LPC, an established 24/7 day access to 
specialist palliative care, access to OOH and acute trust pharmacy on-call 
services. Organisation of palliative care and pharmacy contracts will be 
different in other areas, particularly rural locations, and commissioned 
services and networks will vary. Despite this, there may be some aspects of 
the study that can be compared to practice in other areas. 
Participating pharmacists were highly motivated to be involved in the study, 
citing that the payment offered did not make a difference to their involvement, 
and instead offered altruistic reasons such as for their professional 
development, CPD, the profession of pharmacy practice or reviewing 
provision of services in the pharmacy. They all participated in an in-depth one 
to one interview lasting for approximately 51 minutes (median time of 
interview), providing rich data for analysis. The fact that the pharmacists were 
highly motivated, however, may mean it is difficult to generalise the results to 
other pharmacies/pharmacists that may be less motivated to be involved in 
palliative care or those that are run on locums or temporary staff. In this 
study, the researcher had difficulty recruiting enough pharmacists to take part 
in the pharmacy data collection with some citing insufficient palliative care 
prescriptions, though it was not possible to find out why other pharmacists 
may have refused to take part. The findings relating to pharmacy support 
staff may be less reliable as only pharmacists participated in the interviews. 
6.6 Reflexivity 
Reflexivity is stating clearly the researchers own role, and their assumptions 
and beliefs that could influence the research process as well as the 
interpretation and presentation of the results (Ritchie et al. 2014). This brings 
the researcher into the process and allows the reader to ascertain as to what 
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extent the researcher’s positions and interests may have influenced the 
inquiry (Charmaz 2006). In this section, the researcher reflects on her  own 
role and prior assumptions that may have led to potential sources of bias 
within the study and considers ways that she has  tried to achieve ‘objectivity’ 
in the study.  
The researcher’s role as a pharmacist with previous experience in community 
pharmacy strengthens the study and has provided the researcher with a 
greater understanding of the contextual factors within the analysis. In 
addition, the researcher’s experience in palliative, hospital and primary care 
enables the detail as well as the larger picture to be understood within the 
interpretation. Opposing this as a pharmacist working in palliative care, 
interviewees may fear participation due to professional power or feel that 
their knowledge or decision- making processes are being scrutinised, 
especially where decisions have been made outside of legal requirements in 
the patient’s best interest. The potential for interviewees to modify their 
responses due to perceived or actual social and professional status has been 
recognised by Robson (2002) and Fontana et al. cited in Denzin and Lincoln 
(2005). This may be evident in the interviews with healthcare professionals 
who may provide answers reflecting how they believe they should act in any 
given situation rather than how they have actually acted in the past. There 
can also be the risk of bias due to insider knowledge of working in the 
research location, which was minimised by choosing to study in primary care 
where the researcher is not employed. A potential risk of bias may arise in 
the researchers approach to questions, the prompts used, the topic guide 
development, analysis and interpretation of the data due to clinical 
experience and the researcher unconsciously applying their own beliefs 
(Bryman 2012). This was minimised through notetaking and journal writing to 
ensure the researcher was able to set aside any prior assumptions as well as 
reflection during the transcript writing to ensure interview questions and 
prompts are as objective as possible. Furthermore, during data analysis, the 
researcher was mindful of deviant or negative cases to seek alternate 
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explanations to provide assurance of truth-value in the findings (Mays and 
Pope, 2000; Yin, 2003a; Yin 2003b).  
The researcher had close supervision from two University academics with 
experience in postgraduate and DPharm mixed methods research as well as 
a workplace supervisor experienced in DPharm and qualitative methods. In 
addition, the researcher received training in qualitative approaches, utilising 
the framework method co-ordinated through NatCen (a nationally recognised 
trainer in this qualitative method), providing high quality training over two 
days. The researcher also undertook qualitative interview training at the 
University of Bradford over two days to build confidence in research 
interviewing, and ensuring objectivity in asking interview questions since this 
technique was quite different to previous experience in counselling patients 
as a healthcare professional. The researcher kept notes of supervision 
meetings, discussed emergent findings in the qualitative analysis, and kept a 
reflective diary recording thoughts during the analysis to aid reflexivity. An 
example of a reflexivity memo is provided in appendix S. 
Further to this, the researcher had support from the University of Bradford 
Medicines Optimisation Research Group, which includes staff and PhD 
students from the School of Pharmacy and Medical Sciences and Faculty of 
Life Sciences who were presented with the initial emergent themes from the 
interviews to develop a thematic framework. This helped to refine the 
thematic framework further and aiding interpreting and abstraction. In the 
early interviews, the structure was focused on community pharmacists and 
their role while the interview structure was modified to incorporate healthcare 
professionals’ views in later interviews. Due to a lack of knowledge of 
pharmacy services, there were more prompts given to healthcare 
professionals during the subsequent interviews, which could have had a 
bearing on the findings. 
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In this study, the researcher’s position as a palliative care pharmacist may 
have provided the necessary credentials to recruit a variety of healthcare 
professionals to the study, which is one of the studies greatest strengths. 
There did not appear to be any concerns with the research process with none 
of the community pharmacists making changes to their interview transcript 
during the member checking process and no healthcare professionals 
requesting to check their transcript. 
There was no payment to other healthcare professionals, as this was not 
included in the initial research design that was funded and peer-reviewed 
externally through a research grant. Interviews with health care professionals 
tended to be of shorter duration and were approximately 18.5 minutes long 
(median time for interview) due to time restrictions and less content to 
discuss. All interviewees were given the opportunity to add comments at the 
end of the interview on any thoughts that had arisen, and it was commented 
that the interview was thorough or they felt they had nothing else to add; so it 
appears that the time allowed was sufficient to cover all the issues from the 
healthcare professional’s point of view. The interviews included a variety of 
healthcare professionals, except it was not possible to recruit a GP from the 
OOH service; so their views could not be incorporated and the design did not 
include other pharmacy support staff. 
6.7 Discussion of the Strengths and Limitations of the Study 
6.7.1 Research Setting 
The study occurred in a single city in England, UK, with a mixture of 
pharmacies on high streets, within health-centres and urban locations. 
Sheffield has a vibrant history of innovative community pharmacy services 
and a range of pharmacies open for 100-hours and extended hours that 
provide access to palliative care medicines seven days a week between the 
hours of 6am and 12 midnight Mondays to Saturdays and 8am to 10pm on 
Sundays. Having access to a range of pharmacies that are open extended 
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hours could limit the generalisability of the study findings to other non-urban 
or remote areas with less pharmacy access. 
Since the research took place in a single location, it may not be possible to 
generalise the findings across other areas of England or across the devolved 
government arrangements of the UK due to the different organisation of NHS 
contracted services. One interviewee who had worked outside Sheffield 
commented that the service was more organised in Sheffield than in other 
areas of England; however, another respondent reported a better experience 
when working in an area outside Sheffield, while another when working in a 
different pharmacy in Sheffield; so the location of the pharmacy and working 
relationships with other health care professionals may have a greater impact 
than the specific area. None of the respondents had worked in Scotland, 
where considerable work had been undertaken within community pharmacies 
to support access to palliative care medicines (Bennie et al. 2012; Bennie et 
al. 2015; MacRobbie et al. 2015); however, this was achieved with additional 
external funding in the context of the national Scottish pharmacy contract and 
a devolved government providing a different context to that in England. 
Information on local commissioning of palliative care access schemes from 
PSNC is limited and no outcome data is reported, suggesting that the 
commissioning of palliative care services in England may not be particularly 
well organised and monitored (Kings Fund 2013; PSNC 2016; Stotesbury 
2016, pers. comm., 12 July ). Rural areas may have more difficulty due to 
remoteness, lack of services and lack of pharmacy access (Carney and 
MacRobbie 2008; Bennie et al. 2013). 
Sheffield pharmacists have been working in local surgeries as part of the GP 
Access Fund (formerly the Prime Minister’s Challenge Fund) pilot in Sheffield 
(Primary Care Sheffield (PCS) 2016). This may have supported further joint 
working through building trust, communication, interdependence and 
providing role definition, all of which are required for collaborative working 
(Bardet et al. 2015). Since this pilot is not universally available, this may limit 
the application to other areas not involved in such schemes. On the other 
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hand NHS England is investing in clinical pharmacists to work in GP 
practices, which could support more joint working with local community 
pharmacies and will cover a larger number of GP practices (NHS England 
2017b). 
During the study period, the government announced cuts to the community 
pharmacy budget and it was reported that nationally up to 3000 pharmacies 
could close as a result (Mundasad 2016: BBC News). Due to the timing of 
the study and the government announcement, it is likely that feelings relating 
to remuneration and fees were heightened by participating pharmacists in the 
study, especially those working as independent contractors. This could have 
had an impact on the pharmacists’ attitudes and perspectives to taking on 
roles that are additional or not-remunerated that could have come to light in 
the interviews. 
During the period of interviews, the local GP OOH provider was initiating a 
‘just in case’ box to provide access to a limited range of palliative care 
medicines during OOH visits. Palliative care medicines for the GP OOH 
provider had previously been supplied from the acute hospital pharmacy 
through contacting the on-call pharmacist. However, since the GP 
collaborative palliative care medicines scheme was not introduced until after 
the data collection, it is unlikely to have had any impact on the study findings. 
The impact following introduction of the ‘just in case’ boxes is unclear but it is 
possible that it may reduce the number of GP OOH prescriptions and inter-
pharmacy referrals; however, no published data is available as yet. 
When questioned on their reasons for taking part in the study the 
pharmacists expressed altruistic reasons suggesting they were keen and 
motivated to advance pharmacy practice. The likely consequence is that the 
participating pharmacists may have been more innovative in delivering 
services, interested in research and undertaking relevant education and 
training programmes than other pharmacists not participating in the study. 
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Evidence of this includes some of the community pharmacists working in GP 
surgeries, completing further education and two pharmacists in the study 
working with local surgeries to develop their own list of palliative care 
medicines. This is a strength of the study but also a limitation since findings 
are not transferable to other pharmacists and locations. 
6.7.2 Sampling 
Recruitment of community pharmacies willing to take part in the study was 
low, meaning it was not possible to apply a sampling strategy to either the 
Phase 1 data collection or subsequently within the purposive sample for the 
Phase 2 pharmacist interviews. This is a limitation of the study; nevertheless 
the pharmacies that did take part were diverse in their nature including large 
multiples, independent and small chain pharmacies in high street and urban 
locations. Both those pharmacies participating, as well as those not 
participating in a LCS providing access to palliative care medicines, were 
included helping to draw out contrasting experiences between pharmacists in 
these situations.  
It was remarked by two pharmacists choosing not to take part in the study, 
that there was a low level of palliative care prescriptions at their respective 
non-LCS pharmacies that would make it difficult to take part in the research. 
This appeared to be true as the sample of palliative care prescriptions 
achieved in Phase 1 was much lower than that expected in comparison to a 
previous pilot study done by Tsoneva (2011) and prevalence data calculated 
from HSCIC primary care prescription data. Furthermore, the combination of 
a lack of pharmacy participants and prescription data meant there was an 
insufficient sample of prescription observations for the intended statistical 
analysis. Further to this, the observed prevalence of legal and other errors on 
prescriptions was much lower than expected and reported in other studies. It 
was therefore not possible to establish whether errors varied according to 
practice or prescriber status due to the small sample size. Though both my 
study and a study by Stuart (2013) had similar rates of handwritten 
prescriptions, they had very different error rates with no evidence that 
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handwritten prescriptions had more legal errors in my study compared to 
computer generated prescriptions. There may be important differences and 
processes that we can learn from and share with others in particular OOH 
prescribers that could provide more timely and efficient care. 
Within the qualitative study, sixteen healthcare professionals were 
interviewed; face to face including community pharmacists, GPs, community 
nursing staff, palliative care team members and a member of the 
intermediate care team. Recruitment of community nursing staff was from 
two teams in the city. The sample was varied and included a nurse prescriber 
but did not directly cover the views of OOH GPs, locum GPs, locum 
community pharmacists or pharmacy support staff. Many of the interviewees 
responded to take part as they knew of the researcher or were interested in 
the research topic as there was no payment for the time involved. This may 
have resulted in bias in the research sample. 
6.8 Summary of the chapter 
In this chapter, the results and findings from each of the study components 
has been discussed before the findings were integrated and examined. In the 
next chapter, the conclusions will be stated with implications for practice and 
research. 
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Chapter 7: Conclusion 
This chapter pulls together conclusions from the research and considers the 
implications for local and national practice. Following this, recommendations 
are made for commissioners and providers of palliative care medicines 
access schemes before finally considering future work and further research 
arising from this study. 
7.1 Conclusions from own research 
There was little evidence that prescription errors affected timely access to 
palliative care medicines; however, having the necessary medicines available 
in advance of the prescription was critical to allow pharmacies to respond 
quickly to meet patient and customer needs. 
Pharmacies achieved this in a variety of ways: 
• By participating in a LCS to access palliative medicines and regularly 
monitoring stock levels in the pharmacy. 
• Working collaboratively with local GPs to keep a list of palliative 
medicines in the pharmacy. 
• Requesting patients ring in advance to order non-urgent regular 
medicines including CDs. 
• Making phone calls to refer customers to an alternative pharmacy if 
the requested items were not available or could not be ordered in time. 
 
Pharmacies encountered a number of barriers to this process, namely: 
• Unexpected prescription presentation with no communication to the 
pharmacy in advance. This could mean stock was not ordered or 
insufficient stock was available. 
• Prescription arrives for a non-formulary, unlicensed or expensive 
product including specialist palliative care team prescriptions not 
stocked in the pharmacy. 
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• National drug shortages for a number of palliative care product lines. 
• Errors on CD prescriptions for drugs to be administered via a syringe 
driver, and other prescribing errors. 
• Difficulties checking safety of medication on prescriptions due to a lack 
of clinical information and because not all prescriptions specify a dose. 
• Changes to continuity of care between patient’s regular pharmacy and 
the pharmacy that provides access to urgent palliative medicines or is 
convenient to the customer. This may make it difficult to respond to 
the patient or carers needs. 
There were, however, facilitators to accessing palliative care medicines: 
• Skills of nurses and specialist palliative care team who were 
resourceful in their use of drugs, monitored stocks in the patient’s 
home and informed pharmacy to mind their stock levels for patients 
requiring pre-emptive or syringe driver medicines. 
• Pharmacists working with GP practices who have an agreement to 
keep some palliative care medicines in the pharmacy. 
• Prescribing template on GP clinical prescribing system for pre-emptive 
medication. 
• GP rings or contacts the pharmacy prior to prescribing to allow them to 
order necessary medications in. Knowledge of local pharmacies 
participating in the LCS. 
• Forward planning by primary healthcare team 
In terms of the community pharmacists’ role in palliative care this was 
currently limited to a traditional supply of medicines, often in urgent and or 
difficult situations. Other healthcare professionals were reluctant to share 
confidential information with the pharmacy team until the point that a 
prescription was or had been written for pre-emptive medication giving little 
time for the patient’s regular pharmacy to order medication in or for the 
pharmacist to be proactive in their discussions. Patient benefit will only be 
realised when pharmacists are fully engaged within the primary care team. 
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Health professionals need to feel able to appropriately share clinical 
information with the pharmacy team to support patient care, and pharmacists 
need to have read and write access to the patient’s clinical record through 
SCR. This is likely to improve access to care, support continuity of care, and 
the patient and carers’ experience. 
Likewise community pharmacists’ knowledge of medicines is not utilised and 
opportunities to collaborate in the primary care team are lost. This could 
result in needless calls to the GP or specialist palliative care team. Increased 
integration between pharmacy and nursing teams could help resolve 
medicines queries, reduce professional tension when trying to access urgent 
palliative care medicines, and improve awareness of local pharmacy services 
that could benefit patients in the nurses’ caseload. Improving personal 
relationships and collaboration through joint working and training events 
would enable better integration across the primary healthcare team. 
Customers reported a high level of satisfaction with pharmacy services at a 
difficult time, suggesting pharmacies are responsive to patient and 
customer’s needs. However, limited interventions took place and they 
appeared to be pharmacist-lead, suggesting there were few opportunities for 
patients and carers to discuss medications and little interaction with other 
members of the primary care team. Though pharmacists were willing to do 
more for palliative patients and carers they cited familiar obstacles. There is a 
risk that without a cultural shift, medicines will not be optimised for patient 
benefit, symptoms will not be managed and there will be an increase in 
referrals to the specialist palliative care team. This will lead to poor access for 
more complex patients and ultimately an increase in hospital admissions. 
The pharmacy contract, remuneration and processes need to support a 
patient centred approach during the day and within OOH episodes of care. 
This could be through community pharmacists having read and write access 
to SCR but also informed patient consent to allow family carer involvement. 
There is an urgent need to assess new models of working using remote 
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access and pharmacists linked to community palliative care teams to assess 
patient benefit. 
7.2 Implications for Practice 
In practice, there appears to be little information on commissioned services 
for accessing palliative care medicines, including a lack of national quality 
and outcome data. Data systems that capture outcomes could help 
benchmark practice and share learning across commissioning organisations. 
This could include: nearest access point for end of life medications; time to 
access urgent palliative medications; time elapsed from decision to 
administer to starting a syringe driver; percentage use of local formulary; 
patients with advanced decisions in place who achieve this etc. 
Benchmarking performance will support commissioners as part of monitoring 
the LCS and can be incorporated into standard NHS contracts specifying the 
outcomes to be monitored, local audits, and electronic software for analysis 
and reporting. 
Locally the CCG needs to review the service specification and the 
pharmacies providing the LCS. There was some evidence in the study to 
suggest an enhanced list for accessing specialist palliative care medicines 
may be required to meet the needs of complex patients in the community. 
This should be assessed through the Pharmaceutical Health Needs 
Assessment, planned and commissioned appropriately. The LCS must be 
monitored, and disseminated to all providers including adult emergency and 
OOH providers, health professionals, palliative care teams, intermediate care 
teams, GP, and pharmacy contractors to inform them of where the specific 
drugs can be accessed. Wherever possible the medication list needs to be 
integrated into GP clinical prescribing systems to ensure the correct product 
and strength is prescribed. All pharmacies should be encouraged to work 
with local GP practices to support access to palliative care medicines 
potentially keeping a few basic palliative care medicines in stock. 
Commissioning bodies should consider whether they can contract or 
reimburse such pharmacies not part of the formal LCS for any expired stock. 
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Although end of life prescriptions in community pharmacies were often urgent 
they were also very infrequent so pharmacies do not see this as a large part 
of their workload. There is a concern that contracts for palliative care 
medicines are a burden on contractors and ‘disproportionate to services 
being provided’ (Murray 2016: 29). Obtaining prompt supplies of urgent 
medications near the end of life should follow access pathways for healthcare 
professionals attending to the medicines administration. Commissioners 
should work with urgent and OOH providers to ensure access is meeting 
local needs; considering alternate mechanisms through rapid response, 
OOH, Accident and Emergency (A&E) or other emergency providers. 
Where a commissioned service exists nationally, information needs to be 
disseminated and readily available to all healthcare professionals involved in 
the care of palliative patients. This could be through the NHS choices 
website. Locally commissioned services should be reviewed and updated to 
standard NHS contracts with consideration for different levels of service so 
that more pharmacies provide access to a smaller range of palliative drugs. 
This could include standardised options during intermittent stock shortages. 
Clarification on where to access urgent palliative care medicines needs to be 
available across organisational boundaries and to all healthcare 
professionals including GP locums and all pharmacy staff. Commissioned 
services must be monitored to assess the patient and carers’ experience and 
to ensure palliative care medicines are available. 
Increased complexity together with patients living longer with co-morbid 
conditions will expand the need for palliative and end of life care in the 
community. With this, there will be a greater need for healthcare services and 
professionals to provide coordinated and collaborative patient-centred care. 
Patients and carers view access to healthcare services; including health 
professionals as paramount together with coordinated and continuity of care 
(Sav et al. 2015). But in the event of no access, efforts to provide “patient-
centred” care are meaningless (Sav et al. 2015). With what is an already 
over-stretched GP and community nurse workload, it is even more crucial for 
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healthcare professionals including pharmacists to work collaboratively, to 
support access for patients and families near the end of life. Organisational 
barriers must be overcome to improve capacity, reduce inefficiencies, and 
utilise skills of all team members. Guaranteeing good symptom management 
towards the end of life ensures a positive experience for families and carers 
and a ‘good death’ for their loved one, leaving a lasting legacy and 
minimising impact on their lives. Timely access to medication is part of 
effective symptom management, and can be achieved by advanced care 
planning, and a collaborative approach, utilising the skills of all team 
members.  Community pharmacists working with GP practices and 
community nursing can support continuity of care, and further integration of 
pharmacists in GP practices will help in this respect. 
Complex patients including those who are housebound with cancer, on 
continuous oxygen, suffering from breathlessness or fatigue may be unable 
to access pharmacy services. Family caregivers often manage the patient’s 
medication but may lack support and have their own concerns about 
administering opioids and other medicines near the end of life (Joyce et al. 
2014; Sheehy-Skeffington et al. 2014; Payne et al. 2015; Archer et al. 2017) 
Though a plethora of issues were reported by community healthcare staff it is 
unlikely an MUR will address these concerns especially as there is no QOL 
measurement within the MUR service (Wright 2016), and because a payment 
based on targets and volume does not provide an incentive to provide the 
service to complex patients in their homes (Wright 2016). Following the 
Murray (2016) review, NHS England will review the nationally contracted 
MUR community pharmacy service. Consideration needs to be given on how 
patients with complex conditions in the last year of life access pharmaceutical 
support. This could be through providing support to family caregivers, 
through GP clinical pharmacists or domiciliary pharmacy teams. There could 
also be a role for tele-medicine to allow remote monitoring by multi-
disciplinary teams including specialist pharmacists. Such technology is being 
piloted and NHS Vanguard sites may provide the vision of how this will work 
in future. 
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Electronic transmission of controlled drug prescriptions may improve 
timeliness of accessing medication; however, this is still to be proved in the 
case of controlled drugs. Having a means of transferring electronic 
prescriptions within a patient’s house could reduce the need for OOH 
handwritten prescriptions; however, the researcher is not aware if the 
technology is being developed in this area since local OOH teams have 
instigated ‘just in case’ boxes relieving the need for an FP10. Electronic 
prescriptions and technological advances will improve access to prescriptions 
and provide a vehicle for remote clinical services if community pharmacies 
seize the opportunities to implement these in future. 
Accessing dedicated specialist pharmacist input within community palliative 
care teams would provide support for answering specialist queries as well as 
providing specialist support for individual patients and their family caregivers, 
GPs and community nursing teams. Specialist pharmacists could also 
support training and education of community teams including pharmacy 
support staff. A vision of such a service is provided by RPS Wales (2016) 
and NHS Vanguard sites (NHS England 2016), which could be rolled out 
more widely with technological developments. Integration of pharmacists into 
community palliative care and ambulatory teams has been achieved in 
Australia, US and the UK (Atayee et al. 2008; Hussainy et al. 2011; Bartlett 
2017: pers. comm., 21 September). However, such schemes are not 
reimbursable, there is limited productivity data; and are not widely available 
(Walker 2010). It is unlikely that current hospice or oncology pharmacists 
could take on this additional role since staff resources are already stretched, 
and the pharmacists’ clinical time is dictated by their employer with the 
additional services outlined above not being paid for. There may be a role for 
charitable organisations, large multiple pharmacies and primary care 
pharmacist organisations to support this, in addition to the use of remote 
technologies. A successful model supporting increased community pharmacy 
participation was implemented in Scotland using additional funding (Bennie 
et al. 2012; MacRobbie et al. 2015) and could be considered in England. 
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Controlled drug regulations are required to protect the safety of the public; 
however, they should not prove to be a barrier where a healthcare 
professional is assured of the legitimacy of a prescription and 
appropriateness for the patient. Where a specific dose on prescriptions for 
medication to be given subcutaneously via syringe driver is not provided, this 
could be allowed under a permitted technical change by a registered 
pharmacist according to the prescriber’s intention. Providing a template on 
GP clinical systems would also support any unintentional illegality. As local 
lists of medications may vary across organisational boundaries, CCG teams 
would be responsible for instigating and maintaining the template. 
Further consideration should be given to streamline processes between 
teams and across organisational boundaries, for instance, duplication of 
medicines reconciliation processes between GP and specialist palliative care 
teams. Informal communication methods should be encouraged including 
telephone, NHS mail and secure messaging services to advise pharmacies in 
advance to order CD medications or likely quantities needed for a syringe 
driver over a weekend. Electronic processes will help improve efficiency; yet 
often access to IT systems is not shared across teams including those 
outside the NHS in hospices.  Further to this, there needs to be a systematic 
way of sharing information with community pharmacists and other pharmacy 
professionals where patients give consent. This could include whether a 
patient is palliative or under a palliative care team and previous letters 
advising on dose changes to medication. Having read and write access to 
SCR could be developed in addition to providing access to Electronic 
Palliative Care Coordination Systems (EPaCCS). Community pharmacists 
cannot currently access these records; however, IT developments in this 
area could allow access in the future. Having read and write access to SCR 
could allow community pharmacists to align quantities on prescriptions with 
the patients consent and indicate medications on repeat that are no longer 
needed. In addition, pharmacists could check on the safety and 
appropriateness of an opioid dose, especially for patients who do not usually 
attend the pharmacy or when relatives or neighbours are involved with 
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collecting prescriptions. This would potentially allow the pharmacist to deal 
with any queries without needing to contact the prescriber, providing safe and 
timely access particularly outside surgery hours. 
Capacity in community pharmacy could be increased through additional 
education to pharmacy support staff including: identifying palliative care 
prescriptions; understanding the urgency; signposting to local services; 
dealing with prescription queries and resolving stock issues. Pharmacies 
offer the opportunity to support a wide range of patients and carers who may 
not be known to palliative care teams. Ensuring community pharmacies are 
aware of local services and support including those for non-cancerous life-
limiting conditions will enhance the support they provide to patients, families 
and carers. 
Some pharmacists within the study had independent prescribing status; 
however, there was no evidence of this being used in the area of palliative 
care. Independent prescribers, with the right governance framework, could 
validate changes in prescriptions to formulary choices, or suitable 
alternatives where national stock shortages are a problem. It would be 
necessary for such pharmacists to have read and write access to the 
patient’s SCR to undertake this process and be able to recharge prescribing 
to the practice budget. 
7.3 Recommendations for Healthcare Professionals 
Several recommendations for healthcare professionals have arisen from this 
study as described further below. 
Healthcare professionals need to be encouraged to share information with 
community pharmacists where this would support or enhance patient care 
towards the end of life. This could include seeking advice on medication 
issues, referral for medication concordance support and advising when 
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someone is palliative to ensure end of life medicines are ordered in advance 
of need. 
GPs should work proactively with local community pharmacists on 
establishing services that may be beneficial to their palliative care patients 
such as use of repeat dispensing schemes and EPS. GPs should ensure 
they are aware of local services such as pharmacy opening hours and 
delivery services and any restrictions on these; so they can inform patients 
accordingly. 
GPs should be encouraged to work with local pharmacies to establish what 
necessary stock of urgent palliative care medications should be kept where 
possible for pharmacies not on the CCG LCS list. 
7.4 Recommendations for Providers and Organisations 
Pharmacies, pharmacy companies and pharmacy organisations should be 
encouraged to provide more information to healthcare professionals and the 
public on the range of services provided, and any rules or restrictions on 
these through awareness campaigns, briefings to nursing team leaders and 
joint events. A national campaign on nationally contracted services would 
support awareness of pharmacy services, especially if there are any changes 
following the NHS England review (Murray 2016). Further consideration 
should be given to supporting pharmacy teams to provide work shadowing 
and work experience to newly qualified nurses and GPs in training. 
Consideration needs to be given of how to engage all of the community 
pharmacy team, including support staff, locums and reliefs in education in 
palliative care so all pharmacy staff know about anticipatory medication and 
can assess prescriptions for urgency of supply. Providing face to face training 
would be preferable to ensure pharmacy support staff are able to liaise with 
families, source medication and make referrals. The LPC could have a role to 
ensure this learning is rolled out and available to all pharmacies. Specific 
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training on syringe drivers should be provided for pharmacists involved in a 
specialist LCS. 
Specialist palliative care and acute hospital provider organisations should 
consider running joint educational events for community nursing, GP and 
pharmacy teams to encourage learning, sharing practice and the 
development of local networks. This could include local audit, research, and 
educational events. 
Organisations, providers and professional groups need to collaborate and 
integrate learning to support increased complexity of palliative care patients 
and prevent unnecessary hospital admissions. This could be through the use 
of modern technology, and learning from NHS England Vanguard and 
technology transformation sites. 
7.5 Recommendations for Local Commissioners 
Local commissioners need to plan, commission and monitor co-ordinated 
services that provide timely responsive palliative care medication at all hours 
of the day, seven days a week. This cannot be assessed in isolation but as 
part of commissioning palliative and end of life service provision as a whole 
as well as access to urgent medicines within an appropriate environment. 
Commissioning a scheme that provides urgent access with the facility to 
administer the medication may be more appropriate in some cases and this 
could be achieved through OOH providers or rapid response teams visiting 
palliative patients at home, reducing the need to access urgent medicines 
through community pharmacies. Faster and more responsive access 
provides relief from pain and other symptoms in pre-terminal patients who 
have not been identified in advance, or were not suitable for pre-emptive 
medication and wish to remain in the home environment. Community 
pharmacy services could also be commissioned to ensure access to non-
urgent, pre-emptive and continuation of syringe driver medication in less 
urgent situations. 
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Commissioners should consider whether a locally commissioned service 
could be offered more widely to incorporate all pharmacies willing to hold a 
small number of core medicines for symptom management control at the end 
of life to ensure prompt access and continuity of care. The commissioned 
service could include payment for expired medications as well as delivery 
charges that could be waived for delivery at the end of life. Different levels of 
service could be offered for a smaller set of core drugs or a wider set of more 
specialist medications. Due to the volume and prevalence of prescriptions for 
subcutaneous medicines at the end of life, as witnessed in this study, it is 
unlikely that a volume commissioned model would be cost-effective and 
commissioning contracts need to be non-burdensome for small contractors to 
ensure efficiency in the contracting process. This could be achieved through 
having a national standard framework for commissioning a local service. 
Commissioners of LCS need to review and maintain schemes in line with 
current and future needs to enhance care in the community. Commissioners 
should consider whether there is a need to hold specialist medications in one 
or more pharmacy hubs to allow more complex patients to be supported in 
the community by the specialist palliative care team. Formally commissioning 
such a scheme will ensure any scheme is co-ordinated with information sent 
to healthcare professionals and the public, if necessary, to advise them of the 
arrangements as well as follow due process and fairness. 
The list of core medicines should be reviewed and agreed with 
commissioners, and disseminated widely to ensure it is available to all those 
involved in palliative care services including prescribers and anyone advising 
on palliative care medication in the last days of life. CCG medicines 
management teams and GP practices should consider how to embed this list 
of core medications, including dosages and frequencies within GP 
prescribing systems to ensure this is the default chosen when issuing 
computer generated prescriptions. Consideration should be given to having 
alternative products in case of national shortages in palliative care medicines. 
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Commissioners should consider whether a citywide electronic bulletin could 
be used to disseminate information on those pharmacies holding palliative 
medicines and any issues with stock availability to all healthcare 
professionals. This would require email addresses for community 
pharmacies, GP practices as well as specialist palliative care and community 
nursing team leaders who work across a number of different organisations. 
Alternatively, information could be included on the CCG palliative care 
website, and organisations requested to send a link to staff and contractors 
when any changes in supply are published. 
7.6 Dissemination of findings and recommendations 
Details of external outputs from this research are provided on page iv - v at 
the front of the thesis. This includes presentations at the Royal Society of 
Medicine/ Marie Curie Research Conference and at the University of 
Bradford Faculty of Life Sciences open days. Poster and oral presentations 
have been presented at the RPS Winter Summit, the Association of Palliative 
Medicine Palliative Care Congress and the Health Services Research and 
Pharmacy Practice (HSRPP) conference. Due to limited research in this area 
and to reach a wider international audience as well as meet the requirements 
of the DPharm a publication has been prepared for submission to a peer-
reviewed journal in 2018. 
The researcher has completed research presentations to disseminate 
findings to the University of Bradford MORG, STH Foundation Trust 
pharmacy research training events, and St Luke’s Hospice Clinical 
Development Group. 
As part of the external funding provided by PRUK, the researcher has 
completed six and twelve month progress reports and a final report on the 
research. Details of the research have been entered onto Researchfish® an 
online facility to track study impact and outcomes in relation to research 
funding (Research Councils UK 2014). 
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Findings and recommendations from the research will be discussed with a 
service user panel at the hospice, where the researcher works, to ascertain 
what, if any, changes should be taken forward that are likely to have a 
positive impact. The researcher will support patient co-production of service 
development or changes where possible, so these are structured around 
patients’ needs and preferences. Following this, a report of recommendations 
and key deliverables will be presented to the Sheffield CCG end of life 
planning group, LPC, local professional and palliative care networks. There 
will also be consideration of sharing a report and learning with wider local 
commissioners through the local Sustainability and Transformation Plan 
across South Yorkshire and Bassetlaw. Reports will also be shared with 
national bodies, including the Association of Supportive and Palliative Care 
Pharmacy (ASPCP) and affiliated partners of the RPS. The ASPCP includes 
pharmacists and pharmacy technicians interested or working in the field of 
palliative care, who could assist in sharing results across a wider network, 
including the devolved governments of the UK and NHS commissioners. 
Further electronic means of dissemination will be utilised including ASPCP 
website, twitter, and Researchgate. Study participants will also be issued with 
a copy of the research report if this has been requested on their consent 
form. 
7.6.1 Implications for future research 
This study highlights areas where further research should be undertaken to 
ensure timely access to palliative care medicines in the community and the 
community pharmacists’ role in palliative care. Research priorities have been 
highlighted within the thesis but are summarised further in this section. 
The implication of electronic prescription transfer on timely access to 
palliative care medicines could not be assessed within the current study 
since EPS release 2 roll out did not include CDs. It is likely that EPSr2 will 
improve efficiency and timeliness in accessing medicines particularly CDs at 
the end of life, though it could have the opposite effect if the nominated 
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pharmacy does not keep the requested items in stock. It would be prudent to 
review if EPS r2 has the desired effect in this area of practice. 
Further research is needed to investigate referrals from OOH providers and 
processes for obtaining access to urgent palliative care medication in the 
OOHs period. Schemes offering urgent access through GP OOH providers, 
Accident and Emergency (A&E) or rapid response teams should be piloted to 
assess and evaluate the benefit of these models for timely symptom 
management compared to community pharmacies. These models may not 
be suitable for more rural locations with less demand or limited access to 
seven-day palliative care services. 
Further local research on the way customers access pharmacies near the 
end of life should be investigated to examine whether this is customer choice 
or a consequence of the way the LCS is provided. Change in use may have 
implications for continuity of care. 
Benchmarking outcomes of local schemes and access points is needed 
across the UK to support planning and commissioning of services. This will 
enable commissioners to monitor the use and impact of locally enhanced or 
commissioned services, whether they meet customers’ needs, and whether 
they provide value for money in keeping people out of hospital. 
Supporting community pharmacists to provide symptom management, 
psychological support, treatments and signposting in cancer patients seems 
worthy of further research. There may be scope to support a wider range of 
patients and non-cancerous conditions in future ensuring equity of access. 
Further research on the community pharmacy team involvement in 
supportive care, for those on a ‘living with and beyond cancer programme,’ 
should be undertaken to assess whether pharmacies provide a useful outlet 
for such integrated services. 
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A further area of research is how community pharmacists can develop and 
support collaborative, trusting relationships between themselves, the public 
and members of the primary care team since any future extended role for 
community pharmacists relies on these human relationships. This is in the 
context of new technologies, commercial pressures and the political and 
regulatory environment within pharmacy. 
7.7 Final Conclusion 
The findings from this study raise questions on whether community 
pharmacists can have an extended role within palliative care due to a variety 
of limitations, including the national NHS pharmaceutical contract in England, 
the endemic absence of sharing information on palliative care patients with 
between GPs and community nurses with pharmacy professionals, the need 
for employers to provide sufficiently upskilled pharmacy support staff to allow 
pharmacists to take on extended roles in the context of pharmacy cuts, and 
because pharmacists are not fully integrated within the primary care team. It 
is unclear whether a similar model as used in Scotland (Bennie et al. 2012), 
would be feasible within the fiscal constraints and the higher head of 
population for pharmacies in England. 
Timely access to palliative medicines at the end of life has to be supported 
through effective planning and commissioning to consider the best models of 
care, and this must be communicated to all healthcare professionals, 
healthcare managers and OOH providers.  
Health professionals, provider organisations, acute trusts, voluntary sector 
and private organisations must work together with local and national leaders, 
and local communities to overcome these obstacles through effective use of 
modern technology, providing safe and secure access to patient information, 
and providing local pathways of care that are monitored and managed to 
ensure effective outcomes for palliative care patients and their carers.
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